<SEC-DOCUMENT>0001683168-22-005298.txt : 20220803
<SEC-HEADER>0001683168-22-005298.hdr.sgml : 20220803
<ACCEPTANCE-DATETIME>20220803164314
ACCESSION NUMBER:		0001683168-22-005298
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220803
DATE AS OF CHANGE:		20220803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sunshine Biopharma, Inc
		CENTRAL INDEX KEY:			0001402328
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				205566275
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41282
		FILM NUMBER:		221133295

	BUSINESS ADDRESS:	
		STREET 1:		6500 TRANS-CANADA HIGHWAY
		STREET 2:		4TH FLOOR
		CITY:			POINTE-CLAIRE
		STATE:			A8
		ZIP:			H9R 0A5
		BUSINESS PHONE:		514-426-6161

	MAIL ADDRESS:	
		STREET 1:		6500 TRANS-CANADA HIGHWAY
		STREET 2:		4TH FLOOR
		CITY:			POINTE-CLAIRE
		STATE:			A8
		ZIP:			H9R 0A5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mountain West Business Solutions, Inc
		DATE OF NAME CHANGE:	20071030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	mountain west business solutions,inc
		DATE OF NAME CHANGE:	20070607
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sunshinebio_i10q-063022.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:SBFM="http://sunshinebiopharma.com/20220630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_SBFM_sunshinebiopharma.com_20220630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20220101_20220630 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001402328 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DCurrentFiscalYearEndDate_12/31 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityCentralIndexKey">0001402328</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-04-012022-06-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-04-012022-06-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:PreferredStockPurchasedFromRelatedPartyValue" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:PreferredStockPurchasedFromRelatedPartyValue" contextRef="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:PreferredStockPurchasedFromRelatedPartyValue" contextRef="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SBFM:PreferredStockPurchasedFromRelatedPartyValue" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-06-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-06-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="sbfm-20220630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-162022-02-17_custom_AegisOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">SBFM:AegisOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-16</xbrli:startDate>
        <xbrli:endDate>2022-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-162022-02-17_custom_AegisOfferingMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">SBFM:AegisOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-16</xbrli:startDate>
        <xbrli:endDate>2022-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-162022-02-17_custom_AegisOfferingMember_custom_TradeableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">SBFM:AegisOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-16</xbrli:startDate>
        <xbrli:endDate>2022-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-212022-02-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-21</xbrli:startDate>
        <xbrli:endDate>2022-02-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-13</xbrli:startDate>
        <xbrli:endDate>2022-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_InvestorWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-13</xbrli:startDate>
        <xbrli:endDate>2022-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-13</xbrli:startDate>
        <xbrli:endDate>2022-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-13</xbrli:startDate>
        <xbrli:endDate>2022-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_InvestorWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_PreFundedWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:PreFundedWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-28_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-312019-02-01_custom_FirstReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FirstReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-31</xbrli:startDate>
        <xbrli:endDate>2019-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-052020-04-06_custom_SecondReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:SecondReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-05</xbrli:startDate>
        <xbrli:endDate>2020-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-082022-02-09_custom_ThirdReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:ThirdReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-08</xbrli:startDate>
        <xbrli:endDate>2022-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-20_custom_NotePayable20211Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20211Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-192021-04-20_custom_NotePayable20211Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20211Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-19</xbrli:startDate>
        <xbrli:endDate>2021-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-162022-02-17_custom_NotePayable20211Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20211Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-16</xbrli:startDate>
        <xbrli:endDate>2022-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-06_custom_NotePayable20212Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20212Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-052021-07-06_custom_NotePayable20212Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20212Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-05</xbrli:startDate>
        <xbrli:endDate>2021-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-162022-02-17_custom_NotePayable20212Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20212Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-16</xbrli:startDate>
        <xbrli:endDate>2022-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-18_custom_NotePayable20213Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20213Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-172021-08-18_custom_NotePayable20213Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20213Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-17</xbrli:startDate>
        <xbrli:endDate>2021-08-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-162022-02-17_custom_NotePayable20213Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20213Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-16</xbrli:startDate>
        <xbrli:endDate>2022-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-22_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-22_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-13</xbrli:startDate>
        <xbrli:endDate>2022-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_TradeableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_TradeableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_AprilWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_AprilWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_InvestorWarrantsAndAprilWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsAndAprilWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_custom_AegisOfferingMember_custom_TradeableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">SBFM:AegisOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_AprilWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_TrtPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:TrtPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000695" toRefs="Footnote000710"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="#a_001">Table of Contents</a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Form
<span id="xdx_906_edei--DocumentType_c20220101__20220630_zziHjT4jzXm6"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--DocumentQuarterlyReport_c20220101__20220630_zA3A17C12vQg"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended:&#160;<b><span style="text-decoration: underline"><span id="xdx_901_edei--DocumentPeriodEndDate_c20220101__20220630_zzHcqH58Nhx8"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June
30, 2022</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--DocumentTransitionReport_c20220101__20220630_zwChzuajISY6"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from ____________ to
______________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number:&#160;<span id="xdx_90B_edei--EntityFileNumber_c20220101__20220630_zeEC1H6Iow6k"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityFileNumber">001-41282</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityRegistrantName_c20220101__20220630_zWf27T12FYd2"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityRegistrantName">SUNSHINE BIOPHARMA, INC.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20220101__20220630_zqLmc6pTafG5"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Colorado</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20220101__20220630_zhLqsZy8Xjxc"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityTaxIdentificationNumber">20-5566275</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State of other jurisdiction of incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer ID No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20220101__20220630_zmKawOBLPr52"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressAddressLine1">6500 Trans-Canada Highway</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine2_c20220101__20220630_zJLCB1SWxSg3"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressAddressLine2">4th Floor</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityAddressAddressLine3_c20220101__20220630_z2t4OWLZscbd"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressAddressLine3">Pointe-Claire</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20220101__20220630_z2193essfDTj"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressCityOrTown">Quebec</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressCountry_c20220101__20220630_zH4WlNt6Tc0e"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Canada</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20220101__20220630_zMy9uFUm2prg"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressPostalZipCode">H9R 0A5</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;(Address of principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_901_edei--CityAreaCode_c20220101__20220630_z3J6kbPa6fFj"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:CityAreaCode">(514)</ix:nonNumeric></span> <span id="xdx_903_edei--LocalPhoneNumber_c20220101__20220630_zjdFDjC54dS1"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:LocalPhoneNumber">426-6161</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Issuer&#8217;s Telephone Number)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span style="text-decoration: underline">Title of Each Class</span></span></td>
    <td style="width: 30%; font-size: 10pt; text-align: center; text-indent: 0.35pt"><span style="font-size: 10pt"><span style="text-decoration: underline">Trading Symbol</span></span></td>
    <td style="width: 37%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span style="text-decoration: underline">Name of Each Exchange on Which Registered</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_906_edei--Security12bTitle_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS7YShZvufy4"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_905_edei--Security12bTitle_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxE0CY47Uqd1"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember" name="dei:Security12bTitle">Common Stock Purchase Warrants</ix:nonNumeric></span></p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.35pt"><span id="xdx_90F_edei--TradingSymbol_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv6Qnv4bSXLa"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" name="dei:TradingSymbol">SBFM</ix:nonNumeric></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.35pt"><span id="xdx_90D_edei--TradingSymbol_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEDzSfeFg1J2"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember" name="dei:TradingSymbol">SBFMW</ix:nonNumeric></span></p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The <span id="xdx_907_edei--SecurityExchangeName_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ36RMRftv53"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The <span id="xdx_90B_edei--SecurityExchangeName_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz40xXmDDaRk"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days: <span id="xdx_900_edei--EntityCurrentReportingStatus_c20220101__20220630_z3LA5fTaK766"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9745;</span>&#160; &#8239;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_904_edei--EntityInteractiveDataCurrent_c20220101__20220630_zpEi4RUrsCIh"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9745;</span>
&#8239;&#8239;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;,
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%">&#160;</td>
    <td style="width: 49%; text-align: justify"><span style="font-size: 10pt">Large accelerated filer&#160; <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td>
    <td style="width: 41%; text-align: justify"><span style="font-size: 10pt">Accelerated filer&#160; <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_90A_edei--EntityFilerCategory_c20220101__20220630_zIRb4LuTEhte"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span>&#160; &#9746;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Smaller reporting company&#160; <span id="xdx_900_edei--EntitySmallBusiness_c20220101__20220630_zbZZmaiX24uk"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20220101__20220630_zVVTFtxgc2i"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;Yes&#160;&#160;&#9746;&#160;&#160;<span id="xdx_901_edei--EntityShellCompany_c20220101__20220630_zcikn64Ytcoj"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of the registrant&#8217;s
common stock, par value $0.001, issued and outstanding as of August 3, 2022, was <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20220803_zsbRVELbKHbe"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-08-03" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,885,632</ix:nonFraction></span> shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_001"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 10%">&#160;</td>
    <td style="width: 82%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><a href="#a_014">PART I.</a> FINANCIAL INFORMATION</b></p></td>
    <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-size: 10pt"><b>Page No</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 1.</span></td>
    <td><a href="#a_015"><span style="font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: right; vertical-align: bottom">3</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td> <a href="#q_001"><span style="font-size: 10pt">Condensed Consolidated Balance Sheets as of June 30, 2022 (Unaudited) and
    December 31, 2021</span></a></td>
    <td style="text-align: right; vertical-align: bottom">3</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td> <a href="#q_002"><span style="font-size: 10pt">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited)</span></a></td>
    <td style="text-align: right; vertical-align: bottom">4</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td> <a href="#q_003"><span style="font-size: 10pt">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 (Unaudited)</span></a></td>
    <td style="text-align: right; vertical-align: bottom">5</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td> <a href="#q_004"><span style="font-size: 10pt">Condensed Consolidated Statement of Shareholders' Equity (Unaudited)</span></a></td>
    <td style="text-align: right; vertical-align: bottom">6</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><a href="#q_005"><span style="font-size: 10pt">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></td>
    <td style="text-align: right; vertical-align: bottom">7</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 2.</span></td>
    <td><a href="#a_002"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: right; vertical-align: bottom">12</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 3.</span></td>
    <td><a href="#a_003"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="text-align: right; vertical-align: bottom">17</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 4.</span></td>
    <td><a href="#a_004"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: right; vertical-align: bottom">17</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 10%">&#160;</td>
    <td style="width: 82%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><a href="#a_005">PART II.</a> OTHER INFORMATION</b></p></td>
    <td style="width: 8%; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 1.</span></td>
    <td><a href="#a_006"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item&#160;1A.</span></td>
    <td><a href="#a_007"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 2.</span></td>
    <td><a href="#a_008"><span style="font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 3.</span></td>
    <td><a href="#a_009"><span style="font-size: 10pt">Defaults Upon Senior Securities</span></a></td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 4.</span></td>
    <td><a href="#a_010"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 5.</span></td>
    <td><a href="#a_011"><span style="font-size: 10pt">Other Information</span></a></td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 6.</span></td>
    <td><a href="#a_012"><span style="font-size: 10pt">Exhibits</span></a></td>
    <td style="text-align: right; vertical-align: bottom">18</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><a href="#a_013"><span style="font-size: 10pt">Signatures</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"></span>19</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PART I.&#160;</b>&#160;<b><span id="a_014"></span>FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_015"></span>Item 1. Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma, Inc.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="q_001"></span>Condensed Consolidated Balance Sheets</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_111_zE1iGqi8ono3" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220630" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20211231" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>(Unaudited)</b>&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zfLlKXIC6r28" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrentAbstract_iB_zIc9ju9fSsl3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maCzmPH_zjiwLWrYGhl" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,727,775</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,045,167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_i01I_maCzmPH_z9E6wtDfvFv8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,798</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryNet_i01I_maCzmPH_zNvm5vISMLvg" style="vertical-align: bottom; background-color: White">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,371</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,650</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_i01I_maCzmPH_zia2DowySvY6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,625</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepositsAssetsCurrent_i01I_maCzmPH_zxtK81UWbkY" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Deposits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,590</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,590</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i01TI_mtCzmPH_maCzeLp_ztx10XeQD40k" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Total Current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,989,322</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,195,830</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzeLp_zc0CEfYXhMnc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Equipment (net of $<span id="xdx_907_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c20220630_pp0p0" title="Equipment depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">69,202</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c20211231_pp0p0" title="Equipment depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">64,106</ix:nonFraction></span> depreciation respectively)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,061</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtCzeLp_zJuVIBcuwxtl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,990,964</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,202,891</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAbstract_iB_zpAZrn3qTYj6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">LIABILITIES AND SHAREHOLDERS' EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_iB_zTADhjage0ia" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_i01I_maCzQ8Y_zAmOmcWc7RUf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,684</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_i01I_d0_maCzQ8Y_zx7ZT8i4Ql7j" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Interest payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,287</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i01TI_mtCzQ8Y_maCzy61_zJNA4ziuWSwd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,684</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,229</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermNotesPayable_i01I_d0_maCzy61_zVmPITnuRHnk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Long-term portion of notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,900,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Liabilities_i01TI_mtCzy61_maCzd2v_zoeKiNDWZprb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,684</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,991,229</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquityAbstract_iB_zyOvOsx0OlVe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SHAREHOLDERS' EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockValue_i01I_maCzjY1_z2djvfJrXuvf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Preferred Stock, Series B $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Par or Stated Value Per Share"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></ix:nonFraction></span></span>
    par value per share; <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares authorized;  <span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Issued"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Issued"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_i01I_maCzjY1_zbEn0bTq9AQe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt">Common Stock, $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_c20220630_pdd" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>
    par value per share; <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_c20220630_pdd" title="Common Stock, Shares Authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common Stock, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares authorized;  <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_c20220630_pdd" title="Common Stock, Shares, Outstanding"><span id="xdx_904_eus-gaap--CommonStockSharesIssued_c20220630_pdd" title="Common Stock, Shares, Issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,885,632</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common Stock, Shares, Outstanding"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common Stock, Shares, Issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,591,240</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_i01I_maCzjY1_zKm8OIrROrJh" style="vertical-align: bottom; background-color: White">
    <td>Capital paid in excess of par value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,331,451</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,787,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maCzjY1_zqBytQ3vgBRd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accumulated comprehensive (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,777</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,139</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzjY1_zoT7JvWGKKj6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated (Deficit)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,430,280</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,655,174</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i01TI_mtCzjY1_maCzd2v_zMkNKVXxK6T5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">TOTAL SHAREHOLDERS' EQUITY</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,886,280</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzd2v_z3T62WCW8uIa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,990,964</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,202,891</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See Accompanying Notes.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma, Inc.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="q_002"></span>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_zU2HCC62PWch" summary="xdx: Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220401__20220630_z4OfGaccT0w8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20210401__20210630_z7ZWx3MPjXYk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20220101_20220630" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20210101_20210630" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">3 Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">6 Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_maCzeeS_zF0RaFzISfa6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 48%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,307</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,874</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,932</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_msCzeeS_zeWjkvpLW9Q4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cost of sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,683</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,515</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,528</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,035</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GrossProfit_iT_mtCzeeS_maCzxR7_zfR0DzKMhQI4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,359</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,897</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zhu06TocUH43" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">General and Administrative Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProfessionalFees_i01_maCzywJ_zaGACA5hAMQ1" style="vertical-align: bottom; background-color: White">
    <td>Accounting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,060</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdvertisingExpense_i01_d0_maCzywJ_zly0hYxwFiwk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2021-04-012021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2021-01-012021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ConsultingExpense_i01_maCzywJ_zRV8zt4rf7Hl" style="vertical-align: bottom; background-color: White">
    <td>Consulting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:ConsultingExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:ConsultingExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,677</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:ConsultingExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:ConsultingExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LegalFees_i01_maCzywJ_zlwl2fGrKZ55" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Legal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OfficeExpense_i01_maCzywJ_ztzQG3G2o7sl" style="vertical-align: bottom; background-color: White">
    <td>Office</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:OfficeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:OfficeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:OfficeExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:OfficeExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,803</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--OfficerAndDirectorRemuneration_i01_maCzywJ_zZeWplUd4KCd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Officer and director remuneration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:OfficerAndDirectorRemuneration" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:OfficerAndDirectorRemuneration" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:OfficerAndDirectorRemuneration" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">610,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:OfficerAndDirectorRemuneration" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,043,927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PatentingFees_i01_maCzywJ_zpE8HOfAKFMj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patent fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:PatentingFees" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:PatentingFees" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,377</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:PatentingFees" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:PatentingFees" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzywJ_zYCxCPrHXmgk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>R&amp;D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,595</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,546</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Depreciation_i01_maCzywJ_zc4vAdqakAD" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,397</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,374</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01T_mtCzywJ_msCzxR7_zKOHT108MCp6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Total General and Administrative Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">771,420</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422,957</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,057,584</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,720,141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_i01T_mtCzxR7_maCzios_zvMKkALQ3FJd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">(Loss) from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,796</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">388,598</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,919,160</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,664,244</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zMTHpIkjQfb6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other Income (Expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzVS3_z5TJHSyTYqUg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign exchange gain (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--InterestIncomeDebtSecuritiesOperating_i01_maCzVS3_zoNzLH2lKjZ5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesOperating" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesOperating" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesOperating" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesOperating" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestExpense_i01N_di0_msCzVS3_z3NYuk6KvBue" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-04-012022-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,630</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,864</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,341</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maCzVS3_z9Pp706yIyGl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Debt release</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InducedConversionOfConvertibleDebtExpense_i01N_di0_msCzVS3_zbfcCiL0pjZ8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Loss on debt conversions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2022-04-012022-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,295,057</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,205,843</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzVS3_maCzios_zpIE1R2oUXJg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Total Other Income (Expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,924</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,490,456</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,054</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,399,936</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_i01T_mtCzios_maCzeBl_z5lK3DIKT3B3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Net (loss) before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">538,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,879,054</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,775,106</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,064,180</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_i01N_di0_msCzeBl_z3IIHCI1Mb9b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-04-012022-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01T_mtCzeBl_maCz8IC_zfG9HgZ7vG27" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Net (Loss)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">538,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,879,054</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,775,106</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,064,180</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_i01_maCz8IC_zb6tYunFIKY6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">(Loss) from foreign exchange translation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,645</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,702</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,638</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,765</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCz8IC_zuY0NjSgFLvb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Comprehensive (Loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">551,517</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,885,756</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,786,744</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,072,945</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_zv5oEtJ8vZAb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Basic (Loss) per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.18</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.96</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zilqK1a0Q4i8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted Average Common Shares Outstanding (Basic)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,849,518</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,392,602</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,691,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,293,836</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See Accompanying Notes.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma, Inc.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="q_003"></span>Condensed Consolidated Statements of Cash Flows (Unaudited)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_112_zc8iIx24eiQj" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20220101__20220630_zOnIZA9xHKCi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20210101__20210630_zsARivWUSB39" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">6 Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zvakrxQnqz27" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_i01_maCzeJW_zrHZ2TchSIh2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Net (Loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,775,106</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,064,180</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zDOpVy8cOWt9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepreciationAndAmortization_i02_maCzeJW_zZ0Y6wScBWU4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,397</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_i02N_di_msCzeJW_zCY8tBQjVCc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange (gain) loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_d0_maCzeJW_zjIIbM1w5FCa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-01to2022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">918,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--StockIssuedForPaymentInterestOnNotesPayable_i02_d0_maCzeJW_zPBWZNPZqPAb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Stock issued for payment interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:StockIssuedForPaymentInterestOnNotesPayable" contextRef="From2022-01-01to2022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:StockIssuedForPaymentInterestOnNotesPayable" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InducedConversionOfConvertibleDebtExpense_i02_d0_maCzeJW_zuaPLBUoQt12" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on debt conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,205,843</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzeJW_zdJ28PNhfvXc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Debt release</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,852</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,252</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msCzeJW_zectyrAyq6Q4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Decrease in accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,774</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,916</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msCzeJW_z6DAD7mYyME9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">(Increase) decrease in inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,721</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,736</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzeJW_z2lNNKskHLSe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">(Increase) in prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,937</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,907</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maCzeJW_zQn7aDj2P1Z2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Increase (decrease) in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_maCzeJW_zQf5Dj6osze3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Increase (decrease) in interest payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,287</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,795</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCzeJW_maCzf1R_z0ySpJdlHCxd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows (Used) in Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,878,010</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">916,207</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zJdXf7Wzx41e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsPublicOfferingNet_i01N_di_msCzt48_ziwvMQQ108Y4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds public offering net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:ProceedsPublicOfferingNet" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,560,363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:ProceedsPublicOfferingNet" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,918,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromOtherShortTermDebt_i01_maCzt48_zlJqKXjdh823" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Note payable to pay fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msCzt48_z97r7UTcsmG6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payments of notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,900,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">327,352</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzt48_maCzf1R_zHHRv7eRexak" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Provided by Financing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,561,363</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,652,648</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01S_zpM3KRcgWmY6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash and Cash Equivalents at Beginning of Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,045,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">989,888</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_i01T_mtCzf1R_zTbeRG64H6Uk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,683,353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,441</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01_d0_zIpjKitP9S79" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Effect of exchange rate changes on cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,383</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2021-01-012021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01_zjctv05jZw5l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,638</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,765</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_zYBAUutAxDh3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents at End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,727,775</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,735,094</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zC1izGHflDBk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Supplemental Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedForNoteConversionsIncludingInterest_i01_d0_zOyXEYuyKVlc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Stock issued for note conversions including interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SBFM:StockIssuedForNoteConversionsIncludingInterest" contextRef="From2022-01-01to2022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SBFM:StockIssuedForNoteConversionsIncludingInterest" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,237,072</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestPaidNet_i01_zV3Ug1OdfgX8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,152</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_d0_zBxhcxtc8VCb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See Accompanying Notes.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma, Inc.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="q_004"></span>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_114_zM5lJdjiWg11" summary="xdx: Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zLkLITfIsKml" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z4nhToQwivc1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_z4LfzwKEFMDg" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--ComprehensiveIncomeMember_zs4YBO7nOaNe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zxut3bHSZJ2f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_zo7BbsJoKJM5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Number Of Common</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Capital Paid in Excess</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Number Of Preferred</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: right"><b>&#160;</b></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Shares</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Common</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>of Par</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Shares</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Preferred</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Comprehensive</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: right"><b>&#160;</b></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Issued</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Stock</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Value</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Issued</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Stock</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Income</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Deficit</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Total</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Three Month Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zWHdkbOhps3" style="vertical-align: bottom; background-color: White">
    <td style="width: 28%; text-indent: -5pt; padding-left: 5pt"><b>Balance at March 31, 2022</b></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfwHFIFminyj" title="Beginnig Balance shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,149,778</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,150</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,219,498</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFJ0wV6SDb37" title="Beginnig Balance shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,132</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,891,408</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,314,108</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkHeQJyAQOI3" title="Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs shares" style="text-align: right"><ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,472,820</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,750,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,752,915</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7kHMPROcxh6" title="Exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,263,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,361,511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,370,774</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTax_zvlT4gNkUUXe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -5pt; padding-left: 5pt">Net (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,645</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">538,872</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">551,517</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20220401__20220630_eus-gaap--StockholdersEquity_iE_zLUZd7ze8KJb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt"><b>Balance at June 30, 2022</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0l0Z0YAVqij" title="Ending Balance shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,885,632</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,886</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,331,451</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zoANcyxhBLS" title="Ending Balance shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,777</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,430,280</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,886,280</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt">Six Month Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20220101__20220630_eus-gaap--StockholdersEquity_iS_z52JmsShLFVc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt"><b>Balance December 31, 2021</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zytFYhXjq7Od" title="Beginnig Balance shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,595,620</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,787,379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zECVBCc73ja3" title="Beginnig Balance shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,139</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,655,174</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts_zNlJONlbP8hi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6ZrLX4X9mEg" title="Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs shares" style="text-align: right"><ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,656,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,657</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,360,528</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,367,185</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zVr35tX2Bxlk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOaZ7ASWecE9" title="Exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,633,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,633</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,183,544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,193,177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PreferredStockPurchasedFromRelatedPartyValue_iNP3us-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_di_zQLGa2GDHOP3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Preferred stock purchased from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--PreferredStockPurchasedFromRelatedPartyShares_iP3custom--PreferredStockPurchasedFromRelatedPartyValue_pp0p0_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDiB3ZTeOcm1" title="Preferred stock purchased from related party, shares" style="text-align: right">(<ix:nonFraction name="SBFM:PreferredStockPurchasedFromRelatedPartyShares" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">990,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SBFM:PreferredStockPurchasedFromRelatedPartyValue" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SBFM:PreferredStockPurchasedFromRelatedPartyValue" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTax_zfkbO017rwxe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Net (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,638</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,775,106</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,786,744</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20220630_eus-gaap--StockholdersEquity_iE_zQuM6w1thkg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt"><b>Balance at June 30, 2022</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVoVRyyMUTuh" title="Ending Balance shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,885,632</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,886</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,331,451</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zqXcEJUbeqsb" title="Ending Balance shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,777</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,430,280</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,886,280</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Three Month Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20210401__20210630_eus-gaap--StockholdersEquity_iS_z7VLfh9L0Hvd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt"><b>Balance March 31, 2021</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXsAzd1VvtC2" title="Beginnig Balance shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,325,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,222,073</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2krNunSNskh" title="Beginnig Balance shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,934</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,403,853</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,084,389</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_iP3us-gaap--SharesOutstanding_zBqCHLpn9rk8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Common stock issued for the reduction of notes payable and payment of interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesOther_iP3us-gaap--StockIssuedDuringPeriodValueOther_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi5zaYF29Jgc" title="Common stock issued for the reduction of note payable and payment of interest shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105,437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,097,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,097,435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ComprehensiveIncomeNetOfTax_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,702</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,879,054</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,885,756</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20210401__20210630_eus-gaap--StockholdersEquity_iE_zoA3ajZKOcE3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt"><b>Balance at June 30, 2021</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zciiOMOs3GG5" title="Ending Balance shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,430,466</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,430</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,319,403</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVtOpzGQ4bz6" title="Ending Balance shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,636</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,282,907</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">872,710</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Six Month Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20210101__20210630_eus-gaap--StockholdersEquity_iS_zSk05xCYSZNi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt"><b>Balance December 31, 2020</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9zstcpK8ctd" title="Beginnig Balance shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,732,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,165,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzWNxkEp3BIl" title="Beginnig Balance shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,871</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,218,727</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">954,837</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Common stock issued for the reduction of note payable and payment of interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWwGHRO3tnI6" title="Common stock issued for the reduction of note payable and payment of interest shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">398,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,236,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,237,072</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_iP3us-gaap--StockIssuedDuringPeriodSharesOther_zYnUa0RcRwzd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Common stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_iP3us-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWtjrV2DMhYe" title="Common stock issued for services shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">917,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">918,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTax_zpCzqZ9tbyN4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt">Net (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,765</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,064,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,072,945</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20210101__20210630_eus-gaap--StockholdersEquity_iE_z6Douuo8IIui" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt"><b>Balance at June 30, 2021</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSIKnoD4zNa" title="Ending Balance shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,430,466</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,430</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,319,403</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zu6qenzPQKw8" title="Ending Balance shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,636</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,282,907</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">872,710</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>



<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See Accompanying Notes.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sunshine Biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="q_005"></span>Notes to Unaudited Condensed Consolidated Financial
Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>For the Six Month Interim Periods Ended June 30, 2022 and 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAIBofJQo2X5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 1 &#8211;&#160;<span id="xdx_82E_zt1lXNVsyes9">Nature of Business</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunshine Biopharma, Inc. (the &#8220;Company&#8221;)
was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until
October 2009, the Company was operating as a business consultancy firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 15, 2009, the Company acquired
Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. held an exclusive license to a
new anticancer drug bearing the laboratory name, Adva-27a (the &#8220;License Agreement&#8221;). Upon completion of the reverse acquisition
transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the
development of the licensed Adva-27a anticancer drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, the Company acquired all worldwide
issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a
anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of
these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2018, the Company launched its first
Science-Based Nutritional Supplements product, Essential 9<span style="font-variant: small-caps"><sup>&#8482;</sup></span>, an over-the-counter
capsule comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9<span style="font-variant: small-caps"><sup>&#8482;&#160;</sup></span>has
been authorized for marketing by Health Canada under NPN 80089663.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 22, 2020, the Company filed a provisional
patent application in the United States for a new treatment for Coronavirus infections. The Company&#8217;s patent application covers
composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential
for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application
containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May
22, 2020 has been maintained in the newly filed PCT application. The Company&#8217;s lead Anti-Coronavirus compound arising from these
patents bears the laboratory name SBFM-PL4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 26, 2021, the Company received a Notice
of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains
new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2021, the Company received a Notice
of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject
matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued
in 2019 (US Patent Number 10,272,065).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company filed a patent
application for a potential new treatment for neurodegenerative disorders. The patent application contains experimental results showing
that certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics
neuronal degeneration. This new patent application has a priority date of October 1, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 9, 2022, the Company
completed a 200-for-1 reverse split of its common stock. On February 15, 2022, the Company entered into an underwriting agreement
with Aegis Capital Corp. as underwriter, for the issuance and sale in an underwritten public offering of 1,882,353 Units, each
consisting of one share of common stock and two warrants (&#8220;Tradeable Warrants&#8221;) to purchase shares of common stock at a
public offering price of $4.25 per Unit for total gross proceeds of $8,000,000 (&#8220;Public Offering&#8221;). On February 17,
2022, the Public Offering closed and the Company received net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember_zXezFsvjKvX7" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-02-162022-02-17_custom_AegisOfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,833,071</ix:nonFraction></span>.
Pursuant to the Public Offering, the Company issued and sold an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" title="Stock Issued During Period, Shares, New Issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-162022-02-17_custom_AegisOfferingMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,882,353</ix:nonFraction></span>
shares of common stock and <span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-02-162022-02-17_custom_AegisOfferingMember_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,102,200</ix:nonFraction></span>
Tradeable Warrants (including 337,494 Tradeable Warrants purchased at $0.01 per warrant resulting from partial exercise of the
overallotment option granted to the underwriter). In connection with these transactions, the Company&#8217;s shares of common stock
and Tradeable Warrants began trading on Nasdaq under the symbol &#8220;SBFM&#8221; for the common stock and &#8220;SBFMW&#8221; for
the Tradeable Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_z6ViKp5RC0Q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zxr5g0JjaCth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 7 -->
    <div id="xdx_231_zObZtOGekSTe" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zLJz572PPr8f" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td id="xdx_23B_zSTbwZ89oAi9" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zoMMGzPIEeNk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zlmYRlY45jWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2022, the Company entered
into a research agreement (the &#8220;SRA&#8221;) with the University of Arizona for the purposes of conducting research focused on
determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro
inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the &#8220;Research Project&#8221;). Under the SRA,
the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual
property developed by University of Arizona personnel under the Research Project. In addition, the Company and the University of
Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial
license for the underlying technology of the Research Project.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 22, 2022, the Company redeemed&#160;<span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220221__20220222_pdd"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2022-02-212022-02-22" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">990,000</ix:nonFraction>
</span>shares of the Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2022, the Company completed a private
placement wherein the Company sold (i)&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,301,353</ix:nonFraction></span>&#160;shares
of its common stock together with warrants (the &#8220;Investor Warrants&#8221;) to purchase up to&#160;<span id="xdx_908_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants1Member_pdd"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_InvestorWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,301,353</ix:nonFraction>
</span>shares of common stock, and (ii)&#160;<span id="xdx_90F_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,302,251</ix:nonFraction></span>&#160;pre-funded
warrants (&#8220;Pre-Funded Warrants&#8221;) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor
Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together
at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined
offering price of $2.219. The Company received approximately $8 million in gross proceeds, and $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_pp0p0"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,781,199</ix:nonFraction></span>&#160;in
net proceeds in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2022, the Company completed
another private placement and received net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_zIv0BXUmdJe6" title="Proceeds from Issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,752,915</ix:nonFraction></span>.
In connection with this private placement, the Company issued (i)&#160;<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFyQuhJjUdtk" title="Stock Issued During Period, Shares, New Issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,472,820</ix:nonFraction>&#160;</span>shares
of its common stock together with warrants (&#8220;April Warrants&#8221;) to purchase up to <span id="xdx_900_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants2Member_ztiM83NU0j7" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_InvestorWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,945,640</ix:nonFraction></span>
shares of common stock, and (ii)&#160;<span id="xdx_908_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants1Member_zaCHdbBo9hok" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_PreFundedWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,390,025</ix:nonFraction></span>&#160;pre-funded
warrants (&#8220;Pre-Funded Warrants&#8221;) with each Pre-Funded Warrant exercisable for one share of common stock, together with
April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants
were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold
together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at
a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001,
and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise
price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220428__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrsQ3EVo90nc" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-28_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.76</ix:nonFraction></span>
per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the
date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z4z0pGzB19ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note
2 &#8211; <span id="xdx_821_zM2MV1wCrL4g">Basis of Presentation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited financial statements of the Company
for the six month periods ended June 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted
in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation
S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United
States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring
adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of
operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The
balance sheet information as of December 31, 2021 was derived from the audited financial statements included in the Company's financial
statements as of and for the year ended December 31, 2021 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities
and Exchange Commission (the &#8220;SEC&#8221;) on March 21, 2022. These financial statements should be read in conjunction with that
report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="SBFM:ImpactOfCovid19PandemicTextBlock"><p id="xdx_807_ecustom--ImpactOfCovid19PandemicTextBlock_zeZjd7sj95Ne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 3 &#8211;&#160;<span id="xdx_823_zvNzyqp9M48d">Impact of Coronavirus
(COVID-19) Pandemic</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, the World Health Organization declared
Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are
continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate
the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on
the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of
the adverse conditions of the outbreak and their effects on the Company&#8217;s business or ability to raise funds. No adjustments have
been made to the amounts reported in the Company's financial statements as a result of this matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_z7M6Dgyy1gGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zIO36hSiDu1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zvZeCLAx9Oca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div id="xdx_23F_zA7HcbYRPpDe" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_236_zFGU3PrCXUsg" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zDlqjyJhrrK8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zjPensmtLI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="SBFM:ReverseStockSplitTextBlock"><p id="xdx_80F_ecustom--ReverseStockSplitTextBlock_zwi1bC5n35q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 4 &#8211;&#160;<span id="xdx_820_zJpsbtK6L983">Reverse Stock Splits</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 1, 2019, the Company
completed a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20190131__20190201__us-gaap--TransactionTypeAxis__custom--FirstReverseStockSplitMember" title="Stockholders&apos; Equity, Reverse Stock Split"><ix:nonNumeric contextRef="From2019-01-312019-02-01_custom_FirstReverseStockSplitMember" name="us-gaap:StockholdersEquityReverseStockSplit">20
to 1 reverse split</ix:nonNumeric></span>&#160;of its common stock (the &#8220;First Reverse Stock Split&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective April 6, 2020, the Company
completed another <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20200405__20200406__us-gaap--TransactionTypeAxis__custom--SecondReverseStockSplitMember" title="Stockholders&apos; Equity, Reverse Stock Split"><ix:nonNumeric contextRef="From2020-04-052020-04-06_custom_SecondReverseStockSplitMember" name="us-gaap:StockholdersEquityReverseStockSplit">20
to 1 reverse split</ix:nonNumeric></span>&#160;of its common stock (the &#8220;Second Reverse Stock Split&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 9, 2022, the Company
completed a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220208__20220209__us-gaap--TransactionTypeAxis__custom--ThirdReverseStockSplitMember" title="Stockholders&apos; Equity, Reverse Stock Split"><ix:nonNumeric contextRef="From2022-02-082022-02-09_custom_ThirdReverseStockSplitMember" name="us-gaap:StockholdersEquityReverseStockSplit">1
for 200 reverse split</ix:nonNumeric></span>&#160;of its common stock (the &#8220;Third Reverse Stock Split&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's financial statements reflect the
First, Second, and Third Reverse Stock Split on a retroactive basis for all periods presented and for all references to common stock,
unless specifically stated otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zclClVkoWcSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 5 &#8211;&#160;<span id="xdx_82C_z0XWrLffMlva">Notes Payable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022 and December 31, 2021, the
Company had $-<span id="xdx_904_eus-gaap--NotesPayable_iI_c20220630_z4hJEkHnWqV4"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>- and $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20211231_zi8I1eAmG42g"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,900,000</ix:nonFraction></span>, respectively in notes payable outstanding. At June 30, 2022 and December 31, 2021, total
accrued interest on Notes Payable was $-<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_c20220630_pp0p0" title="Interest Payable"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>- and $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_c20211231_pp0p0" title="Interest Payable"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,287</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Notes Payable at December
31, 2021 consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2021, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zPPcoqZCDRSe" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-04-20_custom_NotePayable20211Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>
with interest accruing at&#160;<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210419__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zwm5d5RTlfy7" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-04-192021-04-20_custom_NotePayable20211Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
due&#160;<span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210419__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zHz4IQAMnoTl" title="Maturity Date"><ix:nonNumeric contextRef="From2021-04-192021-04-20_custom_NotePayable20211Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">April
20, 2023</ix:nonNumeric></span>. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On
February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $<span id="xdx_90C_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-02-162022-02-17_custom_NotePayable20211Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,753</ix:nonFraction></span>&#160;by
making a cash payment of $<span id="xdx_903_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0" title="Repayments of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-02-162022-02-17_custom_NotePayable20211Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">520,753</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company received monies in
exchange for a Note Payable having a Face Value of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-07-06_custom_NotePayable20212Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">900,000</ix:nonFraction></span>&#160;with interest accruing at&#160;<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210705__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_zfA2y1eRgnsh" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-07-052021-07-06_custom_NotePayable20212Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%, due&#160;<span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210705__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_z7TCLKqxPGqf" title="Maturity Date"><ix:nonNumeric contextRef="From2021-07-052021-07-06_custom_NotePayable20212Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">July 6, 2023</ix:nonNumeric></span>. The Note was
convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid
off the entire principal balance of this Note, together with accrued interest of $<span id="xdx_90F_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-02-162022-02-17_custom_NotePayable20212Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,863</ix:nonFraction></span>&#160;by making a cash payment of $<span id="xdx_900_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Repayments of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-02-162022-02-17_custom_NotePayable20212Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">927,863</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-08-18_custom_NotePayable20213Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>&#160;with interest accruing at&#160;<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210817__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_zkcwCKnbVo" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-08-172021-08-18_custom_NotePayable20213Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%, due&#160;<span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210817__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_zbecLUAMckU7" title="Maturity Date"><ix:nonNumeric contextRef="From2021-08-172021-08-18_custom_NotePayable20213Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August 18, 2023</ix:nonNumeric></span>. The Note
was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company
paid off the entire principal balance of this Note, together with accrued of $<span id="xdx_90E_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-02-162022-02-17_custom_NotePayable20213Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,534</ix:nonFraction></span>&#160;by making a cash payment of $<span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Repayments of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-02-162022-02-17_custom_NotePayable20213Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">512,534</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zojQFM97v0k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 6 &#8211;&#160;<span id="xdx_826_zMBU3igjlIM8">Shareholders&#8217;
Equity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17, 2022, the Company&#8217;s Public
Offering closed and the Company received net proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20220201__20220217_zNiKKGiuH9La" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-02-012022-02-17" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,833,071</ix:nonFraction></span>&#160;from the offering. Pursuant to the Public Offering, the Company
issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 Tradeable Warrants (including 337,494 Tradeable Warrants
resulting from partial exercise of the overallotment option granted to the underwriter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 22, 2022, the Company
redeemed&#160;<span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220201__20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Redeemed shares"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2022-02-012022-02-22_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">990,000</ix:nonFraction></span>
shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $<span id="xdx_90A_eus-gaap--PreferredStockRedemptionPricePerShare_c20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Redemption price"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2022-02-22_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span>&#160;per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_z3thBhbCkiK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_z3waXQtFJZTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div id="xdx_23A_zjt8CiuDX8if" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_23B_zZPbRBDYZnEd" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zGJqLpGTPrMj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zBPutEKSs9fl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2022, the Company completed a private
placement and received net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_zMp0U0uSN8Xh" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,781,199</ix:nonFraction></span>. In connection with this private placement, the Company issued (i)&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Stock Issued During Period, Shares, New Issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,301,353</ix:nonFraction></span>&#160;shares
of its common stock together with investor warrants (&#8220;Investor Warrants&#8221;) to purchase up to 2,301,353 shares of common stock,
and (ii)&#160;<span id="xdx_90E_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zA2FPkQpk4ah" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,302,251</ix:nonFraction></span>&#160;pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;) with each Pre-Funded Warrant exercisable for one
share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock
and accompanying Investor Warrant were sold together at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying
Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a
nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor
Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance
and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2022, the Company completed another
private placement and received net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_znVYp6jYYmB4" title="Proceeds from Issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,752,915</ix:nonFraction></span>. In connection with this private placement, the Company issued (i)&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zoXANp3cjiw7" title="Stock Issued During Period, Shares, New Issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,472,820</ix:nonFraction></span>&#160;shares
of its common stock together with warrants (&#8220;April Warrants&#8221;) to purchase up to <span id="xdx_900_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants2Member_pdd" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_InvestorWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,945,640</ix:nonFraction></span> shares of common stock, and (ii)&#160;<span id="xdx_904_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants1Member_pdd" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_PreFundedWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,390,025</ix:nonFraction></span>&#160;pre-funded
warrants (&#8220;Pre-Funded Warrants&#8221;) with each Pre-Funded Warrant exercisable for one share of common stock, together with April
Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and
accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying
two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at
a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April
Warrants have an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220428__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-28_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.76</ix:nonFraction></span> per share (subject
to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company declared&#160;<span id="xdx_90F_eus-gaap--Dividends_pp0p0_do_c20220101__20220630_zBDcFb5wh1jl" title="Dividends"><ix:nonFraction name="us-gaap:Dividends" contextRef="From2022-01-01to2022-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>&#160;dividends through
June 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="SBFM:WarrantsDisclosureTextBlock"><p id="xdx_807_ecustom--WarrantsDisclosureTextBlock_zFMrKuaeW6uk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 7 &#8211; <span id="xdx_822_zTk2EsEnNZk1">Warrants</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5pt 0pt 0; text-align: justify">The Company accounts for issued warrants
either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if
they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not
meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants
should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless
of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance
date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the
consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order
to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether
the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for
at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.6pt 0pt 0; text-align: justify">During the six months ended June 30,
2022, the Company completed three financing events, and in connection therewith, it issued warrants as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="SBFM:WarrantsIssuedWithFinancingTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_892_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zNwwGIHXQWqg" summary="xdx: Disclosure - Warrants (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span id="xdx_8B8_zHel6mXOVqJ5" style="display: none">Warrants issued with financing</span></td>
    <td style="padding-left: 38.8pt">&#160;</td>
    <td style="padding-left: 45.2pt">&#160;</td>
    <td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td>
    <td id="xdx_98E_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" title="Number of shares" style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SBFM:WarrantsIssuedShares" contextRef="From2022-01-012022-06-30_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,692,276</ix:nonFraction></span></td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights" style="padding-left: 45.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z9fDsmqiipj4" title="Warrant Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-06-30_custom_PreFundedWarrantsMember" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td>
    <td id="xdx_987_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Number of shares" style="padding-left: 38.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SBFM:WarrantsIssuedShares" contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,102,200</ix:nonFraction></span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_fKg_____z74M9jRRZxDh" title="Class of Warrant or Right, Exercise Price of Warrants or Rights" style="padding-left: 45.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_custom_TradeableWarrantsMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.22</ix:nonFraction>*</span></td>
    <td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember" title="Warrant Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember" name="SBFM:WarrantExpirationDate">February 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td>
    <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Number of shares" style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SBFM:WarrantsIssuedShares" contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,603,604</ix:nonFraction></span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights" style="padding-left: 45.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.22</ix:nonFraction></span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span id="xdx_901_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember" title="Warrant Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember" name="SBFM:WarrantExpirationDate">March 2027</ix:nonNumeric></span> &#160; &#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April Warrants</span></td>
    <td id="xdx_981_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" title="Number of shares" style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="SBFM:WarrantsIssuedShares" contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,725,690</ix:nonFraction></span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zVMa7JU4jioh" title="Class of Warrant or Right, Exercise Price of Warrants or Rights" style="padding-left: 45.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_custom_AprilWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.76</ix:nonFraction></span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember" title="Warrant Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember" name="SBFM:WarrantExpirationDate">April 2027</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td id="xdx_F0A_zTXk34pRSl4i" style="padding-left: 10pt; text-indent: -10pt; width: 3%">*</td>
  <td id="xdx_F15_zcKElZ7CBjz9" style="width: 97%"><ix:footnote id="Footnote000710" xml:lang="en-US">The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#8217;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.</ix:footnote></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A9_zZZZDsrAp9f3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55pt 0pt 0">During the six months ended June 30, 2022, all of the Pre-Funded
Warrants and a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zGyR0xDlg9cg" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,138,507</ix:nonFraction></span> Tradeable Warrants were exercised resulting in aggregate proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pp0p0" title="Proceeds from Warrant Exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,971,178</ix:nonFraction></span> received by the Company.
In addition, during the six months ended June 30, 2022, a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zxNm0NWhikaj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,802,703</ix:nonFraction></span> Investor Warrants and -<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zDLU153xNiQ3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>- April Warrants were exercised resulting
in aggregate proceeds of $ $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsAndAprilWarrantsMember_zJrmPrF0Mcdi"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsAndAprilWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,222,001</ix:nonFraction></span> received by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_233_zv4ezurUu7ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zMEXdo6EHh67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_z6mLkRrscsYd" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td id="xdx_23C_zzENl878LA33" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zZc5FDcD4tN2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_z2JYeRuEmnXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s outstanding warrants at June 30, 2022 consisted
of the following:&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zs4LKBBWTYh1" summary="xdx: Disclosure - Warrants (Details 1)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span id="xdx_8BB_zRoQ62lWN0z9" style="display: none">Schedule of outstanding warrants</span></td>
    <td style="padding-left: 38.75pt">&#160;</td>
    <td style="padding-left: 45.2pt">&#160;</td>
    <td style="padding-left: 29.9pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td>
    <td style="border-bottom: Black 1pt solid; padding-left: 38.75pt; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td>
    <td style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zruZdMIt0SP9" title="Class of Warrant or Right, Exercise Price of Warrants or Rights" style="padding-left: 45.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></td>
    <td style="padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember" title="Warrant Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-06-30_custom_PreFundedWarrantsMember" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zQz5KJiyVh3i" title="Class of Warrant or Right, Outstanding" style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-06-30_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">963,693</ix:nonFraction></span></td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights" style="padding-left: 45.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.22</ix:nonFraction></span></td>
    <td style="padding-left: 29.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zBwIDdqIx9Sj" title="Warrant Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember" name="SBFM:WarrantExpirationDate">February 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding" style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-06-30_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,901</ix:nonFraction></span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_z9EWSQI6H2R4" title="Class of Warrant or Right, Exercise Price of Warrants or Rights" style="padding-left: 45.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.22</ix:nonFraction></span></td>
    <td style="padding-left: 29.9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zmeTYt42lSJd" title="Warrant Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember" name="SBFM:WarrantExpirationDate">March 2027</ix:nonNumeric></span> &#160; &#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>April Warrants </td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding" style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-06-30_custom_AprilWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,725,690</ix:nonFraction></span></td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zlxMhAV6v2vd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights" style="padding-left: 45.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_custom_AprilWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.76</ix:nonFraction></span></td>
    <td style="padding-left: 29.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zNSXivnrEYn" title="Warrant Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember" name="SBFM:WarrantExpirationDate">April 2027</ix:nonNumeric></span></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zymYOMYDsxH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zBGzjx2UgKuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 8 &#8211;&#160;<span id="xdx_82F_zRFkWoVQ7D42">Net Loss Per Common
Share</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is calculated by dividing
the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common
stock equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted net loss per share is calculated by dividing
the net loss by the weighted-average number of shares of common stock outstanding during the period, taking into consideration common
stock equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2022, the Company
issued&#160;<span id="xdx_902_ecustom--WarrantsIssuedNewShares_c20220201__20220228__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zJOr9LNc4Haa" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-02-012022-02-28_custom_AegisOfferingMember_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,102,200</ix:nonFraction></span>&#160;Tradeable
Warrants pursuant to the Company&#8217;s Public Offering. In March and April 2022, the Company issued <span id="xdx_906_ecustom--WarrantsIssuedNewShares_c20220401__20220422__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zLtdZnW6zXOd" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,603,604</ix:nonFraction></span>
Investor Warrants and <span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20220401__20220422__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zmoOgbNWMhSh" title="Warrants issued new, shares"><ix:nonFraction name="SBFM:WarrantsIssuedNewShares" contextRef="From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_AprilWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,725,690</ix:nonFraction></span>
April Warrants pursuant to two private placements. As of June 30, 2022, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,138,507</ix:nonFraction></span>
Tradeable Warrants, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zGgoJ3U13c58" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,802,703</ix:nonFraction></span>
Investor Warrants, and -<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_z6EonkBgpa99" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>-
April Warrants were exercised, leaving&#160;<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-06-30_custom_TradeableWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">963,693</ix:nonFraction></span>
Tradeable Warrants, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zMKuuL71SByl" title="Class of Warrant or Right, Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-06-30_custom_InvestorWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,901</ix:nonFraction></span>
Investor Warrants and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_ze7R5CLzo3Oh" title="Class of Warrant or Right, Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-06-30_custom_AprilWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,725,690</ix:nonFraction></span>
April Warrants outstanding. These warrants are dilutive and were included in the diluted earnings per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March and April 2022, the Company issued and
sold Pre-Funded Warrants to purchase an aggregate of 3,692,276 shares of common stock at a nominal exercise price of $0.001 per share
(see Note 3). During the six months ended June 30, 2022, all of these warrants were exercised and therefore had no remaining dilutive
effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="SBFM:ManagementCompensationAndDirectorFeesTextBlock"><p id="xdx_807_ecustom--ManagementCompensationAndDirectorFeesTextBlock_z5KkuBDQuDgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note
9 &#8211;&#160;<span id="xdx_822_zDX5ip8QyHte">Management and Director Compensation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid its officers cash
compensation totaling $<span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20220401__20220630_zY34y1KauwCh" title="Salary and Wage, Excluding Cost of Good and Service Sold"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,000</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20210401__20210630_z8RKq5WXxuM9" title="Salary and Wage, Excluding Cost of Good and Service Sold"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span>
and $<span id="xdx_909_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20220101__20220630_z2yvUYFcjz6b" title="Salary and Wage, Excluding Cost of Good and Service Sold"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">510,000</ix:nonFraction></span>
and $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20210101__20210630_zslTEogdehVi" title="Salary and Wage, Excluding Cost of Good and Service Sold"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,927</ix:nonFraction></span>
for the three and six month periods ended June 30, 2022 and 2021, respectively. Of these amounts attributable to the Company&#8217;s
CEO, $<span id="xdx_90B_eus-gaap--SalariesWagesAndOfficersCompensation_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrtPharmaMember_pp0p0" title="Salary and Wage, Excluding Cost of Good and Service Sold"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2022-01-012022-06-30_custom_TrtPharmaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">110,000</ix:nonFraction></span>
was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. In addition, the
Company issued&#160;<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pdd" title="Stock Issued During Period, Shares, Issued for Services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-06-30_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span>
shares of common stock valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pp0p0" title="Stock Issued During Period, Value, Issued for Services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-06-30_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">918,000</ix:nonFraction></span>
to its officers during the three months ended June 30, 2021. The value of these shares was based upon the closing price of the
Company&#8217;s common stock of $3.06 on the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid its directors cash
compensation totaling $<span id="xdx_90E_eus-gaap--NoninterestExpenseDirectorsFees_c20220401__20220630_zJEt2gt7y3X4"><span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20220101__20220630_zwnSBMje7uxk"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></ix:nonFraction></span></span>
and $-<span id="xdx_900_eus-gaap--NoninterestExpenseDirectorsFees_c20210101__20210630_zzSMlS5lHqmc"><span id="xdx_900_eus-gaap--NoninterestExpenseDirectorsFees_c20210401__20210630_zAcALotU9KSb"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span>- for the three and six
month periods ended June 30, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_819_zctOpKsZwN31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_002"></span>Item 2. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
should be read in conjunction with our consolidated financial statements and notes thereto included herein. This discussion includes&#160;forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the
Securities Exchange Act of 1934, as amended, or the Exchange Act. The statements regarding Sunshine Biopharma, Inc. contained in this
Report that are not historical in nature, particularly those that utilize terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221;
&#8220;likely,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;believes&#8221; or &#8220;plans,&#8221;
or comparable terminology, are forward-looking statements based on current expectations and assumptions, and entail various risks and
uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important
factors known to us that could cause such material differences are identified in this report and in our annual report on Form 10-K for
the year ended December 31, 2021. We undertake no obligation to correct or update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as may be required under applicable law. You are advised, however, to consult any
future disclosures we make on related subjects in future reports to the SEC</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a pharmaceutical and
nutritional supplement company focusing on the research and development of proprietary drugs including our anticancer compound Adva-27a,
our anticancer K1.1 mRNA molecules, and anti-coronavirus lead compound, SBFM-PL4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also, through our wholly
owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;), develop science-based nutritional supplements,
and currently sell one nutritional supplement product, Essential 9<span style="font-variant: small-caps"><sup>tm</sup></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Proprietary Drug Development
Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>SBFM-PL4 Anti-Coronavirus Treatment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the development to date of our coronavirus treatment project:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus infections. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the Coronavirus main protease (Mpro) and papain-like protease (PLpro).&#160;&#160;Both enzymes are essential for viral replication. In addition to being involved in maturation of specific viral proteins, PLpro is responsible for suppression of the human immune system making the virus more virulent. The small molecules covered by the patent application were designed by Dr. Steve N. Slilaty, our chief executive officer. The patent application has a priority date of May 22, 2020.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">In August 2020, we completed the synthesis of four different potential inhibitors of PLpro. These compounds are based on the technology described in our patent application filed on May 22, 2020.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">In September 2020, we completed the screening of our four compounds and subsequently identified a lead Anti-Coronavirus drug candidate (SBFM-PL4). The screening which pinpointed the lead compound was performed at the University of Georgia, College of Pharmacy under the leadership of Dr. Scott D. Pegan, Director of the Center for Drug Discovery at the time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The next steps in our SBFM-PL4 drug development plan will involve conducting additional in vitro studies followed by cell culture assays and assessment in Coronavirus infected mice before entering human clinical trials.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">In February 2022, we expanded our search for additional PLpro inhibitors by entering into a research agreement with the University of Arizona for the purposes of conducting research focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2
(the &#8220;Research Project&#8221;). Under the agreement, the University of Arizona granted the Company a first option to negotiate a
commercial, royalty-bearing license for all intellectual property developed by University of Arizona personnel under the Research Project.
In addition, the Company and the University of Arizona entered into an Option Agreement whereby the Company was granted a first option
to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adva-27a Anticancer Compound</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the area of oncology, our
proprietary drug development activities have been focused on the development of a small molecule called Adva-27a for the treatment of
aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer
cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER
RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued patents pertaining to Adva-27a including
U.S. Patents Number 8,236,935 and 10,272,065.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_001.gif" alt="" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Figure 1</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adva-27a is a GEM-difluorinated
C-glycoside derivative of Podophyllotoxin (see Figure 1). Another derivative of Podophyllotoxin called Etoposide is currently on the market
and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer,
bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used
anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding
enzyme, Topoisomerase II. Unlike Etoposide however, Adva-27a is able to penetrate and destroy Multidrug Resistant Cancer cells. In addition,
Adva-27a has been shown to have distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side
studies using Multidrug Resistant Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly greater cell killing activity
(see Figure 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_002.gif" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Figure 2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The next sequence of steps
in our Adva-27a development program includes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">GMP Manufacturing of 2 kilograms for use in IND-Enabling Studies and Phase I Clinical Trials</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">IND-Enabling Studies</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Regulatory Filing (Fast-Track status anticipated)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase I Clinical Trials (Pancreatic Cancer indication)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adva-27a&#8217;s initial indication
will be pancreatic cancer for which there are currently little or no treatment options available. We are planning to conduct our clinical
trials at McGill University&#8217;s Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will employ
FDA standards at all levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the American
Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. While particularly effective against Multidrug
Resistant Cancer, we believe Adva-27a can potentially treat all cancer types, particularly those in which Topoisomerase II has been amplified.
We believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies
to purchase or license our drug. However, there are no assurances that our Phase I Trials will be successful, or if successful, that any
pharmaceutical companies will make an acceptable offer to us. In the event we do not consummate such a transaction, we will require significant
capital in order to secure regulatory approval, manufacture and market our new drug on our own.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>K1.1 Anti-cancer mRNA</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2021, we initiated
a new research project in which we set out to determine if certain mRNA molecules can be used as anti-cancer agents. The data collected
to date have shown that a selected group of mRNA molecules are capable of destroying cancer cells in vitro including multidrug resistant
breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Other studies using non-transformed
(normal) human cells (HMEC cells) showed that these mRNA molecules had little cytotoxic effects. These new mRNA molecules, bearing the
laboratory name K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology. In April 2022, we filed a provisional
patent application in the United States covering the subject mRNA molecules. We plan to commence mice xenograft studies within approximately
the next twelve months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Nutritional Supplements
Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our wholly owned Canadian
subsidiary, Sunshine Canada, focuses on the development and marketing of science-based nutritional supplements. In December 2018, we completed
the development of our first nutritional supplement product which we named Essential 9<span style="font-variant: small-caps"><sup>&#8482;</sup></span>.
On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized us to manufacture and sell the Essential 9&#8482;
product. Our Essential 9&#8482; nutritional supplement product was originally launched as a tablet and has now been reformatted into vegan
capsules. Our Essential 9<span style="font-variant: small-caps"><sup>tm</sup></span> capsules contain a balanced formula of the 9 Essential
Amino Acids that the human body cannot make. Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins
are involved in all body functions &#8211; From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential
Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids
can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Our Essential 9&#8482; provides
all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9&#8482; is currently available
on Amazon.com and Amazon.ca. Figure 3 below shows our reformatted 60-Capsule Essential 9&#8482; product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_001.jpg" alt="" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Figure 3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we received
Health Canada approval for another nutritional supplement, a new Calcium-Vitamin D tablet. Health Canada issued NPN 80093432 through which
it authorized us to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin D&#8482;.
Vitamin D is a group of steroid-like molecules responsible for increasing intestinal absorption of calcium, magnesium, and phosphate.
They are also involved in multiple other biological functions, including proper functioning of the immune system, promoting healthy growth
of bone, and reduction of inflammation. The most important compounds in this group are ergocalciferol (Vitamin D2) and cholecalciferol
(Vitamin D3). Sunshine Biopharma&#8217;s Essential Calcium-Vitamin D&#8482; tablets contain both of these compounds as well as calcium
for optimum health benefits. We are considering potentially launching this product in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also developing additional
nutritional supplement products. We may launch additional nutritional supplement products in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparison of results of operations for
the three months ended June 30, 2022 and 2021</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
June 30 2022, we generated revenues of $150,307, compared to revenue of $52,874 for the three months ended June 30, 2021. The increase
is attributable to new advertising campaigns. All of these revenues were generated from our science-based nutritional supplements operations.
The direct cost for generating these revenues was $74,683 for the three months ended June 30, 2022 (49.7%), compared to $18,515 (35.0%)
for the three months ended June 30, 2021. The increase in cost of sales in 2022 is due to increased cost of manufacturing. Our gross profit
increased to $75,624 for the three months ended June 30, 2022, compared to a gross profit of $34,359 for the same period in 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses during the three month period ended June 30, 2022 were $771,420 compared to $422,957 during the three month period ended June
30, 2021, an increase of $348,463. Overall, we incurred a loss of $695,796 from our operations in the three month period ended June 30,
2022, compared to a loss from operations of $388,598 in the similar period of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we had interest
income of $146,043, interest expense of $0, and debt release of $10,852 during the three months ended June 30, 2022, compared to interest
income of $2, interest expense of $195,630, and debt release of $221 during the three months ended June 30, 2021. This was primarily due
to the transitioning of our financing from convertible debt to equity. We incurred no losses related to debt conversion during the three
months ended June 30, 2022, compared to $2,295,057 in losses arising from debt conversion during the three months ended June 30, 2021.
This was also due to the transitioning of our financing from convertible debt to equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we incurred a
net loss of $538,872 for the three month period ended June 30, 2022, compared to a net loss of $2,879,054 for the three month period ended
June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Comparison of results of operations for the
six months ended June 30, 2022 and 2021</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30 2022, we generated revenues of $272,952, compared to revenue of $92,932 for the six months ended June 30, 2021. The increase is
attributable to new advertising campaigns. All of these revenues were generated from our science-based nutritional supplements operations.
The direct cost for generating these revenues was $134,528 for the six months ended June 30, 2022 (49.3%), compared to $37,035 (39.9%)
for the six months ended June 30, 2021. The increase in cost of sales in 2022 is due to increased cost of manufacturing. Our gross profit
increased to $138,424 for the six months ended June 30, 2022, compared to a gross profit of $55,897 for the same period in 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses during the six month period ended June 30, 2022 were $2,057,584 compared to $1,720,141 during the six month period ended June
30, 2021, an increase of $337,443. Overall, we incurred a loss of $1,919,160 from our operations in the six month period ended June 30,
2022, compared to a loss from operations of $1,664,244 in the similar period of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we had interest
income of $146,046, interest expense of $12,864, and debt release of $10,852 during the six months ended June 30, 2022, compared to interest
income of $2, interest expense of $245,341, and debt release of $51,252 during the six months ended June 30, 2021. This was primarily
due to the transitioning of our financing from convertible debt to equity. We incurred no losses related to debt conversion during the
six months ended June 30, 2022, compared to $7,205,843 in losses arising from debt conversion during the six months ended June 30, 2021.
This was also due to the transitioning of our financing from convertible debt to equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we incurred a
net loss of $1,775,106 for the six month period ended June 30, 2022, compared to a net loss of $9,064,180 for the six month period ended
June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of June 30, 2022, we had cash and cash equivalents
of $41,727,775.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $1,878,010 during the six months ended June 30, 2022, compared to $916,207 during the six month period ended June 30, 2021.
The increase was a result of expenses related to the three equity financings we completed in February, March and April 2022.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash flows provided by financing
activities were $41,561,363 for the six months ended June 30, 2022, compared to $1,652,648 for the six month period ended June 30, 2021.
The increase was a result of the three equity financings we completed in February, March and April 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash flows used in investing
activities were $0 for the six months ended June 30, 2022, compared to $0 for the six month period ended June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not generating adequate
revenues from our operations to fully implement our business plan as set forth herein. On February 17, 2022, we received net proceeds
of approximately $6.8 million from the sale of common stock and warrants in an underwritten public offering. On March 14, 2022, we received
net proceeds of approximately $6.8 million from the sale of common stock and warrants in a private placement. On April 28, 2022, we received
net proceeds of approximately $16.8 million from the sale of common stock and warrants in a private placement. We believe our existing
cash will be sufficient to fund our operations, including general and administrative expenses, expanded research and development activities,
and nutritional supplement business, for the next 24 months.&#160;There is no assurance our estimates will be accurate. We have no committed
sources of capital and we anticipate that we will need to raise additional capital in the future, including for further research and development
activities and possibly clinical trials. Additional capital may not be available on terms acceptable to us, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Critical Accounting Policies and
Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Critical Accounting Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussion and analysis
of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States.&#160;The preparation of these financial statements requires us to make
estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that
are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.&#160;&#160;Actual results may differ from these estimates
under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a detailed list of significant
accounting policies, please see our annual report on Form 10-K for the fiscal year ended December 31, 2021, including our financial statements
and notes thereto included therein as filed with the SEC on March 21, 2022,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recently Adopted Accounting Standards</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, the FASB
issued ASU 2020-02,&#160;<i>Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant
to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02,
Leases (Topic 842)&#160;</i>which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13
and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022.
The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material
impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB issued
ASU 2020-06,&#160;<i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts
in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</i>, (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies the accounting for certain
financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s
own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those
fiscal years.&#160;Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim
periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>G. Off Balance-Sheet Arrangements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_003"></span>Item 3. Quantitative and Qualitative Disclosures
About Market Risk.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting
company and are not required to provide the information under this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_004"></span>Item 4. Controls and Procedures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Evaluation of Disclosure Controls and
Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These controls are designed
to ensure that information required to be disclosed in the reports we file or submit pursuant to the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such
information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required
disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on this evaluation,
our management, including our CEO and CFO concluded that our disclosure controls and procedures were effective as of June 30, 2022, at
reasonable assurance level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Changes in Internal Control Over
Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal control over financial reporting during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_005"></span>PART II. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_006"></span>Item 1. Legal Proceedings.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not party to, and our
property is not the subject of, any material legal proceedings.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_007"></span>Item 1A. Risk Factors.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting
company and are not required to provide the information under this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_008"></span>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
June 30, 2022, the Company issued 2,802,703 shares of common stock upon exercise of warrants with an exercise price of $2.22, and 3,692,276
shares of common stock upon exercise of pre-funded warrants with an exercise price of $0.001.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the foregoing,
we relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions
not involving a public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_009"></span>Item 3. Defaults Upon Senior Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_010"></span>Item 4. Mine Safety Disclosures. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not Applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_011"></span>Item 5. Other Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_012"></span>Item 6. Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: justify"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 89%; text-align: justify"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">31.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="sunshinebio_ex3101.htm"><span style="font-size: 10pt">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">31.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="sunshinebio_ex3102.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2022*</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">32.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="sunshinebio_ex3201.htm"><span style="font-size: 10pt">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">101</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.*</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">*</span></td>
    <td><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">**</span></td>
    <td><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_013"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized, on August 3, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>SUNSHINE BIOPHARMA, INC.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 54%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td>
    <td style="width: 6%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Dr. Steve N. Slilaty</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dr. Steve N. Slilaty</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer (principal executive officer)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ Camille Sebaaly</span></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Camille Sebaaly</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer (principal financial and accounting officer)</p></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sunshinebio_ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exhibit 31.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 USC, SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Dr. Steve N. Slilaty, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 27px; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: August 3, 2022</FONT></TD>
    <TD STYLE="width: 52%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>/s/ Dr. Steve N. Slilaty</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Steve N. Slilaty, Chief Executive Officer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sunshinebio_ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exhibit 31.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 USC, SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Camille Sebaaly, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 27px; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: August 3, 2022</FONT></TD>
    <TD STYLE="width: 52%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>/s/ Camille Sebaaly</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Camille Sebaaly, Chief Financial Officer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sunshinebio_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 USC, SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this quarterly
report of Sunshine Biopharma, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarterly period ended June 30, 2022, as filed with
the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we, the undersigned, in the capacities and on the
date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 27px; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: August 3, 2022</FONT></TD>
    <TD STYLE="width: 52%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>/s/ Dr. Steve N. Slilaty</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Steve N. Slilaty, Chief Executive Officer</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: August 3, 2022</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>/s/ Camille Sebaaly</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Camille Sebaaly, Chief Financial Officer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EAX    7   "'Y! $  /P +     #@   !AP      ,P  9@  F0
MS   _P K   K,P K9@ KF0 KS  K_P!5  !5,P!59@!5F0!5S !5_P"   "
M,P" 9@" F0" S " _P"J  "J,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5
MS #5_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3, S#, _S,K #,K
M,S,K9C,KF3,KS#,K_S-5 #-5,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3.
MS#. _S.J #.J,S.J9C.JF3.JS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_
M,S/_9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68K
MS&8K_V95 &95,V959F95F695S&95_V:  &: ,V: 9F: F6: S&: _V:J &:J
M,V:J9F:JF6:JS&:J_V;5 &;5,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_
MS&;__YD  )D ,YD 9ID F9D S)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5
M,YE59IE5F9E5S)E5_YF  )F ,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJ
MS)FJ_YG5 )G5,YG59IG5F9G5S)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
M,\P 9LP F<P S,P _\PK ,PK,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5
MS,Q5_\R  ,R ,\R 9LR F<R S,R _\RJ ,RJ,\RJ9LRJF<RJS,RJ_\S5 ,S5
M,\S59LS5F<S5S,S5_\S_ ,S_,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\
MS/\ __\K /\K,_\K9O\KF?\KS/\K__]5 /]5,_]59O]5F?]5S/]5__^  /^
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MM> 0&$<:YJCCBF$Y)1=HN]QQUW$9X6@DA@[R:%\TD^V3SQB2L*;0+B4RA&*
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G^;>.'*V1G!D=.\EB.6T!E,F:O,F<W,F>_,G/:,FB/,JD7!@! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M-QBVG1CXB?\!0%\(WG!<@3<(&988F>S9W*Q"JOA=#)\6B,8DYVT')JKTU6/
M<3&H!1VORYZW)*;$9+*"B-,J8Q^G'1JP@AL"31(#9 DB&T.VG(+W:K+?$8-&
MC=V)<:Y AR*HX@V3\*L=N)A&QZ6_TS7)'[/B?8<IK9OFBNR_^;6Z0EB8;OJP
MD/(BV!U!Q!B\3YO[N $N61:>-'''Q)BK3('*3-QO<]%AR.D^FP[87(#1,BFD
M@WH"@*+/R\E(<R/Q)G=NS?SNJ&]S.^\98(T[[P/NN@6>B2/+XE6G+9#13F*
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&UALD(  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!D17AI9@  34T *@    @ !0$2  ,
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M/A?\0[[Q'X<\->,M)OY;P#4]0MX;*XUJS2ZTK6+1PA+B%FDO8Q*B-C,,JAU
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M&D0WUMJ^FZQ=:EJ,<ZY261YS$TD;;F&-R+\O!&X<#(K\3?\ @LIX*UCXB?\
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M.K7=^1\%_P##PRSTKQCX4N-'T:Z\.Z/_ &Y;:OXDAM=.LVN1&MKH >VT^?\
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M?M3^#/B;\-?$6E^&9O$/B(7FD7B_VAI_AG4I-(B MY&W/J!MQ9@'&!B4DE@
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ML/V[48;?)032+&&X.TDTUF\U#_#W/YFHH)FM)5D63YE8%6'J*96R/F[X*_M
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M^!;>#_A[>>"=%:[\%0^&=1U"]T06UYJ%W9V=U%:WPFMA\DERURT5V[)(S6^
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MC._CI7]8W@O_ (-]_P!D?P,D)C^$T.J31P"W:35==U*^$O3+M')<&/><?>5
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--4K3G\3 ****R __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sbfm-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaiByaPty552OYkxvmR/fZkarywnEqAG6i8atOGWYbcK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:SBFM="http://sunshinebiopharma.com/20220630" elementFormDefault="qualified" targetNamespace="http://sunshinebiopharma.com/20220630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" id="StatementsOfShareholdersEquity">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NatureOfBusiness" id="NatureOfBusiness">
	  <link:definition>00000007 - Disclosure - Nature of Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/BasisOfPresentation" id="BasisOfPresentation">
	  <link:definition>00000008 - Disclosure - Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic" id="ImpactOfCoronavirusCovid-19Pandemic">
	  <link:definition>00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" id="ReverseStockSplits">
	  <link:definition>00000010 - Disclosure - Reverse Stock Splits</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000011 - Disclosure - Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ShareholdersEquity" id="ShareholdersEquity">
	  <link:definition>00000012 - Disclosure - Shareholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/Warrants" id="Warrants">
	  <link:definition>00000013 - Disclosure - Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
	  <link:definition>00000014 - Disclosure - Net Loss Per Common Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" id="ManagementAndDirectorCompensation">
	  <link:definition>00000015 - Disclosure - Management and Director Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsTables" id="WarrantsTables">
	  <link:definition>00000016 - Disclosure - Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" id="NatureOfBusinessDetailsNarrative">
	  <link:definition>00000017 - Disclosure - Nature of Business (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" id="ReverseStockSplitsDetailsNarrative">
	  <link:definition>00000018 - Disclosure - Reverse Stock Splits (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000019 - Disclosure - Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
	  <link:definition>00000020 - Disclosure - Shareholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetails" id="WarrantsDetails">
	  <link:definition>00000021 - Disclosure - Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetails1" id="WarrantsDetails1">
	  <link:definition>00000022 - Disclosure - Warrants (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
	  <link:definition>00000023 - Disclosure - Warrants (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" id="NetLossPerCommonShareDetailsNarrative">
	  <link:definition>00000024 - Disclosure - Net Loss Per Common Share (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" id="ManagementAndDirectorCompensationDetailsNarrative">
	  <link:definition>00000025 - Disclosure - Management and Director Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="SBFM_AegisOfferingMember" name="AegisOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_TradeableWarrantsMember" name="TradeableWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InvestorWarrants1Member" name="InvestorWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InvestorWarrants2Member" name="InvestorWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFundedWarrants1Member" name="PreFundedWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_FirstReverseStockSplitMember" name="FirstReverseStockSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_SecondReverseStockSplitMember" name="SecondReverseStockSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ThirdReverseStockSplitMember" name="ThirdReverseStockSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable20211Member" name="NotePayable20211Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable20212Member" name="NotePayable20212Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable20213Member" name="NotePayable20213Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InvestorWarrantsMember" name="InvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AprilWarrantsMember" name="AprilWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InvestorWarrantsAndAprilWarrantsMember" name="InvestorWarrantsAndAprilWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_TrtPharmaMember" name="TrtPharmaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ConsultingExpense" name="ConsultingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_OfficeExpense" name="OfficeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_OfficerAndDirectorRemuneration" name="OfficerAndDirectorRemuneration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PatentingFees" name="PatentingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_StockIssuedForPaymentInterestOnNotesPayable" name="StockIssuedForPaymentInterestOnNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ProceedsPublicOfferingNet" name="ProceedsPublicOfferingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_StockIssuedForNoteConversionsIncludingInterest" name="StockIssuedForNoteConversionsIncludingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" name="CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" name="CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreferredStockPurchasedFromRelatedPartyValue" name="PreferredStockPurchasedFromRelatedPartyValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreferredStockPurchasedFromRelatedPartyShares" name="PreferredStockPurchasedFromRelatedPartyShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract" name="DisclosureImpactOfCoronavirusCovid19PandemicAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ImpactOfCovid19PandemicTextBlock" name="ImpactOfCovid19PandemicTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureReverseStockSplitsAbstract" name="DisclosureReverseStockSplitsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ReverseStockSplitTextBlock" name="ReverseStockSplitTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureManagementAndDirectorCompensationAbstract" name="DisclosureManagementAndDirectorCompensationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ManagementCompensationAndDirectorFeesTextBlock" name="ManagementCompensationAndDirectorFeesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantsIssuedWithFinancingTableTextBlock" name="WarrantsIssuedWithFinancingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantsIssuedNewShares" name="WarrantsIssuedNewShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantsIssuedShares" name="WarrantsIssuedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantExpirationDate" name="WarrantExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sbfm-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Cover" xlink:href="sbfm-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheets" xlink:href="sbfm-20220630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:href="sbfm-20220630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20220630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:href="sbfm-20220630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:href="sbfm-20220630.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusiness" xlink:href="sbfm-20220630.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:href="sbfm-20220630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic" xlink:href="sbfm-20220630.xsd#ImpactOfCoronavirusCovid-19Pandemic" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:href="sbfm-20220630.xsd#ReverseStockSplits" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20220630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:href="sbfm-20220630.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Warrants" xlink:href="sbfm-20220630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NetLossPerCommonShare" xlink:href="sbfm-20220630.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:href="sbfm-20220630.xsd#ManagementAndDirectorCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsTables" xlink:href="sbfm-20220630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" xlink:href="sbfm-20220630.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:href="sbfm-20220630.xsd#ReverseStockSplitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20220630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="sbfm-20220630.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetails" xlink:href="sbfm-20220630.xsd#WarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetails1" xlink:href="sbfm-20220630.xsd#WarrantsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:href="sbfm-20220630.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="sbfm-20220630.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:href="sbfm-20220630.xsd#ManagementAndDirectorCompensationDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ConsultingExpense" xlink:label="loc_SBFMConsultingExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMConsultingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficeExpense" xlink:label="loc_SBFMOfficeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMOfficeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficerAndDirectorRemuneration" xlink:label="loc_SBFMOfficerAndDirectorRemuneration" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMOfficerAndDirectorRemuneration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PatentingFees" xlink:label="loc_SBFMPatentingFees" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMPatentingFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="loc_us-gaapInterestIncomeDebtSecuritiesOperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeDebtSecuritiesOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_StockIssuedForPaymentInterestOnNotesPayable" xlink:label="loc_SBFMStockIssuedForPaymentInterestOnNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SBFMStockIssuedForPaymentInterestOnNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ProceedsPublicOfferingNet" xlink:label="loc_SBFMProceedsPublicOfferingNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SBFMProceedsPublicOfferingNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaapProceedsFromOtherShortTermDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusiness" xlink:title="00000007 - Disclosure - Nature of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic" xlink:title="00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="00000010 - Disclosure - Reverse Stock Splits" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000011 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="00000013 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NetLossPerCommonShare" xlink:title="00000014 - Disclosure - Net Loss Per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="00000015 - Disclosure - Management and Director Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="00000016 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000017 - Disclosure - Nature of Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:title="00000018 - Disclosure - Reverse Stock Splits (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000019 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000020 - Disclosure - Shareholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails" xlink:title="00000021 - Disclosure - Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails1" xlink:title="00000022 - Disclosure - Warrants (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="00000023 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000024 - Disclosure - Net Loss Per Common Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="00000025 - Disclosure - Management and Director Compensation (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sbfm-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Cover" xlink:href="sbfm-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheets" xlink:href="sbfm-20220630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:href="sbfm-20220630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20220630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:href="sbfm-20220630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:href="sbfm-20220630.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusiness" xlink:href="sbfm-20220630.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:href="sbfm-20220630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic" xlink:href="sbfm-20220630.xsd#ImpactOfCoronavirusCovid-19Pandemic" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:href="sbfm-20220630.xsd#ReverseStockSplits" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20220630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:href="sbfm-20220630.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Warrants" xlink:href="sbfm-20220630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NetLossPerCommonShare" xlink:href="sbfm-20220630.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:href="sbfm-20220630.xsd#ManagementAndDirectorCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsTables" xlink:href="sbfm-20220630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" xlink:href="sbfm-20220630.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:href="sbfm-20220630.xsd#ReverseStockSplitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20220630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="sbfm-20220630.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetails" xlink:href="sbfm-20220630.xsd#WarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetails1" xlink:href="sbfm-20220630.xsd#WarrantsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:href="sbfm-20220630.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="sbfm-20220630.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:href="sbfm-20220630.xsd#ManagementAndDirectorCompensationDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaapComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" xlink:label="loc_SBFMCommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMCommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_SBFMCommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMCommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreferredStockPurchasedFromRelatedPartyValue" xlink:label="loc_SBFMPreferredStockPurchasedFromRelatedPartyValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMPreferredStockPurchasedFromRelatedPartyValue_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreferredStockPurchasedFromRelatedPartyShares" xlink:label="loc_SBFMPreferredStockPurchasedFromRelatedPartyShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMPreferredStockPurchasedFromRelatedPartyShares_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_70" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusiness" xlink:title="00000007 - Disclosure - Nature of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic" xlink:title="00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="00000010 - Disclosure - Reverse Stock Splits" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000011 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="00000013 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NetLossPerCommonShare" xlink:title="00000014 - Disclosure - Net Loss Per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="00000015 - Disclosure - Management and Director Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="00000016 - Disclosure - Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000017 - Disclosure - Nature of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionLineItems" xlink:label="loc_us-gaapSecuritiesFinancingTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTable" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaapSecuritiesFinancingTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AegisOfferingMember" xlink:label="loc_SBFMAegisOfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_SBFMAegisOfferingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_us-gaapPrivatePlacementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrants1Member" xlink:label="loc_SBFMInvestorWarrants1Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrants1Member_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="loc_SBFMPreFundedWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrants2Member" xlink:label="loc_SBFMInvestorWarrants2Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrants2Member_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrants1Member" xlink:label="loc_SBFMPreFundedWarrants1Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrants1Member_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedNewShares" xlink:label="loc_SBFMWarrantsIssuedNewShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_SBFMWarrantsIssuedNewShares_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:title="00000018 - Disclosure - Reverse Stock Splits (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_FirstReverseStockSplitMember" xlink:label="loc_SBFMFirstReverseStockSplitMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMFirstReverseStockSplitMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_SecondReverseStockSplitMember" xlink:label="loc_SBFMSecondReverseStockSplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMSecondReverseStockSplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ThirdReverseStockSplitMember" xlink:label="loc_SBFMThirdReverseStockSplitMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMThirdReverseStockSplitMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000019 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20211Member" xlink:label="loc_SBFMNotePayable20211Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable20211Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20212Member" xlink:label="loc_SBFMNotePayable20212Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable20212Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20213Member" xlink:label="loc_SBFMNotePayable20213Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable20213Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000020 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="loc_SBFMPreFundedWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrantsMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrants2Member" xlink:label="loc_SBFMInvestorWarrants2Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrants2Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrants1Member" xlink:label="loc_SBFMPreFundedWarrants1Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrants1Member_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaapSecuritiesFinancingTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_us-gaapPrivatePlacementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedNewShares" xlink:label="loc_SBFMWarrantsIssuedNewShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SBFMWarrantsIssuedNewShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividends_130" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails" xlink:title="00000021 - Disclosure - Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="loc_SBFMPreFundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMAprilWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedShares" xlink:label="loc_SBFMWarrantsIssuedShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMWarrantsIssuedShares_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMWarrantExpirationDate_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails1" xlink:title="00000022 - Disclosure - Warrants (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="loc_SBFMPreFundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMAprilWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMWarrantExpirationDate_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="00000023 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMAprilWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsAndAprilWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsAndAprilWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsAndAprilWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000024 - Disclosure - Net Loss Per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaapSecuritiesFinancingTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AegisOfferingMember" xlink:label="loc_SBFMAegisOfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_SBFMAegisOfferingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_us-gaapPrivatePlacementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMAprilWarrantsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedNewShares" xlink:label="loc_SBFMWarrantsIssuedNewShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_SBFMWarrantsIssuedNewShares_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="00000025 - Disclosure - Management and Director Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TrtPharmaMember" xlink:label="loc_SBFMTrtPharmaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMTrtPharmaMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficersAndDirectorsMember" xlink:label="loc_SBFMOfficersAndDirectorsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMOfficersAndDirectorsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees_70" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sbfm-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeMember" xlink:to="us-gaap_ComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US">Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xml:lang="en-US">Securities Financing Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AegisOfferingMember" xlink:label="SBFM_AegisOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AegisOfferingMember" xlink:to="SBFM_AegisOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AegisOfferingMember_lbl" xml:lang="en-US">Aegis Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="SBFM_TradeableWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_TradeableWarrantsMember" xlink:to="SBFM_TradeableWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_TradeableWarrantsMember_lbl" xml:lang="en-US">Tradeable Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrants1Member" xlink:label="SBFM_InvestorWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InvestorWarrants1Member" xlink:to="SBFM_InvestorWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InvestorWarrants1Member_lbl" xml:lang="en-US">Investor Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="SBFM_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFundedWarrantsMember" xlink:to="SBFM_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrants2Member" xlink:label="SBFM_InvestorWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InvestorWarrants2Member" xlink:to="SBFM_InvestorWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InvestorWarrants2Member_lbl" xml:lang="en-US">Investor Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrants1Member" xlink:label="SBFM_PreFundedWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFundedWarrants1Member" xlink:to="SBFM_PreFundedWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFundedWarrants1Member_lbl" xml:lang="en-US">Pre Funded Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_FirstReverseStockSplitMember" xlink:label="SBFM_FirstReverseStockSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_FirstReverseStockSplitMember" xlink:to="SBFM_FirstReverseStockSplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_FirstReverseStockSplitMember_lbl" xml:lang="en-US">First Reverse Stock Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_SecondReverseStockSplitMember" xlink:label="SBFM_SecondReverseStockSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_SecondReverseStockSplitMember" xlink:to="SBFM_SecondReverseStockSplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_SecondReverseStockSplitMember_lbl" xml:lang="en-US">Second Reverse Stock Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ThirdReverseStockSplitMember" xlink:label="SBFM_ThirdReverseStockSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ThirdReverseStockSplitMember" xlink:to="SBFM_ThirdReverseStockSplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ThirdReverseStockSplitMember_lbl" xml:lang="en-US">Third Reverse Stock Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20211Member" xlink:label="SBFM_NotePayable20211Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable20211Member" xlink:to="SBFM_NotePayable20211Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable20211Member_lbl" xml:lang="en-US">Note payable - April 20, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20212Member" xlink:label="SBFM_NotePayable20212Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable20212Member" xlink:to="SBFM_NotePayable20212Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable20212Member_lbl" xml:lang="en-US">Note payable - July 6, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20213Member" xlink:label="SBFM_NotePayable20213Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable20213Member" xlink:to="SBFM_NotePayable20213Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable20213Member_lbl" xml:lang="en-US">Note payable - August 18, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="SBFM_InvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InvestorWarrantsMember" xlink:to="SBFM_InvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InvestorWarrantsMember_lbl" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="SBFM_AprilWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AprilWarrantsMember" xlink:to="SBFM_AprilWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AprilWarrantsMember_lbl" xml:lang="en-US">April Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsAndAprilWarrantsMember" xlink:label="SBFM_InvestorWarrantsAndAprilWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InvestorWarrantsAndAprilWarrantsMember" xlink:to="SBFM_InvestorWarrantsAndAprilWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InvestorWarrantsAndAprilWarrantsMember_lbl" xml:lang="en-US">Investor Warrants And April Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TrtPharmaMember" xlink:label="SBFM_TrtPharmaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_TrtPharmaMember" xlink:to="SBFM_TrtPharmaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_TrtPharmaMember_lbl" xml:lang="en-US">TRT Pharma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficersAndDirectorsMember" xlink:label="SBFM_OfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_OfficersAndDirectorsMember" xlink:to="SBFM_OfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers And Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment (net of $69,202 and $64,106 depreciation respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Long-term portion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 10,000 and 1,000,000 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 18,885,632 and 2,591,240 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Capital paid in excess of par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated comprehensive (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Equipment depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and Administrative Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ConsultingExpense" xlink:label="SBFM_ConsultingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ConsultingExpense" xlink:to="SBFM_ConsultingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ConsultingExpense_lbl" xml:lang="en-US">Consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficeExpense" xlink:label="SBFM_OfficeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_OfficeExpense" xlink:to="SBFM_OfficeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_OfficeExpense_lbl" xml:lang="en-US">Office</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficerAndDirectorRemuneration" xlink:label="SBFM_OfficerAndDirectorRemuneration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_OfficerAndDirectorRemuneration" xlink:to="SBFM_OfficerAndDirectorRemuneration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_OfficerAndDirectorRemuneration_lbl" xml:lang="en-US">Officer and director remuneration</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PatentingFees" xlink:label="SBFM_PatentingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PatentingFees" xlink:to="SBFM_PatentingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PatentingFees_lbl" xml:lang="en-US">Patent fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="us-gaap_InterestIncomeDebtSecuritiesOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:to="us-gaap_InterestIncomeDebtSecuritiesOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDebtSecuritiesOperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Debt release</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense_lbl" xml:lang="en-US">Loss on debt conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net (loss) before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xml:lang="en-US">(Loss) from foreign exchange translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (Loss) per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding (Basic)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_lbl" xml:lang="en-US">Foreign exchange (gain) loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Stock issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_StockIssuedForPaymentInterestOnNotesPayable" xlink:label="SBFM_StockIssuedForPaymentInterestOnNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForPaymentInterestOnNotesPayable" xlink:to="SBFM_StockIssuedForPaymentInterestOnNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_StockIssuedForPaymentInterestOnNotesPayable_lbl" xml:lang="en-US">Stock issued for payment interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense_2_lbl" xml:lang="en-US">Loss on debt conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Debt release</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">(Increase) decrease in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">(Increase) in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Increase (decrease) in interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Flows (Used) in Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ProceedsPublicOfferingNet" xlink:label="SBFM_ProceedsPublicOfferingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ProceedsPublicOfferingNet" xlink:to="SBFM_ProceedsPublicOfferingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SBFM_ProceedsPublicOfferingNet_lbl" xml:lang="en-US">Proceeds public offering net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xml:lang="en-US">Note payable to pay fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Flows Provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_StockIssuedForNoteConversionsIncludingInterest" xlink:label="SBFM_StockIssuedForNoteConversionsIncludingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForNoteConversionsIncludingInterest" xlink:to="SBFM_StockIssuedForNoteConversionsIncludingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_StockIssuedForNoteConversionsIncludingInterest_lbl" xml:lang="en-US">Stock issued for note conversions including interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginnig Balance shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Common stock issued for the reduction of note payable and payment of interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock issued for the reduction of note payable and payment of interest shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services shares</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" xlink:label="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" xlink:to="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" xlink:label="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" xlink:to="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreferredStockPurchasedFromRelatedPartyValue" xlink:label="SBFM_PreferredStockPurchasedFromRelatedPartyValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreferredStockPurchasedFromRelatedPartyValue" xlink:to="SBFM_PreferredStockPurchasedFromRelatedPartyValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SBFM_PreferredStockPurchasedFromRelatedPartyValue_lbl" xml:lang="en-US">Preferred stock purchased from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreferredStockPurchasedFromRelatedPartyShares" xlink:label="SBFM_PreferredStockPurchasedFromRelatedPartyShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreferredStockPurchasedFromRelatedPartyShares" xlink:to="SBFM_PreferredStockPurchasedFromRelatedPartyShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreferredStockPurchasedFromRelatedPartyShares_lbl" xml:lang="en-US">Preferred stock purchased from related party, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Net (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending Balance shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Nature of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract" xlink:label="SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract" xlink:to="SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract_lbl" xml:lang="en-US">Impact Of Coronavirus Covid-19 Pandemic</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ImpactOfCovid19PandemicTextBlock" xlink:label="SBFM_ImpactOfCovid19PandemicTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ImpactOfCovid19PandemicTextBlock" xlink:to="SBFM_ImpactOfCovid19PandemicTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ImpactOfCovid19PandemicTextBlock_lbl" xml:lang="en-US">Impact of Coronavirus (COVID-19) Pandemic</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureReverseStockSplitsAbstract" xlink:label="SBFM_DisclosureReverseStockSplitsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureReverseStockSplitsAbstract" xlink:to="SBFM_DisclosureReverseStockSplitsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureReverseStockSplitsAbstract_lbl" xml:lang="en-US">Reverse Stock Splits</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ReverseStockSplitTextBlock" xlink:label="SBFM_ReverseStockSplitTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ReverseStockSplitTextBlock" xlink:to="SBFM_ReverseStockSplitTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_ReverseStockSplitTextBlock_lbl" xml:lang="en-US">Reverse Stock Splits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="SBFM_DisclosureWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureWarrantsAbstract" xlink:to="SBFM_DisclosureWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsDisclosureTextBlock" xlink:label="SBFM_WarrantsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsDisclosureTextBlock" xlink:to="SBFM_WarrantsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="SBFM_DisclosureManagementAndDirectorCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:to="SBFM_DisclosureManagementAndDirectorCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureManagementAndDirectorCompensationAbstract_lbl" xml:lang="en-US">Management And Director Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ManagementCompensationAndDirectorFeesTextBlock" xlink:label="SBFM_ManagementCompensationAndDirectorFeesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ManagementCompensationAndDirectorFeesTextBlock" xlink:to="SBFM_ManagementCompensationAndDirectorFeesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ManagementCompensationAndDirectorFeesTextBlock_lbl" xml:lang="en-US">Management and Director Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedWithFinancingTableTextBlock" xlink:label="SBFM_WarrantsIssuedWithFinancingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsIssuedWithFinancingTableTextBlock" xlink:to="SBFM_WarrantsIssuedWithFinancingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantsIssuedWithFinancingTableTextBlock_lbl" xml:lang="en-US">Warrants issued with financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of outstanding warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTable" xlink:label="us-gaap_SecuritiesFinancingTransactionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionTable" xlink:to="us-gaap_SecuritiesFinancingTransactionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesFinancingTransactionTable_lbl" xml:lang="en-US">Securities Financing Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionLineItems" xlink:label="us-gaap_SecuritiesFinancingTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionLineItems" xlink:to="us-gaap_SecuritiesFinancingTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesFinancingTransactionLineItems_lbl" xml:lang="en-US">Securities Financing Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedNewShares" xlink:label="SBFM_WarrantsIssuedNewShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsIssuedNewShares" xlink:to="SBFM_WarrantsIssuedNewShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantsIssuedNewShares_lbl" xml:lang="en-US">Warrants issued new, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Stock Redeemed or Called During Period, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Face Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_2_lbl" xml:lang="en-US">Redeemed shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Redemption price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Dividends_lbl" xml:lang="en-US">Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedShares" xlink:label="SBFM_WarrantsIssuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsIssuedShares" xlink:to="SBFM_WarrantsIssuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantsIssuedShares_lbl" xml:lang="en-US">Number of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantExpirationDate" xlink:label="SBFM_WarrantExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantExpirationDate" xlink:to="SBFM_WarrantExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantExpirationDate_lbl" xml:lang="en-US">Warrant Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="us-gaap_NoninterestExpenseDirectorsFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseDirectorsFees" xlink:to="us-gaap_NoninterestExpenseDirectorsFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseDirectorsFees_lbl" xml:lang="en-US">Noninterest Expense Directors Fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ProceedsPublicOfferingNet" xlink:to="SBFM_ProceedsPublicOfferingNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ProceedsPublicOfferingNet_2_lbl" xml:lang="en-US">ProceedsPublicOfferingNet</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreferredStockPurchasedFromRelatedPartyValue" xlink:to="SBFM_PreferredStockPurchasedFromRelatedPartyValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreferredStockPurchasedFromRelatedPartyValue_2_lbl" xml:lang="en-US">PreferredStockPurchasedFromRelatedPartyValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ReverseStockSplitTextBlock" xlink:to="SBFM_ReverseStockSplitTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ReverseStockSplitTextBlock_2_lbl" xml:lang="en-US">ReverseStockSplitTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsDisclosureTextBlock" xlink:to="SBFM_WarrantsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantsDisclosureTextBlock_2_lbl" xml:lang="en-US">WarrantsDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes Payable [Default Label]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sbfm-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Cover" xlink:href="sbfm-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheets" xlink:href="sbfm-20220630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:href="sbfm-20220630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20220630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:href="sbfm-20220630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:href="sbfm-20220630.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusiness" xlink:href="sbfm-20220630.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:href="sbfm-20220630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic" xlink:href="sbfm-20220630.xsd#ImpactOfCoronavirusCovid-19Pandemic" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:href="sbfm-20220630.xsd#ReverseStockSplits" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20220630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:href="sbfm-20220630.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Warrants" xlink:href="sbfm-20220630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NetLossPerCommonShare" xlink:href="sbfm-20220630.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:href="sbfm-20220630.xsd#ManagementAndDirectorCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsTables" xlink:href="sbfm-20220630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" xlink:href="sbfm-20220630.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:href="sbfm-20220630.xsd#ReverseStockSplitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20220630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="sbfm-20220630.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetails" xlink:href="sbfm-20220630.xsd#WarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetails1" xlink:href="sbfm-20220630.xsd#WarrantsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:href="sbfm-20220630.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="sbfm-20220630.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:href="sbfm-20220630.xsd#ManagementAndDirectorCompensationDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ConsultingExpense" xlink:label="loc_SBFMConsultingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMConsultingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficeExpense" xlink:label="loc_SBFMOfficeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMOfficeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficerAndDirectorRemuneration" xlink:label="loc_SBFMOfficerAndDirectorRemuneration" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMOfficerAndDirectorRemuneration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PatentingFees" xlink:label="loc_SBFMPatentingFees" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMPatentingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="loc_us-gaapInterestIncomeDebtSecuritiesOperating" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeDebtSecuritiesOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_StockIssuedForPaymentInterestOnNotesPayable" xlink:label="loc_SBFMStockIssuedForPaymentInterestOnNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SBFMStockIssuedForPaymentInterestOnNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ProceedsPublicOfferingNet" xlink:label="loc_SBFMProceedsPublicOfferingNet" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SBFMProceedsPublicOfferingNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaapProceedsFromOtherShortTermDebt" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_StockIssuedForNoteConversionsIncludingInterest" xlink:label="loc_SBFMStockIssuedForNoteConversionsIncludingInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SBFMStockIssuedForNoteConversionsIncludingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaapComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" xlink:label="loc_SBFMCommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMCommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_SBFMCommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMCommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreferredStockPurchasedFromRelatedPartyValue" xlink:label="loc_SBFMPreferredStockPurchasedFromRelatedPartyValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMPreferredStockPurchasedFromRelatedPartyValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreferredStockPurchasedFromRelatedPartyShares" xlink:label="loc_SBFMPreferredStockPurchasedFromRelatedPartyShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMPreferredStockPurchasedFromRelatedPartyShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusiness" xlink:title="00000007 - Disclosure - Nature of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic" xlink:title="00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract" xlink:label="loc_SBFMDisclosureImpactOfCoronavirusCovid19PandemicAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ImpactOfCovid19PandemicTextBlock" xlink:label="loc_SBFMImpactOfCovid19PandemicTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureImpactOfCoronavirusCovid19PandemicAbstract" xlink:to="loc_SBFMImpactOfCovid19PandemicTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="00000010 - Disclosure - Reverse Stock Splits">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureReverseStockSplitsAbstract" xlink:label="loc_SBFMDisclosureReverseStockSplitsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ReverseStockSplitTextBlock" xlink:label="loc_SBFMReverseStockSplitTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureReverseStockSplitsAbstract" xlink:to="loc_SBFMReverseStockSplitTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000011 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="00000013 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsDisclosureTextBlock" xlink:label="loc_SBFMWarrantsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_SBFMWarrantsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NetLossPerCommonShare" xlink:title="00000014 - Disclosure - Net Loss Per Common Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="00000015 - Disclosure - Management and Director Compensation">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ManagementCompensationAndDirectorFeesTextBlock" xlink:label="loc_SBFMManagementCompensationAndDirectorFeesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" xlink:to="loc_SBFMManagementCompensationAndDirectorFeesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="00000016 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedWithFinancingTableTextBlock" xlink:label="loc_SBFMWarrantsIssuedWithFinancingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_SBFMWarrantsIssuedWithFinancingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" xlink:title="00000017 - Disclosure - Nature of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTable" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionLineItems" xlink:label="loc_us-gaapSecuritiesFinancingTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaapSecuritiesFinancingTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AegisOfferingMember" xlink:label="loc_SBFMAegisOfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_SBFMAegisOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrants1Member" xlink:label="loc_SBFMInvestorWarrants1Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="loc_SBFMPreFundedWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrants2Member" xlink:label="loc_SBFMInvestorWarrants2Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrants1Member" xlink:label="loc_SBFMPreFundedWarrants1Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedNewShares" xlink:label="loc_SBFMWarrantsIssuedNewShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_SBFMWarrantsIssuedNewShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:title="00000018 - Disclosure - Reverse Stock Splits (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureReverseStockSplitsAbstract" xlink:label="loc_SBFMDisclosureReverseStockSplitsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureReverseStockSplitsAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_FirstReverseStockSplitMember" xlink:label="loc_SBFMFirstReverseStockSplitMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMFirstReverseStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_SecondReverseStockSplitMember" xlink:label="loc_SBFMSecondReverseStockSplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMSecondReverseStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_ThirdReverseStockSplitMember" xlink:label="loc_SBFMThirdReverseStockSplitMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMThirdReverseStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000019 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20211Member" xlink:label="loc_SBFMNotePayable20211Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable20211Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20212Member" xlink:label="loc_SBFMNotePayable20212Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable20212Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_NotePayable20213Member" xlink:label="loc_SBFMNotePayable20213Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable20213Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000020 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="loc_SBFMPreFundedWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrants2Member" xlink:label="loc_SBFMInvestorWarrants2Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrants1Member" xlink:label="loc_SBFMPreFundedWarrants1Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaapSecuritiesFinancingTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedNewShares" xlink:label="loc_SBFMWarrantsIssuedNewShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SBFMWarrantsIssuedNewShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividends" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails" xlink:title="00000021 - Disclosure - Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="loc_SBFMPreFundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMAprilWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedShares" xlink:label="loc_SBFMWarrantsIssuedShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMWarrantsIssuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMWarrantExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails1" xlink:title="00000022 - Disclosure - Warrants (Details 1)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_PreFundedWarrantsMember" xlink:label="loc_SBFMPreFundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMAprilWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMWarrantExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="00000023 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMAprilWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsAndAprilWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsAndAprilWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsAndAprilWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000024 - Disclosure - Net Loss Per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaapSecuritiesFinancingTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AegisOfferingMember" xlink:label="loc_SBFMAegisOfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_SBFMAegisOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMAprilWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_WarrantsIssuedNewShares" xlink:label="loc_SBFMWarrantsIssuedNewShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_SBFMWarrantsIssuedNewShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="00000025 - Disclosure - Management and Director Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_TrtPharmaMember" xlink:label="loc_SBFMTrtPharmaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMTrtPharmaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20220630.xsd#SBFM_OfficersAndDirectorsMember" xlink:label="loc_SBFMOfficersAndDirectorsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687985594496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SUNSHINE BIOPHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001402328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5566275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6500 Trans-Canada Highway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Pointe-Claire<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Quebec<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H9R 0A5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">426-6161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,885,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SBFM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Purchase Warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SBFMW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687981431872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,727,775<span></span>
</td>
<td class="nump">$ 2,045,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">7,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">205,371<span></span>
</td>
<td class="nump">105,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">48,562<span></span>
</td>
<td class="nump">29,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">7,590<span></span>
</td>
<td class="nump">7,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">41,989,322<span></span>
</td>
<td class="nump">2,195,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment (net of $69,202 and $64,106 depreciation respectively)</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">7,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">41,990,964<span></span>
</td>
<td class="nump">2,202,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">104,684<span></span>
</td>
<td class="nump">42,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">104,684<span></span>
</td>
<td class="nump">91,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term portion of notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">104,684<span></span>
</td>
<td class="nump">1,991,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 10,000 and 1,000,000 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 18,885,632 and 2,591,240 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">18,886<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital paid in excess of par value</a></td>
<td class="nump">76,331,451<span></span>
</td>
<td class="nump">32,787,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated comprehensive (loss)</a></td>
<td class="num">(34,777)<span></span>
</td>
<td class="num">(23,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated (Deficit)</a></td>
<td class="num">(34,430,280)<span></span>
</td>
<td class="num">(32,655,174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">41,886,280<span></span>
</td>
<td class="nump">211,662<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 41,990,964<span></span>
</td>
<td class="nump">$ 2,202,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687981420560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Equipment depreciation</a></td>
<td class="nump">$ 69,202<span></span>
</td>
<td class="nump">$ 64,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">18,885,632<span></span>
</td>
<td class="nump">2,591,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">18,885,632<span></span>
</td>
<td class="nump">2,591,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687984848448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 150,307<span></span>
</td>
<td class="nump">$ 52,874<span></span>
</td>
<td class="nump">$ 272,952<span></span>
</td>
<td class="nump">$ 92,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">74,683<span></span>
</td>
<td class="nump">18,515<span></span>
</td>
<td class="nump">134,528<span></span>
</td>
<td class="nump">37,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">75,624<span></span>
</td>
<td class="nump">34,359<span></span>
</td>
<td class="nump">138,424<span></span>
</td>
<td class="nump">55,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accounting</a></td>
<td class="nump">41,060<span></span>
</td>
<td class="nump">19,800<span></span>
</td>
<td class="nump">114,860<span></span>
</td>
<td class="nump">61,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising</a></td>
<td class="nump">87,680<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">182,720<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_ConsultingExpense', window );">Consulting</a></td>
<td class="nump">101,683<span></span>
</td>
<td class="nump">21,677<span></span>
</td>
<td class="nump">107,181<span></span>
</td>
<td class="nump">32,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal</a></td>
<td class="nump">109,130<span></span>
</td>
<td class="nump">95,034<span></span>
</td>
<td class="nump">245,355<span></span>
</td>
<td class="nump">102,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_OfficeExpense', window );">Office</a></td>
<td class="nump">90,407<span></span>
</td>
<td class="nump">61,117<span></span>
</td>
<td class="nump">372,912<span></span>
</td>
<td class="nump">100,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_OfficerAndDirectorRemuneration', window );">Officer and director remuneration</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="nump">1,043,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_PatentingFees', window );">Patent fees</a></td>
<td class="nump">3,230<span></span>
</td>
<td class="nump">8,377<span></span>
</td>
<td class="nump">11,564<span></span>
</td>
<td class="nump">14,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D</a></td>
<td class="nump">45,943<span></span>
</td>
<td class="nump">191,760<span></span>
</td>
<td class="nump">407,595<span></span>
</td>
<td class="nump">358,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">3,192<span></span>
</td>
<td class="nump">5,397<span></span>
</td>
<td class="nump">6,374<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total General and Administrative Expenses</a></td>
<td class="nump">771,420<span></span>
</td>
<td class="nump">422,957<span></span>
</td>
<td class="nump">2,057,584<span></span>
</td>
<td class="nump">1,720,141<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) from operations</a></td>
<td class="num">(695,796)<span></span>
</td>
<td class="num">(388,598)<span></span>
</td>
<td class="num">(1,919,160)<span></span>
</td>
<td class="num">(1,664,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeDebtSecuritiesOperating', window );">Interest income</a></td>
<td class="nump">146,043<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">146,046<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(195,630)<span></span>
</td>
<td class="num">(12,864)<span></span>
</td>
<td class="num">(245,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt release</a></td>
<td class="nump">10,852<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">10,852<span></span>
</td>
<td class="nump">51,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Loss on debt conversions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,295,057)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,205,843)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="nump">156,924<span></span>
</td>
<td class="num">(2,490,456)<span></span>
</td>
<td class="nump">144,054<span></span>
</td>
<td class="num">(7,399,936)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) before income taxes</a></td>
<td class="num">(538,872)<span></span>
</td>
<td class="num">(2,879,054)<span></span>
</td>
<td class="num">(1,775,106)<span></span>
</td>
<td class="num">(9,064,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss)</a></td>
<td class="num">(538,872)<span></span>
</td>
<td class="num">(2,879,054)<span></span>
</td>
<td class="num">(1,775,106)<span></span>
</td>
<td class="num">(9,064,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">(Loss) from foreign exchange translation</a></td>
<td class="num">(12,645)<span></span>
</td>
<td class="num">(6,702)<span></span>
</td>
<td class="num">(11,638)<span></span>
</td>
<td class="num">(8,765)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (Loss)</a></td>
<td class="num">$ (551,517)<span></span>
</td>
<td class="num">$ (2,885,756)<span></span>
</td>
<td class="num">$ (1,786,744)<span></span>
</td>
<td class="num">$ (9,072,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (Loss) per common share</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (3.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Outstanding (Basic)</a></td>
<td class="nump">15,849,518<span></span>
</td>
<td class="nump">2,392,602<span></span>
</td>
<td class="nump">9,691,265<span></span>
</td>
<td class="nump">2,293,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ConsultingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ConsultingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_OfficeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_OfficeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_OfficerAndDirectorRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_OfficerAndDirectorRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PatentingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PatentingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDebtSecuritiesOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDebtSecuritiesOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687984862064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (Loss)</a></td>
<td class="num">$ (1,775,106)<span></span>
</td>
<td class="num">$ (9,064,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,397<span></span>
</td>
<td class="nump">6,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Foreign exchange (gain) loss</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock issued for services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">918,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_StockIssuedForPaymentInterestOnNotesPayable', window );">Stock issued for payment interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Loss on debt conversion</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">7,205,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt release</a></td>
<td class="num">(10,852)<span></span>
</td>
<td class="num">(51,252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in accounts receivable</a></td>
<td class="nump">7,774<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) decrease in inventory</a></td>
<td class="num">(99,721)<span></span>
</td>
<td class="num">(27,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) in prepaid expenses</a></td>
<td class="num">(18,937)<span></span>
</td>
<td class="num">(12,907)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accrued expenses</a></td>
<td class="nump">61,742<span></span>
</td>
<td class="nump">35,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Increase (decrease) in interest payable</a></td>
<td class="num">(48,287)<span></span>
</td>
<td class="nump">33,795<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Flows (Used) in Operations</a></td>
<td class="num">(1,878,010)<span></span>
</td>
<td class="num">(916,207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_ProceedsPublicOfferingNet', window );">Proceeds public offering net</a></td>
<td class="nump">43,560,363<span></span>
</td>
<td class="nump">1,918,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Note payable to pay fees</a></td>
<td class="num">(99,000)<span></span>
</td>
<td class="nump">61,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of notes payable</a></td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="num">(327,352)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Flows Provided by Financing Activities</a></td>
<td class="nump">41,561,363<span></span>
</td>
<td class="nump">1,652,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">2,045,167<span></span>
</td>
<td class="nump">989,888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">39,683,353<span></span>
</td>
<td class="nump">736,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(12,383)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Foreign currency translation adjustment</a></td>
<td class="nump">11,638<span></span>
</td>
<td class="nump">8,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">41,727,775<span></span>
</td>
<td class="nump">1,735,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_StockIssuedForNoteConversionsIncludingInterest', window );">Stock issued for note conversions including interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,237,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">61,151<span></span>
</td>
<td class="nump">142,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ProceedsPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ProceedsPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_StockIssuedForNoteConversionsIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_StockIssuedForNoteConversionsIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_StockIssuedForPaymentInterestOnNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_StockIssuedForPaymentInterestOnNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687979661632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Comprehensive Income [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 1,732<span></span>
</td>
<td class="nump">$ 19,165,029<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">$ (2,871)<span></span>
</td>
<td class="num">$ (20,218,727)<span></span>
</td>
<td class="num">$ (954,837)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginnig Balance shares at Dec. 31, 2020</a></td>
<td class="nump">1,732,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for the reduction of note payable and payment of interest</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">8,236,674<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,237,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for the reduction of note payable and payment of interest shares</a></td>
<td class="nump">398,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">917,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">918,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,765)<span></span>
</td>
<td class="num">(9,064,180)<span></span>
</td>
<td class="num">(9,072,945)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 2,430<span></span>
</td>
<td class="nump">28,319,403<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">(11,636)<span></span>
</td>
<td class="num">(29,282,907)<span></span>
</td>
<td class="num">(872,710)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance shares at Jun. 30, 2021</a></td>
<td class="nump">2,430,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 2,325<span></span>
</td>
<td class="nump">25,222,073<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">(4,934)<span></span>
</td>
<td class="num">(26,403,853)<span></span>
</td>
<td class="num">(1,084,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginnig Balance shares at Mar. 31, 2021</a></td>
<td class="nump">2,325,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for the reduction of note payable and payment of interest</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">3,097,330<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,097,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for the reduction of note payable and payment of interest shares</a></td>
<td class="nump">105,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,702)<span></span>
</td>
<td class="num">(2,879,054)<span></span>
</td>
<td class="num">(2,885,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 2,430<span></span>
</td>
<td class="nump">28,319,403<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">(11,636)<span></span>
</td>
<td class="num">(29,282,907)<span></span>
</td>
<td class="num">(872,710)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance shares at Jun. 30, 2021</a></td>
<td class="nump">2,430,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 2,596<span></span>
</td>
<td class="nump">32,787,379<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">(23,139)<span></span>
</td>
<td class="num">(32,655,174)<span></span>
</td>
<td class="nump">211,662<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginnig Balance shares at Dec. 31, 2021</a></td>
<td class="nump">2,595,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts', window );">Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs</a></td>
<td class="nump">$ 6,657<span></span>
</td>
<td class="nump">30,360,528<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30,367,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares', window );">Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs shares</a></td>
<td class="nump">6,656,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exercise of warrants</a></td>
<td class="nump">$ 9,633<span></span>
</td>
<td class="nump">13,183,544<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,193,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of warrants, shares</a></td>
<td class="nump">9,633,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_PreferredStockPurchasedFromRelatedPartyValue', window );">Preferred stock purchased from related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(99,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(99,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_PreferredStockPurchasedFromRelatedPartyShares', window );">Preferred stock purchased from related party, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(990,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,638)<span></span>
</td>
<td class="num">(1,775,106)<span></span>
</td>
<td class="num">(1,786,744)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 18,886<span></span>
</td>
<td class="nump">76,331,451<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="num">(34,777)<span></span>
</td>
<td class="num">(34,430,280)<span></span>
</td>
<td class="nump">41,886,280<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance shares at Jun. 30, 2022</a></td>
<td class="nump">18,885,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 7,150<span></span>
</td>
<td class="nump">47,219,498<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="num">(22,132)<span></span>
</td>
<td class="num">(33,891,408)<span></span>
</td>
<td class="nump">13,314,108<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginnig Balance shares at Mar. 31, 2022</a></td>
<td class="nump">7,149,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts', window );">Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs</a></td>
<td class="nump">$ 2,473<span></span>
</td>
<td class="nump">16,750,442<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,752,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares', window );">Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs shares</a></td>
<td class="nump">2,472,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exercise of warrants</a></td>
<td class="nump">$ 9,263<span></span>
</td>
<td class="nump">12,361,511<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,370,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of warrants, shares</a></td>
<td class="nump">9,263,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,645)<span></span>
</td>
<td class="num">(538,872)<span></span>
</td>
<td class="num">(551,517)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 18,886<span></span>
</td>
<td class="nump">$ 76,331,451<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="num">$ (34,777)<span></span>
</td>
<td class="num">$ (34,430,280)<span></span>
</td>
<td class="nump">$ 41,886,280<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance shares at Jun. 30, 2022</a></td>
<td class="nump">18,885,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PreferredStockPurchasedFromRelatedPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PreferredStockPurchasedFromRelatedPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PreferredStockPurchasedFromRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PreferredStockPurchasedFromRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687987772656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAIBofJQo2X5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 1 &#8211;&#160;<span id="xdx_82E_zt1lXNVsyes9">Nature of Business</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunshine Biopharma, Inc. (the &#8220;Company&#8221;)
was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until
October 2009, the Company was operating as a business consultancy firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 15, 2009, the Company acquired
Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. held an exclusive license to a
new anticancer drug bearing the laboratory name, Adva-27a (the &#8220;License Agreement&#8221;). Upon completion of the reverse acquisition
transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the
development of the licensed Adva-27a anticancer drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, the Company acquired all worldwide
issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a
anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of
these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2018, the Company launched its first
Science-Based Nutritional Supplements product, Essential 9<span style="font-variant: small-caps"><sup>&#8482;</sup></span>, an over-the-counter
capsule comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9<span style="font-variant: small-caps"><sup>&#8482;&#160;</sup></span>has
been authorized for marketing by Health Canada under NPN 80089663.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 22, 2020, the Company filed a provisional
patent application in the United States for a new treatment for Coronavirus infections. The Company&#8217;s patent application covers
composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential
for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application
containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May
22, 2020 has been maintained in the newly filed PCT application. The Company&#8217;s lead Anti-Coronavirus compound arising from these
patents bears the laboratory name SBFM-PL4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 26, 2021, the Company received a Notice
of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains
new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2021, the Company received a Notice
of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject
matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued
in 2019 (US Patent Number 10,272,065).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company filed a patent
application for a potential new treatment for neurodegenerative disorders. The patent application contains experimental results showing
that certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics
neuronal degeneration. This new patent application has a priority date of October 1, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 9, 2022, the Company
completed a 200-for-1 reverse split of its common stock. On February 15, 2022, the Company entered into an underwriting agreement
with Aegis Capital Corp. as underwriter, for the issuance and sale in an underwritten public offering of 1,882,353 Units, each
consisting of one share of common stock and two warrants (&#8220;Tradeable Warrants&#8221;) to purchase shares of common stock at a
public offering price of $4.25 per Unit for total gross proceeds of $8,000,000 (&#8220;Public Offering&#8221;). On February 17,
2022, the Public Offering closed and the Company received net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember_zXezFsvjKvX7" title="Proceeds from Issuance or Sale of Equity">6,833,071</span>.
Pursuant to the Public Offering, the Company issued and sold an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" title="Stock Issued During Period, Shares, New Issues">1,882,353</span>
shares of common stock and <span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Warrants issued new, shares">4,102,200</span>
Tradeable Warrants (including 337,494 Tradeable Warrants purchased at $0.01 per warrant resulting from partial exercise of the
overallotment option granted to the underwriter). In connection with these transactions, the Company&#8217;s shares of common stock
and Tradeable Warrants began trading on Nasdaq under the symbol &#8220;SBFM&#8221; for the common stock and &#8220;SBFMW&#8221; for
the Tradeable Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2022, the Company entered
into a research agreement (the &#8220;SRA&#8221;) with the University of Arizona for the purposes of conducting research focused on
determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro
inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the &#8220;Research Project&#8221;). Under the SRA,
the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual
property developed by University of Arizona personnel under the Research Project. In addition, the Company and the University of
Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial
license for the underlying technology of the Research Project.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 22, 2022, the Company redeemed&#160;<span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220221__20220222_pdd">990,000
</span>shares of the Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2022, the Company completed a private
placement wherein the Company sold (i)&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd">2,301,353</span>&#160;shares
of its common stock together with warrants (the &#8220;Investor Warrants&#8221;) to purchase up to&#160;<span id="xdx_908_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants1Member_pdd">2,301,353
</span>shares of common stock, and (ii)&#160;<span id="xdx_90F_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd">1,302,251</span>&#160;pre-funded
warrants (&#8220;Pre-Funded Warrants&#8221;) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor
Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together
at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined
offering price of $2.219. The Company received approximately $8 million in gross proceeds, and $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_pp0p0">6,781,199</span>&#160;in
net proceeds in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2022, the Company completed
another private placement and received net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_zIv0BXUmdJe6" title="Proceeds from Issuance of private placement">16,752,915</span>.
In connection with this private placement, the Company issued (i)&#160;<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFyQuhJjUdtk" title="Stock Issued During Period, Shares, New Issues">2,472,820&#160;</span>shares
of its common stock together with warrants (&#8220;April Warrants&#8221;) to purchase up to <span id="xdx_900_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants2Member_ztiM83NU0j7" title="Warrants issued new, shares">4,945,640</span>
shares of common stock, and (ii)&#160;<span id="xdx_908_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants1Member_zaCHdbBo9hok" title="Warrants issued new, shares">2,390,025</span>&#160;pre-funded
warrants (&#8220;Pre-Funded Warrants&#8221;) with each Pre-Funded Warrant exercisable for one share of common stock, together with
April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants
were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold
together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at
a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001,
and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise
price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220428__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrsQ3EVo90nc" title="Warrants exercise price">3.76</span>
per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the
date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139688070786656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z4z0pGzB19ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note
2 &#8211; <span id="xdx_821_zM2MV1wCrL4g">Basis of Presentation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited financial statements of the Company
for the six month periods ended June 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted
in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation
S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United
States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring
adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of
operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The
balance sheet information as of December 31, 2021 was derived from the audited financial statements included in the Company's financial
statements as of and for the year ended December 31, 2021 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities
and Exchange Commission (the &#8220;SEC&#8221;) on March 21, 2022. These financial statements should be read in conjunction with that
report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139688088124704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of Coronavirus (COVID-19) Pandemic<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract', window );"><strong>Impact Of Coronavirus Covid-19 Pandemic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_ImpactOfCovid19PandemicTextBlock', window );">Impact of Coronavirus (COVID-19) Pandemic</a></td>
<td class="text"><p id="xdx_807_ecustom--ImpactOfCovid19PandemicTextBlock_zeZjd7sj95Ne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 3 &#8211;&#160;<span id="xdx_823_zvNzyqp9M48d">Impact of Coronavirus
(COVID-19) Pandemic</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, the World Health Organization declared
Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are
continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate
the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on
the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of
the adverse conditions of the outbreak and their effects on the Company&#8217;s business or ability to raise funds. No adjustments have
been made to the amounts reported in the Company's financial statements as a result of this matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ImpactOfCovid19PandemicTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ImpactOfCovid19PandemicTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139688074774016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Stock Splits<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_DisclosureReverseStockSplitsAbstract', window );"><strong>Reverse Stock Splits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_ReverseStockSplitTextBlock', window );">Reverse Stock Splits</a></td>
<td class="text"><p id="xdx_80F_ecustom--ReverseStockSplitTextBlock_zwi1bC5n35q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 4 &#8211;&#160;<span id="xdx_820_zJpsbtK6L983">Reverse Stock Splits</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 1, 2019, the Company
completed a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20190131__20190201__us-gaap--TransactionTypeAxis__custom--FirstReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split">20
to 1 reverse split</span>&#160;of its common stock (the &#8220;First Reverse Stock Split&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective April 6, 2020, the Company
completed another <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20200405__20200406__us-gaap--TransactionTypeAxis__custom--SecondReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split">20
to 1 reverse split</span>&#160;of its common stock (the &#8220;Second Reverse Stock Split&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 9, 2022, the Company
completed a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220208__20220209__us-gaap--TransactionTypeAxis__custom--ThirdReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split">1
for 200 reverse split</span>&#160;of its common stock (the &#8220;Third Reverse Stock Split&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's financial statements reflect the
First, Second, and Third Reverse Stock Split on a retroactive basis for all periods presented and for all references to common stock,
unless specifically stated otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureReverseStockSplitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureReverseStockSplitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ReverseStockSplitTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ReverseStockSplitTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687988489776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zclClVkoWcSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 5 &#8211;&#160;<span id="xdx_82C_z0XWrLffMlva">Notes Payable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022 and December 31, 2021, the
Company had $-<span id="xdx_904_eus-gaap--NotesPayable_iI_c20220630_z4hJEkHnWqV4">0</span>- and $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20211231_zi8I1eAmG42g">1,900,000</span>, respectively in notes payable outstanding. At June 30, 2022 and December 31, 2021, total
accrued interest on Notes Payable was $-<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_c20220630_pp0p0" title="Interest Payable">0</span>- and $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_c20211231_pp0p0" title="Interest Payable">48,287</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Notes Payable at December
31, 2021 consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2021, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zPPcoqZCDRSe" title="Face Value">500,000</span>
with interest accruing at&#160;<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210419__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zwm5d5RTlfy7" title="Interest Rate">5</span>%
due&#160;<span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210419__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zHz4IQAMnoTl" title="Maturity Date">April
20, 2023</span>. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On
February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $<span id="xdx_90C_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities">20,753</span>&#160;by
making a cash payment of $<span id="xdx_903_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0" title="Repayments of notes payable">520,753</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company received monies in
exchange for a Note Payable having a Face Value of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Face Value">900,000</span>&#160;with interest accruing at&#160;<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210705__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_zfA2y1eRgnsh" title="Interest Rate">5</span>%, due&#160;<span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210705__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_z7TCLKqxPGqf" title="Maturity Date">July 6, 2023</span>. The Note was
convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid
off the entire principal balance of this Note, together with accrued interest of $<span id="xdx_90F_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities">27,863</span>&#160;by making a cash payment of $<span id="xdx_900_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Repayments of notes payable">927,863</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Face Value">500,000</span>&#160;with interest accruing at&#160;<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210817__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_zkcwCKnbVo" title="Interest Rate">5</span>%, due&#160;<span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210817__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_zbecLUAMckU7" title="Maturity Date">August 18, 2023</span>. The Note
was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company
paid off the entire principal balance of this Note, together with accrued of $<span id="xdx_90E_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities">12,534</span>&#160;by making a cash payment of $<span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Repayments of notes payable">512,534</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687988460784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zojQFM97v0k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 6 &#8211;&#160;<span id="xdx_826_zMBU3igjlIM8">Shareholders&#8217;
Equity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17, 2022, the Company&#8217;s Public
Offering closed and the Company received net proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20220201__20220217_zNiKKGiuH9La" title="Net proceeds">6,833,071</span>&#160;from the offering. Pursuant to the Public Offering, the Company
issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 Tradeable Warrants (including 337,494 Tradeable Warrants
resulting from partial exercise of the overallotment option granted to the underwriter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 22, 2022, the Company
redeemed&#160;<span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220201__20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Redeemed shares">990,000</span>
shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $<span id="xdx_90A_eus-gaap--PreferredStockRedemptionPricePerShare_c20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Redemption price">0.10</span>&#160;per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2022, the Company completed a private
placement and received net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_zMp0U0uSN8Xh" title="Proceeds from Issuance or Sale of Equity">6,781,199</span>. In connection with this private placement, the Company issued (i)&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Stock Issued During Period, Shares, New Issues">2,301,353</span>&#160;shares
of its common stock together with investor warrants (&#8220;Investor Warrants&#8221;) to purchase up to 2,301,353 shares of common stock,
and (ii)&#160;<span id="xdx_90E_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zA2FPkQpk4ah" title="Warrants issued new, shares">1,302,251</span>&#160;pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;) with each Pre-Funded Warrant exercisable for one
share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock
and accompanying Investor Warrant were sold together at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying
Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a
nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor
Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance
and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2022, the Company completed another
private placement and received net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_znVYp6jYYmB4" title="Proceeds from Issuance of private placement">16,752,915</span>. In connection with this private placement, the Company issued (i)&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zoXANp3cjiw7" title="Stock Issued During Period, Shares, New Issues">2,472,820</span>&#160;shares
of its common stock together with warrants (&#8220;April Warrants&#8221;) to purchase up to <span id="xdx_900_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants2Member_pdd" title="Warrants issued new, shares">4,945,640</span> shares of common stock, and (ii)&#160;<span id="xdx_904_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants1Member_pdd" title="Warrants issued new, shares">2,390,025</span>&#160;pre-funded
warrants (&#8220;Pre-Funded Warrants&#8221;) with each Pre-Funded Warrant exercisable for one share of common stock, together with April
Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and
accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying
two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at
a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April
Warrants have an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220428__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants exercise price">3.76</span> per share (subject
to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company declared&#160;<span id="xdx_90F_eus-gaap--Dividends_pp0p0_do_c20220101__20220630_zBDcFb5wh1jl" title="Dividends">no</span>&#160;dividends through
June 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687987779072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_807_ecustom--WarrantsDisclosureTextBlock_zFMrKuaeW6uk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 7 &#8211; <span id="xdx_822_zTk2EsEnNZk1">Warrants</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5pt 0pt 0; text-align: justify">The Company accounts for issued warrants
either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if
they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not
meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants
should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless
of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance
date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the
consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order
to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether
the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for
at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.6pt 0pt 0; text-align: justify">During the six months ended June 30,
2022, the Company completed three financing events, and in connection therewith, it issued warrants as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zNwwGIHXQWqg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details)">
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span id="xdx_8B8_zHel6mXOVqJ5" style="display: none">Warrants issued with financing</span></td>
    <td style="padding-left: 38.8pt">&#160;</td>
    <td style="padding-left: 45.2pt">&#160;</td>
    <td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td>
    <td id="xdx_98E_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,692,276</span></td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.001</span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z9fDsmqiipj4" title="Warrant Expiration Date">Unlimited</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td>
    <td id="xdx_987_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="padding-left: 38.8pt" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,102,200</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_fKg_____z74M9jRRZxDh" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22*</span></td>
    <td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember" title="Warrant Expiration Date">February 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td>
    <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,603,604</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span id="xdx_901_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember" title="Warrant Expiration Date">March 2027</span> &#160; &#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April Warrants</span></td>
    <td id="xdx_981_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,725,690</span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zVMa7JU4jioh" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.76</span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember" title="Warrant Expiration Date">April 2027</span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td id="xdx_F0A_zTXk34pRSl4i" style="padding-left: 10pt; text-indent: -10pt; width: 3%">*</td>
  <td id="xdx_F15_zcKElZ7CBjz9" style="width: 97%">The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#8217;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.</td></tr>
</table>


<p id="xdx_8A9_zZZZDsrAp9f3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55pt 0pt 0">During the six months ended June 30, 2022, all of the Pre-Funded
Warrants and a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zGyR0xDlg9cg" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised">3,138,507</span> Tradeable Warrants were exercised resulting in aggregate proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pp0p0" title="Proceeds from Warrant Exercises">6,971,178</span> received by the Company.
In addition, during the six months ended June 30, 2022, a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zxNm0NWhikaj">2,802,703</span> Investor Warrants and -<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zDLU153xNiQ3">0</span>- April Warrants were exercised resulting
in aggregate proceeds of $ $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsAndAprilWarrantsMember_zJrmPrF0Mcdi">6,222,001</span> received by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s outstanding warrants at June 30, 2022 consisted
of the following:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zs4LKBBWTYh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details 1)">
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span id="xdx_8BB_zRoQ62lWN0z9" style="display: none">Schedule of outstanding warrants</span></td>
    <td style="padding-left: 38.75pt">&#160;</td>
    <td style="padding-left: 45.2pt">&#160;</td>
    <td style="padding-left: 29.9pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td>
    <td style="border-bottom: Black 1pt solid; padding-left: 38.75pt; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td>
    <td style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zruZdMIt0SP9" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.001</span></td>
    <td style="padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember" title="Warrant Expiration Date">Unlimited</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zQz5KJiyVh3i" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">963,693</span></td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td>
    <td style="padding-left: 29.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zBwIDdqIx9Sj" title="Warrant Expiration Date">February 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">800,901</span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_z9EWSQI6H2R4" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td>
    <td style="padding-left: 29.9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zmeTYt42lSJd" title="Warrant Expiration Date">March 2027</span> &#160; &#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>April Warrants </td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,725,690</span></td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zlxMhAV6v2vd" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.76</span></td>
    <td style="padding-left: 29.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zNSXivnrEYn" title="Warrant Expiration Date">April 2027</span></span></td></tr>
  </table>

<p id="xdx_8A1_zymYOMYDsxH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687988424208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zBGzjx2UgKuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 8 &#8211;&#160;<span id="xdx_82F_zRFkWoVQ7D42">Net Loss Per Common
Share</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is calculated by dividing
the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common
stock equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted net loss per share is calculated by dividing
the net loss by the weighted-average number of shares of common stock outstanding during the period, taking into consideration common
stock equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2022, the Company
issued&#160;<span id="xdx_902_ecustom--WarrantsIssuedNewShares_c20220201__20220228__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zJOr9LNc4Haa" title="Warrants issued new, shares">4,102,200</span>&#160;Tradeable
Warrants pursuant to the Company&#8217;s Public Offering. In March and April 2022, the Company issued <span id="xdx_906_ecustom--WarrantsIssuedNewShares_c20220401__20220422__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zLtdZnW6zXOd" title="Warrants issued new, shares">3,603,604</span>
Investor Warrants and <span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20220401__20220422__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zmoOgbNWMhSh" title="Warrants issued new, shares">9,725,690</span>
April Warrants pursuant to two private placements. As of June 30, 2022, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised">3,138,507</span>
Tradeable Warrants, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zGgoJ3U13c58" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised">2,802,703</span>
Investor Warrants, and -<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_z6EonkBgpa99" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised">0</span>-
April Warrants were exercised, leaving&#160;<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding">963,693</span>
Tradeable Warrants, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zMKuuL71SByl" title="Class of Warrant or Right, Outstanding">800,901</span>
Investor Warrants and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_ze7R5CLzo3Oh" title="Class of Warrant or Right, Outstanding">9,725,690</span>
April Warrants outstanding. These warrants are dilutive and were included in the diluted earnings per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March and April 2022, the Company issued and
sold Pre-Funded Warrants to purchase an aggregate of 3,692,276 shares of common stock at a nominal exercise price of $0.001 per share
(see Note 3). During the six months ended June 30, 2022, all of these warrants were exercised and therefore had no remaining dilutive
effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687988538688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management and Director Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_DisclosureManagementAndDirectorCompensationAbstract', window );"><strong>Management And Director Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_ManagementCompensationAndDirectorFeesTextBlock', window );">Management and Director Compensation</a></td>
<td class="text"><p id="xdx_807_ecustom--ManagementCompensationAndDirectorFeesTextBlock_z5KkuBDQuDgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note
9 &#8211;&#160;<span id="xdx_822_zDX5ip8QyHte">Management and Director Compensation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid its officers cash
compensation totaling $<span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20220401__20220630_zY34y1KauwCh" title="Salary and Wage, Excluding Cost of Good and Service Sold">240,000</span>
and $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20210401__20210630_z8RKq5WXxuM9" title="Salary and Wage, Excluding Cost of Good and Service Sold">25,000</span>
and $<span id="xdx_909_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20220101__20220630_z2yvUYFcjz6b" title="Salary and Wage, Excluding Cost of Good and Service Sold">510,000</span>
and $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20210101__20210630_zslTEogdehVi" title="Salary and Wage, Excluding Cost of Good and Service Sold">125,927</span>
for the three and six month periods ended June 30, 2022 and 2021, respectively. Of these amounts attributable to the Company&#8217;s
CEO, $<span id="xdx_90B_eus-gaap--SalariesWagesAndOfficersCompensation_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrtPharmaMember_pp0p0" title="Salary and Wage, Excluding Cost of Good and Service Sold">110,000</span>
was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. In addition, the
Company issued&#160;<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pdd" title="Stock Issued During Period, Shares, Issued for Services">300,000</span>
shares of common stock valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pp0p0" title="Stock Issued During Period, Value, Issued for Services">918,000</span>
to its officers during the three months ended June 30, 2021. The value of these shares was based upon the closing price of the
Company&#8217;s common stock of $3.06 on the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid its directors cash
compensation totaling $<span id="xdx_90E_eus-gaap--NoninterestExpenseDirectorsFees_c20220401__20220630_zJEt2gt7y3X4"><span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20220101__20220630_zwnSBMje7uxk">50,000</span></span>
and $-<span id="xdx_900_eus-gaap--NoninterestExpenseDirectorsFees_c20210101__20210630_zzSMlS5lHqmc"><span id="xdx_900_eus-gaap--NoninterestExpenseDirectorsFees_c20210401__20210630_zAcALotU9KSb">0</span></span>- for the three and six
month periods ended June 30, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureManagementAndDirectorCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureManagementAndDirectorCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ManagementCompensationAndDirectorFeesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ManagementCompensationAndDirectorFeesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687987778640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedWithFinancingTableTextBlock', window );">Warrants issued with financing</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zNwwGIHXQWqg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details)">
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span id="xdx_8B8_zHel6mXOVqJ5" style="display: none">Warrants issued with financing</span></td>
    <td style="padding-left: 38.8pt">&#160;</td>
    <td style="padding-left: 45.2pt">&#160;</td>
    <td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td>
    <td id="xdx_98E_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,692,276</span></td>
    <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.001</span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z9fDsmqiipj4" title="Warrant Expiration Date">Unlimited</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td>
    <td id="xdx_987_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="padding-left: 38.8pt" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,102,200</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_fKg_____z74M9jRRZxDh" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22*</span></td>
    <td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember" title="Warrant Expiration Date">February 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td>
    <td id="xdx_98B_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,603,604</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span id="xdx_901_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember" title="Warrant Expiration Date">March 2027</span> &#160; &#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April Warrants</span></td>
    <td id="xdx_981_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,725,690</span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zVMa7JU4jioh" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.76</span></td>
    <td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember" title="Warrant Expiration Date">April 2027</span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td id="xdx_F0A_zTXk34pRSl4i" style="padding-left: 10pt; text-indent: -10pt; width: 3%">*</td>
  <td id="xdx_F15_zcKElZ7CBjz9" style="width: 97%">The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#8217;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of outstanding warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zs4LKBBWTYh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details 1)">
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span id="xdx_8BB_zRoQ62lWN0z9" style="display: none">Schedule of outstanding warrants</span></td>
    <td style="padding-left: 38.75pt">&#160;</td>
    <td style="padding-left: 45.2pt">&#160;</td>
    <td style="padding-left: 29.9pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td>
    <td style="border-bottom: Black 1pt solid; padding-left: 38.75pt; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td>
    <td style="padding-left: 38.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zruZdMIt0SP9" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.001</span></td>
    <td style="padding-left: 29.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember" title="Warrant Expiration Date">Unlimited</span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zQz5KJiyVh3i" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">963,693</span></td>
    <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td>
    <td style="padding-left: 29.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zBwIDdqIx9Sj" title="Warrant Expiration Date">February 2027</span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">800,901</span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_z9EWSQI6H2R4" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td>
    <td style="padding-left: 29.9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zmeTYt42lSJd" title="Warrant Expiration Date">March 2027</span> &#160; &#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>April Warrants </td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,725,690</span></td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zlxMhAV6v2vd" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.76</span></td>
    <td style="padding-left: 29.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zNSXivnrEYn" title="Warrant Expiration Date">April 2027</span></span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsIssuedWithFinancingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsIssuedWithFinancingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687984342880">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Feb. 22, 2022</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Stock Redeemed or Called During Period, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=SBFM_AegisOfferingMember', window );">Aegis Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,833,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=SBFM_AegisOfferingMember', window );">Aegis Offering [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=SBFM_AegisOfferingMember', window );">Aegis Offering [Member] | Tradeable Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,102,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,102,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,781,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,752,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,301,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,472,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Investor Warrants 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,301,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Pre Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,302,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Investor Warrants 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,945,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Pre Funded Warrants 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,390,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#8217;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsIssuedNewShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsIssuedNewShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=SBFM_AegisOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=SBFM_AegisOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687985516096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reverse Stock Splits (Details Narrative)<br></strong></div></th>
<th class="th"><div>Feb. 09, 2022</div></th>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th"><div>Feb. 01, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_FirstReverseStockSplitMember', window );">First Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20
to 1 reverse split<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_SecondReverseStockSplitMember', window );">Second Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20
to 1 reverse split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_ThirdReverseStockSplitMember', window );">Third Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">1
for 200 reverse split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_FirstReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_FirstReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_SecondReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_SecondReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_ThirdReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_ThirdReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687980265664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Aug. 18, 2021</div></th>
<th class="th"><div>Jul. 06, 2021</div></th>
<th class="th"><div>Apr. 20, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 327,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20211Member', window );">Note payable - April 20, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 20,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</a></td>
<td class="nump">$ 20,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="nump">520,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20212Member', window );">Note payable - July 6, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  06,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</a></td>
<td class="nump">27,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="nump">927,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20213Member', window );">Note payable - August 18, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 18,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</a></td>
<td class="nump">12,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="nump">$ 512,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20211Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20211Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20212Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20212Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20213Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable20213Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687985701824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Feb. 22, 2022</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
<th class="th"><div>Apr. 22, 2022</div></th>
<th class="th"><div>Feb. 22, 2022</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,833,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redeemed shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 6,781,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,752,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redeemed shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">2,301,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,603,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="nump">1,302,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">2,301,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,472,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrants2Member', window );">Investor Warrants 2 [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,945,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrants1Member', window );">Pre Funded Warrants 1 [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,390,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsIssuedNewShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsIssuedNewShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687984226416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedShares', window );">Number of shares | shares</a></td>
<td class="nump">3,692,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedShares', window );">Number of shares | shares</a></td>
<td class="nump">4,102,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">February 2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedShares', window );">Number of shares | shares</a></td>
<td class="nump">3,603,604<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">March 2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember', window );">April Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedShares', window );">Number of shares | shares</a></td>
<td class="nump">9,725,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">April 2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#8217;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687982207120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details 1)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">February 2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding | shares</a></td>
<td class="nump">963,693<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">March 2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding | shares</a></td>
<td class="nump">800,901<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember', window );">April Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">April 2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding | shares</a></td>
<td class="nump">9,725,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#8217;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687980254000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="nump">3,138,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="nump">$ 6,971,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="nump">2,802,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember', window );">April Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsAndAprilWarrantsMember', window );">Investor Warrants And April Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="nump">$ 6,222,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsAndAprilWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsAndAprilWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687981455104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Apr. 22, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,138,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,802,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember', window );">April Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,725,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=SBFM_AegisOfferingMember', window );">Aegis Offering [Member] | Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="nump">4,102,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,102,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,603,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | April Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_WarrantsIssuedNewShares', window );">Warrants issued new, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,725,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsIssuedNewShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsIssuedNewShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_AprilWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=SBFM_AegisOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=SBFM_AegisOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139687984723184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management and Director Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salary and Wage, Excluding Cost of Good and Service Sold</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 510,000<span></span>
</td>
<td class="nump">$ 125,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Noninterest Expense Directors Fees</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_TrtPharmaMember', window );">TRT Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salary and Wage, Excluding Cost of Good and Service Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember', window );">Officers And Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 918,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_TrtPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_TrtPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>sunshinebio_i10q-063022_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SBFM="http://sunshinebiopharma.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sbfm-20220630.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2022-02-162022-02-17_custom_AegisOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">SBFM:AegisOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="From2022-02-162022-02-17_custom_AegisOfferingMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">SBFM:AegisOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="From2022-02-162022-02-17_custom_AegisOfferingMember_custom_TradeableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">SBFM:AegisOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="From2022-02-212022-02-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2022-02-21</startDate>
            <endDate>2022-02-22</endDate>
        </period>
    </context>
    <context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-13</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_InvestorWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-13</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-13</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-13</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_InvestorWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_PreFundedWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:PreFundedWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-28_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="From2019-01-312019-02-01_custom_FirstReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FirstReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-31</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="From2020-04-052020-04-06_custom_SecondReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:SecondReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-05</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="From2022-02-082022-02-09_custom_ThirdReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:ThirdReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_NotePayable20211Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="From2021-04-192021-04-20_custom_NotePayable20211Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="From2022-02-162022-02-17_custom_NotePayable20211Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="AsOf2021-07-06_custom_NotePayable20212Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20212Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-06</instant>
        </period>
    </context>
    <context id="From2021-07-052021-07-06_custom_NotePayable20212Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20212Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="From2022-02-162022-02-17_custom_NotePayable20212Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20212Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-18_custom_NotePayable20213Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20213Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-18</instant>
        </period>
    </context>
    <context id="From2021-08-172021-08-18_custom_NotePayable20213Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20213Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-17</startDate>
            <endDate>2021-08-18</endDate>
        </period>
    </context>
    <context id="From2022-02-162022-02-17_custom_NotePayable20213Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable20213Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-22_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-22_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-13</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_TradeableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_TradeableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_AprilWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_AprilWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_InvestorWarrantsAndAprilWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsAndAprilWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_AegisOfferingMember_custom_TradeableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">SBFM:AegisOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-22</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_AprilWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-22</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_TrtPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:TrtPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-06-30">0001402328</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-06-30">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-04-012022-06-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012022-06-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:PreferredStockPurchasedFromRelatedPartyValue
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:PreferredStockPurchasedFromRelatedPartyValue
      contextRef="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:PreferredStockPurchasedFromRelatedPartyValue
      contextRef="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <SBFM:PreferredStockPurchasedFromRelatedPartyValue
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-06-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-06-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-01-01to2022-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-06-30">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-06-30">001-41282</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-06-30">SUNSHINE BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-06-30">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-06-30">20-5566275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-06-30">6500 Trans-Canada Highway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-06-30">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2022-01-01to2022-06-30">Pointe-Claire</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-06-30">Quebec</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2022-01-01to2022-06-30">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-06-30">H9R 0A5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-06-30">(514)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-06-30">426-6161</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember">Common Stock</dei:Security12bTitle>
    <dei:Security12bTitle contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember">Common Stock Purchase Warrants</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember">SBFM</dei:TradingSymbol>
    <dei:TradingSymbol contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember">SBFMW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-08-03" decimals="INF" unitRef="Shares">18885632</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41727775</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2045167</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">24</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7798</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">205371</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">105650</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">48562</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">29625</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">7590</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7590</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41989322</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2195830</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">69202</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">64106</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1642</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7061</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41990964</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2202891</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">104684</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">42942</us-gaap:AccountsPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">0</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">48287</us-gaap:InterestPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">104684</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">91229</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1900000</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">104684</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1991229</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">100000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">18885632</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">18885632</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">2591240</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">2591240</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">18886</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2591</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">76331451</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">32787384</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">-34777</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-23139</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">-34430280</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-32655174</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41886280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">211662</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41990964</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2202891</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">150307</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">52874</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">272952</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">92932</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">74683</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">18515</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">134528</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">37035</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">75624</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">34359</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">138424</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">55897</us-gaap:GrossProfit>
    <us-gaap:ProfessionalFees
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">41060</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">19800</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">114860</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">61200</us-gaap:ProfessionalFees>
    <us-gaap:AdvertisingExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">87680</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">182720</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:AdvertisingExpense>
    <SBFM:ConsultingExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">101683</SBFM:ConsultingExpense>
    <SBFM:ConsultingExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">21677</SBFM:ConsultingExpense>
    <SBFM:ConsultingExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">107181</SBFM:ConsultingExpense>
    <SBFM:ConsultingExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">32570</SBFM:ConsultingExpense>
    <us-gaap:LegalFees
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">109130</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">95034</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">245355</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">102151</us-gaap:LegalFees>
    <SBFM:OfficeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">90407</SBFM:OfficeExpense>
    <SBFM:OfficeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">61117</SBFM:OfficeExpense>
    <SBFM:OfficeExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">372912</SBFM:OfficeExpense>
    <SBFM:OfficeExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">100803</SBFM:OfficeExpense>
    <SBFM:OfficerAndDirectorRemuneration
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">290000</SBFM:OfficerAndDirectorRemuneration>
    <SBFM:OfficerAndDirectorRemuneration
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">22000</SBFM:OfficerAndDirectorRemuneration>
    <SBFM:OfficerAndDirectorRemuneration
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">610000</SBFM:OfficerAndDirectorRemuneration>
    <SBFM:OfficerAndDirectorRemuneration
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">1043927</SBFM:OfficerAndDirectorRemuneration>
    <SBFM:PatentingFees
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3230</SBFM:PatentingFees>
    <SBFM:PatentingFees
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">8377</SBFM:PatentingFees>
    <SBFM:PatentingFees
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">11564</SBFM:PatentingFees>
    <SBFM:PatentingFees
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">14570</SBFM:PatentingFees>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">45943</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">191760</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">407595</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">358546</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Depreciation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">2287</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">3192</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">5397</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">6374</us-gaap:Depreciation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">771420</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">422957</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">2057584</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">1720141</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-695796</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-388598</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1919160</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-1664244</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">29</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">8</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">20</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-6</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">146043</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">146046</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">2</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">195630</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">12864</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">245341</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">10852</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">221</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">10852</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">51252</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2295057</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">7205843</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">156924</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-2490456</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">144054</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-7399936</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-538872</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-2879054</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1775106</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-9064180</us-gaap:ProfitLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-538872</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-2879054</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1775106</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-9064180</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-12645</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-6702</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-11638</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-8765</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-551517</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-2885756</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1786744</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-9072945</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-3.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">15849518</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">2392602</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-06-30"
      decimals="INF"
      unitRef="Shares">9691265</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-06-30"
      decimals="INF"
      unitRef="Shares">2293836</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1775106</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-9064180</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">5397</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">6374</us-gaap:DepreciationAndAmortization>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">20</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">6</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">918000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <SBFM:StockIssuedForPaymentInterestOnNotesPayable
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">0</SBFM:StockIssuedForPaymentInterestOnNotesPayable>
    <SBFM:StockIssuedForPaymentInterestOnNotesPayable
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">38422</SBFM:StockIssuedForPaymentInterestOnNotesPayable>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">7205843</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">10852</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">51252</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-7774</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-1916</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">99721</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">27736</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">18937</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">12907</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">61742</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">35524</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-48287</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">33795</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1878010</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-916207</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <SBFM:ProceedsPublicOfferingNet
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-43560363</SBFM:ProceedsPublicOfferingNet>
    <SBFM:ProceedsPublicOfferingNet
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-1918500</SBFM:ProceedsPublicOfferingNet>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-99000</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">61500</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">1900000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">327352</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">41561363</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">1652648</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2045167</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">989888</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">39683353</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">736441</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-12383</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">11638</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">8765</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41727775</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1735094</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <SBFM:StockIssuedForNoteConversionsIncludingInterest
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">0</SBFM:StockIssuedForNoteConversionsIncludingInterest>
    <SBFM:StockIssuedForNoteConversionsIncludingInterest
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">8237072</SBFM:StockIssuedForNoteConversionsIncludingInterest>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">61151</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">142152</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7149778</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7150</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">47219498</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-22132</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-33891408</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">13314108</us-gaap:StockholdersEquity>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2472820</SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2473</SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">16750442</SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">16752915</SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9263034</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9263</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">12361511</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">12370774</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-12645</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-538872</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-551517</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18885632</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18886</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">76331451</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-34777</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-34430280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41886280</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2595620</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2596</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">32787379</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-23139</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-32655174</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">211662</us-gaap:StockholdersEquity>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6656526</SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6657</SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">30360528</SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts>
    <SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">30367185</SBFM:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9633486</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9633</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">13183544</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">13193177</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <SBFM:PreferredStockPurchasedFromRelatedPartyShares
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">-990000</SBFM:PreferredStockPurchasedFromRelatedPartyShares>
    <SBFM:PreferredStockPurchasedFromRelatedPartyValue
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">99000</SBFM:PreferredStockPurchasedFromRelatedPartyValue>
    <SBFM:PreferredStockPurchasedFromRelatedPartyValue
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">99000</SBFM:PreferredStockPurchasedFromRelatedPartyValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-11638</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1775106</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1786744</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18885632</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18886</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">76331451</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-34777</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-34430280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">41886280</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2325030</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2325</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">25222073</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-4934</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-26403853</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1084389</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">105437</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">105</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3097330</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">3097435</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-6702</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2879054</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-2885756</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2430466</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">28319403</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-11636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-29282907</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-872710</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1732096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1732</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">19165029</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-2871</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-20218727</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-954837</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">398370</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">398</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8236674</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">8237072</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">300</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">917700</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">918000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-8765</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-9064180</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-9072945</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2430466</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">28319403</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-11636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-29282907</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-872710</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAIBofJQo2X5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 1 &#x2013;&#160;&lt;span id="xdx_82E_zt1lXNVsyes9"&gt;Nature of Business&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sunshine Biopharma, Inc. (the &#x201c;Company&#x201d;)
was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until
October 2009, the Company was operating as a business consultancy firm.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective October 15, 2009, the Company acquired
Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. held an exclusive license to a
new anticancer drug bearing the laboratory name, Adva-27a (the &#x201c;License Agreement&#x201d;). Upon completion of the reverse acquisition
transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the
development of the licensed Adva-27a anticancer drug.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2015, the Company acquired all worldwide
issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a
anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of
these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2018, the Company launched its first
Science-Based Nutritional Supplements product, Essential 9&lt;span style="font-variant: small-caps"&gt;&lt;sup&gt;&#x2122;&lt;/sup&gt;&lt;/span&gt;, an over-the-counter
capsule comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9&lt;span style="font-variant: small-caps"&gt;&lt;sup&gt;&#x2122;&#160;&lt;/sup&gt;&lt;/span&gt;has
been authorized for marketing by Health Canada under NPN 80089663.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 22, 2020, the Company filed a provisional
patent application in the United States for a new treatment for Coronavirus infections. The Company&#x2019;s patent application covers
composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential
for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application
containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May
22, 2020 has been maintained in the newly filed PCT application. The Company&#x2019;s lead Anti-Coronavirus compound arising from these
patents bears the laboratory name SBFM-PL4.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 26, 2021, the Company received a Notice
of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains
new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 9, 2021, the Company received a Notice
of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject
matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued
in 2019 (US Patent Number 10,272,065).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 1, 2021, the Company filed a patent
application for a potential new treatment for neurodegenerative disorders. The patent application contains experimental results showing
that certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics
neuronal degeneration. This new patent application has a priority date of October 1, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective February 9, 2022, the Company
completed a 200-for-1 reverse split of its common stock. On February 15, 2022, the Company entered into an underwriting agreement
with Aegis Capital Corp. as underwriter, for the issuance and sale in an underwritten public offering of 1,882,353 Units, each
consisting of one share of common stock and two warrants (&#x201c;Tradeable Warrants&#x201d;) to purchase shares of common stock at a
public offering price of $4.25 per Unit for total gross proceeds of $8,000,000 (&#x201c;Public Offering&#x201d;). On February 17,
2022, the Public Offering closed and the Company received net proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember_zXezFsvjKvX7" title="Proceeds from Issuance or Sale of Equity"&gt;6,833,071&lt;/span&gt;.
Pursuant to the Public Offering, the Company issued and sold an aggregate of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" title="Stock Issued During Period, Shares, New Issues"&gt;1,882,353&lt;/span&gt;
shares of common stock and &lt;span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Warrants issued new, shares"&gt;4,102,200&lt;/span&gt;
Tradeable Warrants (including 337,494 Tradeable Warrants purchased at $0.01 per warrant resulting from partial exercise of the
overallotment option granted to the underwriter). In connection with these transactions, the Company&#x2019;s shares of common stock
and Tradeable Warrants began trading on Nasdaq under the symbol &#x201c;SBFM&#x201d; for the common stock and &#x201c;SBFMW&#x201d; for
the Tradeable Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 18, 2022, the Company entered
into a research agreement (the &#x201c;SRA&#x201d;) with the University of Arizona for the purposes of conducting research focused on
determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro
inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the &#x201c;Research Project&#x201d;). Under the SRA,
the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual
property developed by University of Arizona personnel under the Research Project. In addition, the Company and the University of
Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial
license for the underlying technology of the Research Project.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 22, 2022, the Company redeemed&#160;&lt;span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220221__20220222_pdd"&gt;990,000
&lt;/span&gt;shares of the Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per
share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 14, 2022, the Company completed a private
placement wherein the Company sold (i)&#160;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd"&gt;2,301,353&lt;/span&gt;&#160;shares
of its common stock together with warrants (the &#x201c;Investor Warrants&#x201d;) to purchase up to&#160;&lt;span id="xdx_908_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants1Member_pdd"&gt;2,301,353
&lt;/span&gt;shares of common stock, and (ii)&#160;&lt;span id="xdx_90F_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd"&gt;1,302,251&lt;/span&gt;&#160;pre-funded
warrants (&#x201c;Pre-Funded Warrants&#x201d;) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor
Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together
at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined
offering price of $2.219. The Company received approximately $8 million in gross proceeds, and $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_pp0p0"&gt;6,781,199&lt;/span&gt;&#160;in
net proceeds in this offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 28, 2022, the Company completed
another private placement and received net proceeds of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_zIv0BXUmdJe6" title="Proceeds from Issuance of private placement"&gt;16,752,915&lt;/span&gt;.
In connection with this private placement, the Company issued (i)&#160;&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFyQuhJjUdtk" title="Stock Issued During Period, Shares, New Issues"&gt;2,472,820&#160;&lt;/span&gt;shares
of its common stock together with warrants (&#x201c;April Warrants&#x201d;) to purchase up to &lt;span id="xdx_900_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants2Member_ztiM83NU0j7" title="Warrants issued new, shares"&gt;4,945,640&lt;/span&gt;
shares of common stock, and (ii)&#160;&lt;span id="xdx_908_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants1Member_zaCHdbBo9hok" title="Warrants issued new, shares"&gt;2,390,025&lt;/span&gt;&#160;pre-funded
warrants (&#x201c;Pre-Funded Warrants&#x201d;) with each Pre-Funded Warrant exercisable for one share of common stock, together with
April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants
were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold
together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at
a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001,
and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise
price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220428__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrsQ3EVo90nc" title="Warrants exercise price"&gt;3.76&lt;/span&gt;
per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the
date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-02-162022-02-17_custom_AegisOfferingMember"
      decimals="0"
      unitRef="USD">6833071</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-162022-02-17_custom_AegisOfferingMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1882353</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-02-162022-02-17_custom_AegisOfferingMember_custom_TradeableWarrantsMember"
      decimals="INF"
      unitRef="Shares">4102200</SBFM:WarrantsIssuedNewShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2022-02-212022-02-22"
      decimals="INF"
      unitRef="Shares">990000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2301353</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_InvestorWarrants1Member"
      decimals="INF"
      unitRef="Shares">2301353</SBFM:WarrantsIssuedNewShares>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">1302251</SBFM:WarrantsIssuedNewShares>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">6781199</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">16752915</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2472820</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_InvestorWarrants2Member"
      decimals="INF"
      unitRef="Shares">4945640</SBFM:WarrantsIssuedNewShares>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_PreFundedWarrants1Member"
      decimals="INF"
      unitRef="Shares">2390025</SBFM:WarrantsIssuedNewShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-28_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z4z0pGzB19ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
2 &#x2013; &lt;span id="xdx_821_zM2MV1wCrL4g"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unaudited financial statements of the Company
for the six month periods ended June 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted
in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation
S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United
States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring
adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of
operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The
balance sheet information as of December 31, 2021 was derived from the audited financial statements included in the Company's financial
statements as of and for the year ended December 31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities
and Exchange Commission (the &#x201c;SEC&#x201d;) on March 21, 2022. These financial statements should be read in conjunction with that
report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <SBFM:ImpactOfCovid19PandemicTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_807_ecustom--ImpactOfCovid19PandemicTextBlock_zeZjd7sj95Ne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 3 &#x2013;&#160;&lt;span id="xdx_823_zvNzyqp9M48d"&gt;Impact of Coronavirus
(COVID-19) Pandemic&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2020, the World Health Organization declared
Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are
continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate
the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on
the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of
the adverse conditions of the outbreak and their effects on the Company&#x2019;s business or ability to raise funds. No adjustments have
been made to the amounts reported in the Company's financial statements as a result of this matter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</SBFM:ImpactOfCovid19PandemicTextBlock>
    <SBFM:ReverseStockSplitTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_80F_ecustom--ReverseStockSplitTextBlock_zwi1bC5n35q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 4 &#x2013;&#160;&lt;span id="xdx_820_zJpsbtK6L983"&gt;Reverse Stock Splits&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective February 1, 2019, the Company
completed a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20190131__20190201__us-gaap--TransactionTypeAxis__custom--FirstReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split"&gt;20
to 1 reverse split&lt;/span&gt;&#160;of its common stock (the &#x201c;First Reverse Stock Split&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective April 6, 2020, the Company
completed another &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20200405__20200406__us-gaap--TransactionTypeAxis__custom--SecondReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split"&gt;20
to 1 reverse split&lt;/span&gt;&#160;of its common stock (the &#x201c;Second Reverse Stock Split&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective February 9, 2022, the Company
completed a &lt;span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220208__20220209__us-gaap--TransactionTypeAxis__custom--ThirdReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split"&gt;1
for 200 reverse split&lt;/span&gt;&#160;of its common stock (the &#x201c;Third Reverse Stock Split&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company's financial statements reflect the
First, Second, and Third Reverse Stock Split on a retroactive basis for all periods presented and for all references to common stock,
unless specifically stated otherwise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</SBFM:ReverseStockSplitTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2019-01-312019-02-01_custom_FirstReverseStockSplitMember">20
to 1 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2020-04-052020-04-06_custom_SecondReverseStockSplitMember">20
to 1 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-02-082022-02-09_custom_ThirdReverseStockSplitMember">1
for 200 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zclClVkoWcSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 5 &#x2013;&#160;&lt;span id="xdx_82C_z0XWrLffMlva"&gt;Notes Payable&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2022 and December 31, 2021, the
Company had $-&lt;span id="xdx_904_eus-gaap--NotesPayable_iI_c20220630_z4hJEkHnWqV4"&gt;0&lt;/span&gt;- and $&lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_c20211231_zi8I1eAmG42g"&gt;1,900,000&lt;/span&gt;, respectively in notes payable outstanding. At June 30, 2022 and December 31, 2021, total
accrued interest on Notes Payable was $-&lt;span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_c20220630_pp0p0" title="Interest Payable"&gt;0&lt;/span&gt;- and $&lt;span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_c20211231_pp0p0" title="Interest Payable"&gt;48,287&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s Notes Payable at December
31, 2021 consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 20, 2021, the Company received
monies in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zPPcoqZCDRSe" title="Face Value"&gt;500,000&lt;/span&gt;
with interest accruing at&#160;&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210419__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zwm5d5RTlfy7" title="Interest Rate"&gt;5&lt;/span&gt;%
due&#160;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210419__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zHz4IQAMnoTl" title="Maturity Date"&gt;April
20, 2023&lt;/span&gt;. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On
February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $&lt;span id="xdx_90C_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities"&gt;20,753&lt;/span&gt;&#160;by
making a cash payment of $&lt;span id="xdx_903_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0" title="Repayments of notes payable"&gt;520,753&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 6, 2021, the Company received monies in
exchange for a Note Payable having a Face Value of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Face Value"&gt;900,000&lt;/span&gt;&#160;with interest accruing at&#160;&lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210705__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_zfA2y1eRgnsh" title="Interest Rate"&gt;5&lt;/span&gt;%, due&#160;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210705__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_z7TCLKqxPGqf" title="Maturity Date"&gt;July 6, 2023&lt;/span&gt;. The Note was
convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid
off the entire principal balance of this Note, together with accrued interest of $&lt;span id="xdx_90F_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities"&gt;27,863&lt;/span&gt;&#160;by making a cash payment of $&lt;span id="xdx_900_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Repayments of notes payable"&gt;927,863&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 18, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Face Value"&gt;500,000&lt;/span&gt;&#160;with interest accruing at&#160;&lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210817__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_zkcwCKnbVo" title="Interest Rate"&gt;5&lt;/span&gt;%, due&#160;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210817__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_zbecLUAMckU7" title="Maturity Date"&gt;August 18, 2023&lt;/span&gt;. The Note
was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company
paid off the entire principal balance of this Note, together with accrued of $&lt;span id="xdx_90E_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities"&gt;12,534&lt;/span&gt;&#160;by making a cash payment of $&lt;span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Repayments of notes payable"&gt;512,534&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:NotesPayable contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1900000</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">48287</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-04-20_custom_NotePayable20211Member"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-04-192021-04-20_custom_NotePayable20211Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-192021-04-20_custom_NotePayable20211Member">2023-04-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:InterestPaid
      contextRef="From2022-02-162022-02-17_custom_NotePayable20211Member"
      decimals="0"
      unitRef="USD">20753</us-gaap:InterestPaid>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-02-162022-02-17_custom_NotePayable20211Member"
      decimals="0"
      unitRef="USD">520753</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-07-06_custom_NotePayable20212Member"
      decimals="0"
      unitRef="USD">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-07-052021-07-06_custom_NotePayable20212Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-07-052021-07-06_custom_NotePayable20212Member">2023-07-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:InterestPaid
      contextRef="From2022-02-162022-02-17_custom_NotePayable20212Member"
      decimals="0"
      unitRef="USD">27863</us-gaap:InterestPaid>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-02-162022-02-17_custom_NotePayable20212Member"
      decimals="0"
      unitRef="USD">927863</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-08-18_custom_NotePayable20213Member"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-08-172021-08-18_custom_NotePayable20213Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-08-172021-08-18_custom_NotePayable20213Member">2023-08-18</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:InterestPaid
      contextRef="From2022-02-162022-02-17_custom_NotePayable20213Member"
      decimals="0"
      unitRef="USD">12534</us-gaap:InterestPaid>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-02-162022-02-17_custom_NotePayable20213Member"
      decimals="0"
      unitRef="USD">512534</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zojQFM97v0k4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 6 &#x2013;&#160;&lt;span id="xdx_826_zMBU3igjlIM8"&gt;Shareholders&#x2019;
Equity&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 17, 2022, the Company&#x2019;s Public
Offering closed and the Company received net proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20220201__20220217_zNiKKGiuH9La" title="Net proceeds"&gt;6,833,071&lt;/span&gt;&#160;from the offering. Pursuant to the Public Offering, the Company
issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 Tradeable Warrants (including 337,494 Tradeable Warrants
resulting from partial exercise of the overallotment option granted to the underwriter).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 22, 2022, the Company
redeemed&#160;&lt;span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220201__20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Redeemed shares"&gt;990,000&lt;/span&gt;
shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $&lt;span id="xdx_90A_eus-gaap--PreferredStockRedemptionPricePerShare_c20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Redemption price"&gt;0.10&lt;/span&gt;&#160;per
share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 14, 2022, the Company completed a private
placement and received net proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_zMp0U0uSN8Xh" title="Proceeds from Issuance or Sale of Equity"&gt;6,781,199&lt;/span&gt;. In connection with this private placement, the Company issued (i)&#160;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Stock Issued During Period, Shares, New Issues"&gt;2,301,353&lt;/span&gt;&#160;shares
of its common stock together with investor warrants (&#x201c;Investor Warrants&#x201d;) to purchase up to 2,301,353 shares of common stock,
and (ii)&#160;&lt;span id="xdx_90E_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zA2FPkQpk4ah" title="Warrants issued new, shares"&gt;1,302,251&lt;/span&gt;&#160;pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;) with each Pre-Funded Warrant exercisable for one
share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock
and accompanying Investor Warrant were sold together at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying
Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a
nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor
Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance
and will expire five years from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 28, 2022, the Company completed another
private placement and received net proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_znVYp6jYYmB4" title="Proceeds from Issuance of private placement"&gt;16,752,915&lt;/span&gt;. In connection with this private placement, the Company issued (i)&#160;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zoXANp3cjiw7" title="Stock Issued During Period, Shares, New Issues"&gt;2,472,820&lt;/span&gt;&#160;shares
of its common stock together with warrants (&#x201c;April Warrants&#x201d;) to purchase up to &lt;span id="xdx_900_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants2Member_pdd" title="Warrants issued new, shares"&gt;4,945,640&lt;/span&gt; shares of common stock, and (ii)&#160;&lt;span id="xdx_904_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants1Member_pdd" title="Warrants issued new, shares"&gt;2,390,025&lt;/span&gt;&#160;pre-funded
warrants (&#x201c;Pre-Funded Warrants&#x201d;) with each Pre-Funded Warrant exercisable for one share of common stock, together with April
Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and
accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying
two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at
a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April
Warrants have an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220428__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants exercise price"&gt;3.76&lt;/span&gt; per share (subject
to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company declared&#160;&lt;span id="xdx_90F_eus-gaap--Dividends_pp0p0_do_c20220101__20220630_zBDcFb5wh1jl" title="Dividends"&gt;no&lt;/span&gt;&#160;dividends through
June 30, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-02-012022-02-17"
      decimals="0"
      unitRef="USD">6833071</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2022-02-012022-02-22_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">990000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2022-02-22_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">6781199</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="Shares">2301353</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-03-132022-03-14_us-gaap_PrivatePlacementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">1302251</SBFM:WarrantsIssuedNewShares>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">16752915</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2472820</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_InvestorWarrants2Member"
      decimals="INF"
      unitRef="Shares">4945640</SBFM:WarrantsIssuedNewShares>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-04-012022-04-28_us-gaap_PrivatePlacementMember_custom_PreFundedWarrants1Member"
      decimals="INF"
      unitRef="Shares">2390025</SBFM:WarrantsIssuedNewShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-28_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:Dividends
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:Dividends>
    <SBFM:WarrantsDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_807_ecustom--WarrantsDisclosureTextBlock_zFMrKuaeW6uk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 7 &#x2013; &lt;span id="xdx_822_zTk2EsEnNZk1"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5pt 0pt 0; text-align: justify"&gt;The Company accounts for issued warrants
either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if
they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not
meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants
should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless
of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance
date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the
consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order
to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether
the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for
at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.6pt 0pt 0; text-align: justify"&gt;During the six months ended June 30,
2022, the Company completed three financing events, and in connection therewith, it issued warrants as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zNwwGIHXQWqg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details)"&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span id="xdx_8B8_zHel6mXOVqJ5" style="display: none"&gt;Warrants issued with financing&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 38.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 45.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TYPE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 38.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NUMBER&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EXERCISE PRICE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EXPIRY DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,692,276&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$0.001&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z9fDsmqiipj4" title="Warrant Expiration Date"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tradeable Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="padding-left: 38.8pt" title="Number of shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,102,200&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_fKg_____z74M9jRRZxDh" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember" title="Warrant Expiration Date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,603,604&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"&gt;&lt;span id="xdx_901_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember" title="Warrant Expiration Date"&gt;March 2027&lt;/span&gt; &#160; &#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,725,690&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zVMa7JU4jioh" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$3.76&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember" title="Warrant Expiration Date"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td id="xdx_F0A_zTXk34pRSl4i" style="padding-left: 10pt; text-indent: -10pt; width: 3%"&gt;*&lt;/td&gt;
  &lt;td id="xdx_F15_zcKElZ7CBjz9" style="width: 97%"&gt;The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#x2019;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A9_zZZZDsrAp9f3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55pt 0pt 0"&gt;During the six months ended June 30, 2022, all of the Pre-Funded
Warrants and a total of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zGyR0xDlg9cg" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"&gt;3,138,507&lt;/span&gt; Tradeable Warrants were exercised resulting in aggregate proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pp0p0" title="Proceeds from Warrant Exercises"&gt;6,971,178&lt;/span&gt; received by the Company.
In addition, during the six months ended June 30, 2022, a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zxNm0NWhikaj"&gt;2,802,703&lt;/span&gt; Investor Warrants and -&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zDLU153xNiQ3"&gt;0&lt;/span&gt;- April Warrants were exercised resulting
in aggregate proceeds of $ $&lt;span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsAndAprilWarrantsMember_zJrmPrF0Mcdi"&gt;6,222,001&lt;/span&gt; received by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s outstanding warrants at June 30, 2022 consisted
of the following:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zs4LKBBWTYh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details 1)"&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span id="xdx_8BB_zRoQ62lWN0z9" style="display: none"&gt;Schedule of outstanding warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 38.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 45.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 29.9pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TYPE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 38.75pt; width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NUMBER&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EXERCISE PRICE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EXPIRY DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 38.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;None&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zruZdMIt0SP9" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$0.001&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 29.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember" title="Warrant Expiration Date"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tradeable Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zQz5KJiyVh3i" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;963,693&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 29.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zBwIDdqIx9Sj" title="Warrant Expiration Date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;800,901&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_z9EWSQI6H2R4" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 29.9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zmeTYt42lSJd" title="Warrant Expiration Date"&gt;March 2027&lt;/span&gt; &#160; &#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;April Warrants &lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,725,690&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zlxMhAV6v2vd" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$3.76&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 29.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zNSXivnrEYn" title="Warrant Expiration Date"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zymYOMYDsxH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</SBFM:WarrantsDisclosureTextBlock>
    <SBFM:WarrantsIssuedWithFinancingTableTextBlock contextRef="From2022-01-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zNwwGIHXQWqg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details)"&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span id="xdx_8B8_zHel6mXOVqJ5" style="display: none"&gt;Warrants issued with financing&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 38.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 45.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TYPE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 38.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NUMBER&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EXERCISE PRICE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EXPIRY DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,692,276&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$0.001&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z9fDsmqiipj4" title="Warrant Expiration Date"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tradeable Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="padding-left: 38.8pt" title="Number of shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,102,200&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_fKg_____z74M9jRRZxDh" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.9pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember" title="Warrant Expiration Date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,603,604&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"&gt;&lt;span id="xdx_901_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember" title="Warrant Expiration Date"&gt;March 2027&lt;/span&gt; &#160; &#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--WarrantsIssuedShares_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="padding-left: 38.75pt" title="Number of shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,725,690&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zVMa7JU4jioh" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$3.76&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 29.85pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember" title="Warrant Expiration Date"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td id="xdx_F0A_zTXk34pRSl4i" style="padding-left: 10pt; text-indent: -10pt; width: 3%"&gt;*&lt;/td&gt;
  &lt;td id="xdx_F15_zcKElZ7CBjz9" style="width: 97%"&gt;The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#x2019;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</SBFM:WarrantsIssuedWithFinancingTableTextBlock>
    <SBFM:WarrantsIssuedShares
      contextRef="From2022-01-012022-06-30_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">3692276</SBFM:WarrantsIssuedShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate contextRef="From2022-01-012022-06-30_custom_PreFundedWarrantsMember">Unlimited</SBFM:WarrantExpirationDate>
    <SBFM:WarrantsIssuedShares
      contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember"
      decimals="INF"
      unitRef="Shares">4102200</SBFM:WarrantsIssuedShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_custom_TradeableWarrantsMember"
      decimals="INF"
      id="Fact000695"
      unitRef="USDPShares">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember">February 2027</SBFM:WarrantExpirationDate>
    <SBFM:WarrantsIssuedShares
      contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="Shares">3603604</SBFM:WarrantsIssuedShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember">March 2027</SBFM:WarrantExpirationDate>
    <SBFM:WarrantsIssuedShares
      contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember"
      decimals="INF"
      unitRef="Shares">9725690</SBFM:WarrantsIssuedShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_custom_AprilWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember">April 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember"
      decimals="INF"
      unitRef="Shares">3138507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember"
      decimals="0"
      unitRef="USD">6971178</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="Shares">2802703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsAndAprilWarrantsMember"
      decimals="0"
      unitRef="USD">6222001</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zs4LKBBWTYh1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details 1)"&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span id="xdx_8BB_zRoQ62lWN0z9" style="display: none"&gt;Schedule of outstanding warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 38.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 45.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 29.9pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TYPE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 38.75pt; width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NUMBER&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 41.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EXERCISE PRICE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 25%; padding-left: 29.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EXPIRY DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 38.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;None&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zruZdMIt0SP9" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$0.001&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 29.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember" title="Warrant Expiration Date"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tradeable Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zQz5KJiyVh3i" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;963,693&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="padding-left: 45.2pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 29.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zBwIDdqIx9Sj" title="Warrant Expiration Date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;800,901&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_z9EWSQI6H2R4" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 29.9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zmeTYt42lSJd" title="Warrant Expiration Date"&gt;March 2027&lt;/span&gt; &#160; &#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td&gt;April Warrants &lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="padding-left: 38.75pt" title="Class of Warrant or Right, Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,725,690&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zlxMhAV6v2vd" style="padding-left: 45.15pt" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$3.76&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 29.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDate_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zNSXivnrEYn" title="Warrant Expiration Date"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate contextRef="From2022-01-012022-06-30_custom_PreFundedWarrantsMember">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-06-30_custom_TradeableWarrantsMember"
      decimals="INF"
      unitRef="Shares">963693</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_custom_TradeableWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember">February 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-06-30_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="Shares">800901</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember">March 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-06-30_custom_AprilWarrantsMember"
      decimals="INF"
      unitRef="Shares">9725690</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_custom_AprilWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember">April 2027</SBFM:WarrantExpirationDate>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zBGzjx2UgKuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 8 &#x2013;&#160;&lt;span id="xdx_82F_zRFkWoVQ7D42"&gt;Net Loss Per Common
Share&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per share is calculated by dividing
the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common
stock equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Diluted net loss per share is calculated by dividing
the net loss by the weighted-average number of shares of common stock outstanding during the period, taking into consideration common
stock equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2022, the Company
issued&#160;&lt;span id="xdx_902_ecustom--WarrantsIssuedNewShares_c20220201__20220228__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zJOr9LNc4Haa" title="Warrants issued new, shares"&gt;4,102,200&lt;/span&gt;&#160;Tradeable
Warrants pursuant to the Company&#x2019;s Public Offering. In March and April 2022, the Company issued &lt;span id="xdx_906_ecustom--WarrantsIssuedNewShares_c20220401__20220422__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zLtdZnW6zXOd" title="Warrants issued new, shares"&gt;3,603,604&lt;/span&gt;
Investor Warrants and &lt;span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20220401__20220422__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zmoOgbNWMhSh" title="Warrants issued new, shares"&gt;9,725,690&lt;/span&gt;
April Warrants pursuant to two private placements. As of June 30, 2022, &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"&gt;3,138,507&lt;/span&gt;
Tradeable Warrants, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zGgoJ3U13c58" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"&gt;2,802,703&lt;/span&gt;
Investor Warrants, and -&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_z6EonkBgpa99" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"&gt;0&lt;/span&gt;-
April Warrants were exercised, leaving&#160;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding"&gt;963,693&lt;/span&gt;
Tradeable Warrants, &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zMKuuL71SByl" title="Class of Warrant or Right, Outstanding"&gt;800,901&lt;/span&gt;
Investor Warrants and &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_ze7R5CLzo3Oh" title="Class of Warrant or Right, Outstanding"&gt;9,725,690&lt;/span&gt;
April Warrants outstanding. These warrants are dilutive and were included in the diluted earnings per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March and April 2022, the Company issued and
sold Pre-Funded Warrants to purchase an aggregate of 3,692,276 shares of common stock at a nominal exercise price of $0.001 per share
(see Note 3). During the six months ended June 30, 2022, all of these warrants were exercised and therefore had no remaining dilutive
effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-02-012022-02-28_custom_AegisOfferingMember_custom_TradeableWarrantsMember"
      decimals="INF"
      unitRef="Shares">4102200</SBFM:WarrantsIssuedNewShares>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="Shares">3603604</SBFM:WarrantsIssuedNewShares>
    <SBFM:WarrantsIssuedNewShares
      contextRef="From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_AprilWarrantsMember"
      decimals="INF"
      unitRef="Shares">9725690</SBFM:WarrantsIssuedNewShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-06-30_custom_TradeableWarrantsMember"
      decimals="INF"
      unitRef="Shares">3138507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-06-30_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="Shares">2802703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-06-30_custom_AprilWarrantsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-06-30_custom_TradeableWarrantsMember"
      decimals="INF"
      unitRef="Shares">963693</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-06-30_custom_InvestorWarrantsMember"
      decimals="INF"
      unitRef="Shares">800901</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-06-30_custom_AprilWarrantsMember"
      decimals="INF"
      unitRef="Shares">9725690</us-gaap:ClassOfWarrantOrRightOutstanding>
    <SBFM:ManagementCompensationAndDirectorFeesTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_807_ecustom--ManagementCompensationAndDirectorFeesTextBlock_z5KkuBDQuDgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
9 &#x2013;&#160;&lt;span id="xdx_822_zDX5ip8QyHte"&gt;Management and Director Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company paid its officers cash
compensation totaling $&lt;span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20220401__20220630_zY34y1KauwCh" title="Salary and Wage, Excluding Cost of Good and Service Sold"&gt;240,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20210401__20210630_z8RKq5WXxuM9" title="Salary and Wage, Excluding Cost of Good and Service Sold"&gt;25,000&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20220101__20220630_z2yvUYFcjz6b" title="Salary and Wage, Excluding Cost of Good and Service Sold"&gt;510,000&lt;/span&gt;
and $&lt;span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20210101__20210630_zslTEogdehVi" title="Salary and Wage, Excluding Cost of Good and Service Sold"&gt;125,927&lt;/span&gt;
for the three and six month periods ended June 30, 2022 and 2021, respectively. Of these amounts attributable to the Company&#x2019;s
CEO, $&lt;span id="xdx_90B_eus-gaap--SalariesWagesAndOfficersCompensation_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrtPharmaMember_pp0p0" title="Salary and Wage, Excluding Cost of Good and Service Sold"&gt;110,000&lt;/span&gt;
was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. In addition, the
Company issued&#160;&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pdd" title="Stock Issued During Period, Shares, Issued for Services"&gt;300,000&lt;/span&gt;
shares of common stock valued at $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pp0p0" title="Stock Issued During Period, Value, Issued for Services"&gt;918,000&lt;/span&gt;
to its officers during the three months ended June 30, 2021. The value of these shares was based upon the closing price of the
Company&#x2019;s common stock of $3.06 on the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company paid its directors cash
compensation totaling $&lt;span id="xdx_90E_eus-gaap--NoninterestExpenseDirectorsFees_c20220401__20220630_zJEt2gt7y3X4"&gt;&lt;span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20220101__20220630_zwnSBMje7uxk"&gt;50,000&lt;/span&gt;&lt;/span&gt;
and $-&lt;span id="xdx_900_eus-gaap--NoninterestExpenseDirectorsFees_c20210101__20210630_zzSMlS5lHqmc"&gt;&lt;span id="xdx_900_eus-gaap--NoninterestExpenseDirectorsFees_c20210401__20210630_zAcALotU9KSb"&gt;0&lt;/span&gt;&lt;/span&gt;- for the three and six
month periods ended June 30, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</SBFM:ManagementCompensationAndDirectorFeesTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">240000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">25000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">510000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">125927</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2022-01-012022-06-30_custom_TrtPharmaMember"
      decimals="0"
      unitRef="USD">110000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-06-30_custom_OfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Shares">300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-06-30_custom_OfficersAndDirectorsMember"
      decimals="0"
      unitRef="USD">918000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:NoninterestExpenseDirectorsFees>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000695"
          xlink:label="Fact000695"
          xlink:type="locator"/>
        <link:footnote id="Footnote000710" xlink:label="Footnote000710" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Tradeable Warrants had an initial exercise price of $4.25, subject to
  adjustment. Upon the closing of the Company&#x2019;s private placement on March 14, 2022, the exercise price of the Tradeable
  Warrants was reduced to $2.22, in accordance with the terms thereof.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000695"
          xlink:to="Footnote000710"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !EA0-5LJ8RXD$&   [)   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6:_W.:2!B'_Y4=;^:FG8D1%C6V9YPQ-&F\:XR)Z75Z-_?#!E9E"JRW+#'Y
M[^_EBV![RRMEPB^)*._'?5AV?188[X3\%FTX5^0Y\,/HO+-1:ON^UXN<#0]8
M="JV/(1/5D(&3,&F7/>BK>3,38L"OT<-8]@+F!=V)N/TO86<C$6L?"_D"TFB
M. B8?+G@OMB==\S._HU[;[U1R1N]R7C+UGS)U>?M0L)6KTAQO8"'D2="(OGJ
MO#,UW]O6*"E(]_C3X[OHX#5)4!Z%^)9LS-SSCI&TB/O<44D$@W]/W.:^GR1!
M._[-0SO%=R:%AZ_WZ5<I/, \LHC;PO_BN6ISWAEUB,M7+/;5O=A=\QQHD.0Y
MPH_2OV27[=OO=X@31TH$>3&T(/#"[#][S@_$08%E5A30O(#^4&!6?8.5%U@I
M:-:R%.L#4VPREF)'9+(WI"4OTF.35@.-%R;=N%02/O6@3DUL\<0EZ9)HPR2/
MQCT%F<DG/2>OO\CJ:47]D-R(4&TB<AFZW/V^O@=M*1I$]PVZH&C@[W%X2BSC
MA%"#4DU[;+Q\&J]/B6'IRK]KCE4<'RO-LRKR/@@GAK-6D8>7+=<='KS<-+IW
M.@BT*AFZ[Z,M<_AY!\9FQ.43[TQ^_<4<&K\A2/T"J8^V:0H\;LITY;.UC@FO
M7S$_TAT*&RUK"#4HH ;U^NDN9E)QZ;^0>[X54NGX\"@E8RT>6M40;UC@#6N>
MAI+!%)K.@-5\>%9E_Z%E#0'/"L"S>H ++CWA)M,)@0E-.^3PI&("J9Q!T/J&
MG*."<U2/\\J+'.;O<:_@;>WLBZ?=:?G0FH9\[PJ^=S_%]Y4S64V'9U7U'UK5
MD,\TRA], VV5'4OY(R!VMAZ)ZW9-VK5,'2=>V13TP Q,M&67H?+4"W#ZG,SC
MX)%++1X>8AAFMV_2D;8C\=JF@+0$I'4 [_G:BQ3,JXK,6:#O0SQH^7F^O)[-
M+\G%['9Q/;V_F9Z0V=P^U3*C44V92YTQ<2')F6TX@R6<O3.PMF?R!W_14N-1
M!O1MWZ 6'6DYVU <LW0<$Y>4G/.!/9.9"[#>RG-8^K.)G,IX)#6Z@\%P2,\&
M6MXV[,<L]<?$I27GG86.D* %*>H)62J8E(B0Q!8Q=#CTNW#U)SB>;M]JD=LP
M(K-4(A/WF!QYZKJ0'IWL7Y!/L!^Y#?6<>.1P8!B98G5M%C*7D6M8!NZ8;GC8
M>%93_%*83-QS4/R'G=#BXY%]M8$U@1"ZT6'CM4UQ2V\R<=7!<3>2Z_L;#UT(
M+U2\:_O,DUHEQNN;0I<R9>(&]".TG6S!<'X0NU"+B\?=Q?R1.UK.-IR*EDY%
M<0GZ'V<V7>D0CR394^TU@S9,BI8F16N95(&W$)&"']^_O&WEA'PD\?K=/3&F
MVA\BO+(I:RE5%'>A]!2=2LZJT?" -P.S_U8+UH8YT=*<**X[GT2Z7MN($-/A
M(R%].NP.S:%6]_'2IGRE,=%:QK1?WF17%[QPG4J$?OEV)/&K]H*BC5<UY2Q-
MB=8T)<5E=A$Y6;JQ/;B6$T^LXFQ#CVBI1[26'B7+-_ _\,"UJ)A1\9RY"+O,
M<3C$0(B;!6IYV_ A6OH0K>5#RX#Y/KF((_@XTI^U>$[5Y3^\K"E>Z3^TEO]<
M!ERNDU'Y$1) UVP1;%FH[U<\L/(R(%[7%+1T'EK+>98;#OV(X>$QU7AMJ(Y5
MJHY52W4 +(#%Z%()YQNLT]*[+^0V5B &H0O]J[W5\$H6D]^"R-+Z:5IRM^]I
M8HY&H\'0HN/>DXZQ]!T+MY-#./+W#4]^+/_1$KV2J^1$;9B/59J/A8O+@Z=\
M6&ROB$G?/+XE2^[$$KI:RWW$H0Z.GQ:T#1.R#FZ)X1(#"V0W%8.7X%'X6CX\
M8'EQ=:/E:L. K-* +-Q7]CU&+I^=#0O7O/)ZX)&@^73Y8:J_[]>&^UBE^UBX
MJ7QA,KW.B8[)5]*6'+@-";)*";)P>?F9,8DG?3>G+6()9TC$27Y M?Z'!S9%
M+WW(PCVFQBC% Y)1^D4+UH8)6:4)6;BX_,0PQ8.08?JJ"M0[>#PCT;?TJ96(
M.,E%CNQ)C>+=XLF8:?H\2*_</7NLYH8E]A<1GZ^@U#@]@^$ELR=5L@TEMNG#
M'H]"*1&D+S><N5PF.\#G*R'4?B/Y@N)YH<E_4$L#!!0    ( &6% U4??.<=
MEP4  /X4   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULO5C_3^LV$/]7
MK YM/*F/QLYW5BJ5PO0ZL3U&8=-^-*E+K9?$>;%3'OOK=TY"TC9.'I/0D  G
MOCM_[G*^S]G39Y%_D5O&%/J6Q*F\&&V5RLXG$QEM64+EF<A8"C,;D2=4P6/^
M-)%9SNBZ5$KB";$L;Y)0GHYFT_+=;3Z;BD+%/&6W.9)%DM#\Y9+%XOEBA$>O
M+^[XTU;I%Y/9-*-/;,740W:;P].DL;+F"4LE%RG*V>9B-,?G"^)HA5+B3\Z>
MY=X8:5<>A?BB'Y;KBY&E$;&814J;H/!OQQ8LCK4EP/&U-CIJUM2*^^-7Z[^4
MSH,SCU2RA8C_XFNUO1@%([1F&UK$ZDX\?V*U0ZZV%XE8EG_1<RUKC5!42"62
M6AD0)#RM_M-O=2#V%+#3HT!J!?)6!;M6L$M'*V2E6U=4T=DT%\\HU])@30_*
MV)3:X U/]6=<J1QF.>BIV4*D:_@H;(U@)$7,UU3!PR6-:1HQM-*&)3I]2&FQ
MYC#S 7U$#ZLK='KR83I1 $";F43U8I?58J1GL5^+] S9UA@1BQ"#^F)8_8I%
MH(Y+=7RH/@&W&]])XSLI[;E]OA=YSE*%YE*"D^<F?RH#MMF WF+G,J,1NQC!
M'I(LW['1[,<?L&?];/+NG8P=^&HWOMI#UF<+*K>(IFL4Z0'[6O =C<%Y:?*Z
M,N65IG0=V,T<[!/?]]WI9+?O45>06(Z+/;^1.P#K-&"=0;#S*!(%8(,Z$3$
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M+YE8<'2R !8[;8+I II8&,Y(<(33(1.[4:8]RM2+\D'+_#LJZWH#&04LC$S
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MJRK90PGZ2S!A$N9E)BHM6QSN.8I!G7R2/T0+D_M/N*X\/.!(5#OBG9T)H3S
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MO?*72YPOA*$%>#_7X"O5#2EH_JOB^C]02P,$%     @ 984#5;O0E(9.!
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M&)%-S8J*M(K6$NE-<J#R>@#;2A(^Y7ZP9VT:J=D.Z=9"T^7 H@/06*!S='?
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MV@70?JGH$]Q.7('N7V?V"U!+ P04    " !EA0-5GLWI>N0"   %!P  &0
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M%P/OWSA\*7!K]^;@,UEI_<,;[[)YP+P@E)@ZCR!H>,!+E-(#D8S[#C/84?K
M_?DS^G63.^6R$A8OM?Q:9"Z?!Y, ,ER+6KJ/>OL6NWR&'B_5TC9?V+:^G!C3
MVCI==L%DEX5J1_'8G<->P(2]$,"[ -[H;HD:E6^$$XN9T5LPWIO0_*1)M8DF
M<87REW+G#.T6%.<6=[DPF&N9H;$GKR8\'I_!U7U=N*=9Y C?>T5IAW718O$7
ML$9PHY7++5RI#+/?XR/2M1/'G\5=\*. [VO5AX2%P!GG1_"27;))@S=\ :]-
M#+Z=KZPS]!Z^'\JQA4@.0_@:.;652'$>4!%8- \8+$Y>Q2-V=D3@8"=P< S]
M/V_C*-9AI1^T0QA!@QV?P0&^7G=(MPJN<65JJE2(Q^T5A.!RA$M=5D(]=?X6
MEO5*%FGO=KU&4Z@-I%);S$"H;-^=*CA%*L ,%+6:RN@4,;.@U_ :1N$D24(V
MCG]C]7Q_L/8,9H@EP4RG+&2, >O'S,?=")/F$ \.!$%*HT3G51%U\2 <]BI)
M9T/MQ35*CZH;3^(PGDZ!APF+PV28 'T9#_FP47Q.D!+XY"_,2M.&Z77\\,_\
M,0D8\G :#TG 8,S#"6<P"*>#83@:,"_*GP0?0M(?C^#3'GF&J:0+)E -AUYG
MM-<W2C2;ICM:TEPKU[:0W>JN 9^W?>>7>]N]Z?0WA;(@<4VAK#^F&C1M1VP-
MIZNF"ZVTHY[63'/ZB:#Q#K2_UO0T.\,3['Y+BY]02P,$%     @ 984#56_B
MS$C<!0  6@X  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULI5=M;]LV
M$/ZN7W%PBWXH%%N6G=A)DP!.ZFX9UL+(R[I^I*6SQ98259**D_WZW5&R[#2.
M5W1 4XODO3QW]_!(GJZT^68S1 </N2KL62=SKCSI]6R282YL5Y=8T,I"FUPX
M&IIESY8&1>J5<M6+H^BHEPM9=,Y/_=S,G)_JRBE9X,R K?)<F,<+5'IUUNEW
MUA/7<IDYGNB=GY9BB3?H[LJ9H5&OM9+*' LK=0$&%V>=2?_D8LCR7N OB2N[
M]0T<R5SK;SRX2L\Z$0-"A8EC"X)^[O$2E6)#!.-[8[/3NF3%[>^U]0\^=HIE
M+BQ>:O59IBX[ZXP[D.)"5,I=Z]7OV,1SR/82K:S_'U:U;'_0@:2R3N>-,B'(
M95'_BH<F#UL*X^@%A;A1B#WNVI%'^5XX<7YJ] H,2Y,U_O"A>FT")PLNRHTS
MM"I)SYU_%L:(PMG3GB-K/-=+&LV+6C-^0?,(/NK"91:F18KI4_T>H6BAQ&LH
M%_%>@W]411<&40AQ%,=[[ W:T ;>WN$OA%9K#G9K\D8XL:5(\*Q#3+=H[K%S
M_N95_RAZMP?7L,4UW&=]+ZZ]FKMQ?=(.801O7HWC?O\=K*W#;89PJ?-2%(_$
M_417/$F[&*2U%::P:@0#E"Y# \*" "7%7"KI'H$$\7O%7[+P^B8518)$3Y?!
MY.82AN/HH!^Q'(_&_<.#8=2%.R*#V5H/6S\@#$*B:3N3!/G?=B87 6%X]"*Y
M*%+AM)'JD79]BM2$Y@J!9L'+&(9%<A:=4TC]P3'"1-@L!-U$0FLV9&@"[H61
MWD!1Y7-:U NP&?FQ7;A:;,"E&@KM@IS[X 97HLB67,A$^!92/0O.;25Y'9OU
MLPU,QF?9Z29)X#3U#8>&MC/E,T,/FG7:DMA,5RJ%.;8(.&'/"D0S=8VV\UX[
M"1F.,]3T&(YPE-:=J6-"<.Y\ZM?&)5+V#"Z%215:&Q!\AE<:/6^]UU,Z22IC
MD(G1S#@CETLTLE@"WI.'+ORYAGRP%<P35N0H;.4Y08"$-%0T59'%PEMDOC+U
M J)%S0,2XP6D3_**(LD(;:F-8Z\E.==I%R9<DDP42V1^L/RVZ<63A(-8N*8&
M:V_@O4E+EIG[!*ZV$G"9M9*\G()U]-/6F(Y*XYEBZV(MZ5#D.BEM=]*M+<A/
M,&Y=5F^1)@-B$4%)5)5NQ?$2<6J:/.4K;Q/^MY."OBZ2O#^0 7(E:2K1>4Z8
MZ$Q*OODZ-(K!,\5=SI_%PIEI-FQ9*HJ8=^EOD\F,LTH]P% 1IU[U1>(T?8VF
MB<?!7O;4]?3=J] -,2QG<TN%2[TLY#\,>S<ANO"^\MSF%2L?(*_/0.0S$.@$
M0S[! C[!?FP.>:F0D;K,('%1%F2TW26TWSBAW,AT430W%LX-,F*JNONQ;7-B
M%UK1I<J>!&W37PMQF*V+X/;+; J?[CY>3*]A^O?T^O+J9@JSZZO+*0UG5]=?
MX/WD=AK,#!Y\J'PDK<%!>'0<A_'H"%Y'W2CJ4Z-1,I<42'!K1(J^:*WT,.Q'
M)!U%\#KNQO%;^(!S4]%EC\_T47!5W".QQSPQ'_'?L%: C\+09O;"DY*.@(WD
M<3B*#PD,F1YT"4Z]["7?^K-N!YQ,4"$+RBJU-*& N&P2:;F1R;IAO1YVR2C=
M2.=?*>?$\T"D7^G2E?O&=5<V'$IH W.IFJ[1U-2?N*-WELW=,[E*14>S[ZJD
M5T?2'];7F9H,SP&X;>";,JX$]YVT2NK-YW,3[CJ(?<>ED\369-&+GR-H@TDH
MM0:QJ?T&A6^UY-\)+S8(^X-Q>!B-X"@\'O7#_F@,<3BF@H^B 40T&Y-1YLCM
MCB31@\!O:\:VX;!["JD^0RVSJ\%54YR43H(;>I"DE?)YVV7M_]#\DR84/\/P
MXR/>$8.&KO]%[W$4A<=D\M?)#;LNG+VM^WZ.9NE?-=R?J1?65_]VMGTX3>KW
MPD:\?G41IJ6D\TKA@E2C[HANTZ9^R=0#ITO_>IAK1V\1_YG1XP\-"]#Z0M/]
MLQFP@_8Y>?XO4$L#!!0    ( &6% U5IFKVXC ,  "P(   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;,U638_;-A"]^U<,E")H <62):\_-K:!]2:+
MIF@"(XLVAZ('6AI;Q%*D0E+6[K_OD)*U;FL;Z*V'7?%CYLU[0W+&BT;I)U,@
M6G@NA33+H+"VNHTBDQ58,C-4%4K:V2E=,DM3O8],I9'EWJD441+'DZAD7 :K
MA5_;Z-5"U59PB1L-IBY+IE_6*%2S#$;!<>$KWQ?6+42K1<7V^(CVMVJC:1;U
M*#DO41JN)&C<+8.[T>UZ[.R]P>\<&W,R!J=DJ]23FWS*ET'L"*' S#H$1I\#
MWJ,0#HAH?.\P@SZD<SP=']$?O';2LF4&[Y7XQG-;+(-9 #GN6"WL5]7\C)V>
M&X>7*6'\?VA:VS0.(*N-567G3 Q*+MLO>^[R<.(PN^20= Z)Y]T&\BP_,,M6
M"ZT:T,Z:T-S 2_7>1(Y+=RB/5M,N)S^[^D+G_JLR!C:HX5Z5)67JL6 :%Y$E
M>&<491W4NH5*+D!-X+.2MC#P4>:8_]T_(EH]M^3(;9U<!?REED-(XQ"2.$FN
MX*6]UM3CW5S ^\BTY'+?:O4BX8^[K;&:KL:?Y_2V<.EY./=<;DW%,EP&]!X,
MZ@,&J[=O1I/X_16RXY[L^!KZ?SN8JU#GB7Y1%F$&;]_,DM'H/9P)-VA3M&:&
M9R!I7[C]BO:-W^ &,B:R6C"+.6Q?(.<'GE."![; 5P?:<//&OP_,W[$#:GKN
M(.MR2UAJU\(9-\I:G73KLR>@$F(LDPX1\EJ[CP,B ESE(;T36Y )^5"%R G3
MOW(J4QW*H$7![S4_,(&2:A=\X*)V9/]_:BQ[<DM<6O4/19?5?)+P@%M=4S'U
M3R3TB'1X%9,O VY,34K&X2A.0JK1D(:3V/V-81Y.DYMP,G=KHW06WL132,(9
MV4WC%&*83\ANGL(LCL-Y/#JQIY"?F<X*("5P5VDN_AT9NLAD,C!*Y+#1^.ZA
M=D4!OC&M&9$'DEG5!$0%E0R![?<:]Y1ZES<7G"A/)Y=RR2PPD(K*(1. SZ@S
M3C#$)O/^/\3#F%CW9SOXT2""O_#I3W0)7K-O^#.4;=%"SX]*#O8E)P0FA ,D
M4\)OCMP;I/MR#.MU.@OJ)HK6"T;72U&_<AW1'[:[<]1Y!KC;42L:PKGB$)U4
M\!+UWO<INI&JEK8MYOUJWPKOV@[P:M[V43J?/9<&!.[(-1Y.J1SJMC>U$ZLJ
MWP^VRE)W\<."VCEJ9T#[.T69ZB8N0/\#8?474$L#!!0    ( &6% U5=\9]Z
M5 (  +H%   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;)U4WT_;,!!^
MYZ\XA8DG1!RWA0)M) J;MDE,"/;CV227QB*Q,]NE\-_O;(>LDTK9]I+SG>^^
M^^Z<N]E:FP=;(SIX:AMEYTGM7'>6IK:HL17V2'>HZ*;2IA6.5+-,;6=0E"&H
M;5+.V'':"JF2?!9L-R:?Z95KI,(; W;5ML(\+[#1ZWF2)2^&6[FLG3>D^:P3
M2[Q#]ZV[,:2E THI6U16:@4&JWERD9TMQMX_.'R7N+8;9_"5W&O]X)5/Y3QA
MGA V6#B/($@\XB4VC0<B&C][S&1(Z0,WSR_H'T+M5,N]L'BIFQ^R=/4\F290
M8B56C;O5ZX_8US/Q>(5N;/C".OJ.3A(H5M;IM@\F!JU448JGO@\; 5/V2@#O
M WC@'1,%EE?"B7QF]!J,]R8T?PBEAF@B)Y5_E#MGZ%92G,NOA:+>4Y<="%7"
ME334+FW@4K?T[E;XULU21YF\?UKTJ(N(RE]!/89KK5QMX;TJL?PS/B6& TW^
M0G/!=P)^7JDC&+%#X(SS'7BCH>Q1P)N\7?;%OY0=44?;4?T G=E.%#A/:$(L
MFD=,\H/][)B=[^ \'CB/=Z'_]U/M1-W.^8MVN'<*!_M3GF7G\#>9X6N-P2#4
M,W1"EB"=!5U5LD!CH1"VWBLV_9UV@L@LX1WP,3MDC &?!#')HIJ1?LI/(.OU
M$8OR-)L&N35CV9-[(^4D0C'8]C#IQCRU:)9A:Q"@7BD71VNP#HOI(L[C;_>X
MU:Z%64IEH<&*0MG1"?V1)FZ*J#C=A>F\UXYF/1QK6JYHO /=5YK>HE=\@F%=
MY[\ 4$L#!!0    ( &6% U7@U/:W3P,  !H(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;*56;7/:.!#^SJ_8<3.=:X>SC<U+D@(S@9(Y.I,.0\CU
M^E'8"U9K2SY)#NF_[\HB#IT2<G/Y &BE?1X]JUVM&.ZD^JXS1 ,/12[TR,N,
M*2^#0"<9%DS[LD1!*QNI"F;(5-M EPI96H.*/(C"L!\4C MO/*SG%FH\E)7)
MN<"% ET5!5,_)IC+W<CK>(\32[[-C)T(QL.2;?$6S5VY4&0%#4O*"Q2:2P$*
M-R/OJG,YZ5G_VN%OCCM], 8;R5K*[]:8IR,OM((PQ\18!D8_]SC%/+=$)./?
M/:?7;&F!A^-']NLZ=HIES31.9?Z%IR8;>><>I+AA56Z6<O<7[N.I!28RU_4W
M[)QO''N05-K(8@\F!047[I<][,_A ' >/@.(]H"HUNTVJE5^9(:-ATKN0%EO
M8K.#.M0:3>*XL$FY-8I6.>',^ M3B@FCX8\56^>HWPT#0[1V,4CV%!-'$3U#
MT8<;*4RF82923'_%!R2GT10]:II$)PD_5<*'.&Q#%$;1";ZXB3&N^7HOQ'@L
M-(>,CR/MC;C4)4MPY%'):U3WZ(W?ONGTPP\G='4;7=U3[$]GS[6N,*7,FPPV
M7#"1<+$]IO8U?*W5U\4,/M_=3&9+F/TS6T[GMS-8+.?3&9F+^?(K?+Q:S5H+
MA7]>5S:5T!#&[?Y%U(X&?3@+_3#LP!UM7G"#:6NE6(JV=)Z\N^U.2-YA"&>1
M'T7OX1K7JJ(K;Q,Z:,W%/5)=JU_H0_OI.@#<,)5DSOFJ5#Q_\KQH#Z(>B2'J
MV"<Y;KGV? ^K#.&(G(REP 1PP0UG.> #JH1K!((F"'(#9UV?2*DOK;]1KP C
M6RS]1E>/>H_QX:ZDYF&(.LFEIG.T"&M.95$R\>/MF_.H,_B@+=T],T2;4[U8
M*!#.1=+INEINU\#?!9A#X:U&^(YIZGMIE5 JC'1GTZ8XJ)4E4J645G0YMGB#
MJM!VI%!N_!/5V6NJLW>RFFZI_Z=57@ND;JX-$ZD-?W?B-KV.\345^ED*_$_%
M>=&WQ1SO*^VERCP/P_8%4?[_NCR6B>"@7Q>HMO6KI"&1E3"N=3>SS<-WY?K]
MD[M[-4G2E@L-.6X(&OH#2H%R+Y$SC"SK[K^6AMZ2>IC1XXW*.M#Z1DKS:-@-
MFK\#XY]02P,$%     @ 984#51@K<F.?"   $UT  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&ULM9S=;]NV&L;O]U<07C%L0(XM4?)7EAAH$U'L<-H3
M-.O91;$+1:9CK?KP)#IN@?WQHV3%,AV9M;;'N8CU]?Y>RGS UWY$\VJ3Y9^+
MI1"2?$GBM+CN+:5<70X&1;@425#TLY5(U9E%EB>!5+OYXZ!8Y2*85T%)/*"6
M-1HD093V9E?5L;M\=I6M91REXBXGQ3I)@OSK&Q%GF^N>W7L^\"%Z7,KRP&!V
MM0H>Q;V0'U=WN=H;["CS*!%I$64IR<7BNO?:ON2N4P945_P_$IMB;YN4M_*0
M99_+G;?SZYY5MDC$(I0E(E O3^)&Q'%)4NWXLX;V=CG+P/WM9SJK;E[=S$-0
MB)LL_BV:R^5U;](C<[$(UK'\D&VXJ&]H6/+"+"ZJ_V137VOU2+@N9);4P:H%
M291N7X,O]1NQ%V [1P)H'4 / ]PC 4X=X)P:X-8![JD!PSI@>!@P/!(PJ@-&
MIV88UP'C4P,F=<"DZMUM=U1]>1O(8':59QN2EU<K6KE1":**5ET8I:5V[V6N
MSD8J3L[>!W*="Y(MR)MUH<X5!?GQ5L@@B@OR/LCSH)363^0_Y./]+?GQU4]7
M ZFREK&#L,[ MAGHD0PV>9>E<ED0+YV+N1X_4*W=-9D^-_F&&H'O@KQ/;/>"
M4(O2EO;<FL.9>.@32H^&>R>$V^.CX<P<_GJE&D\G1\/]4QI_/)R;PW]9IWWB
M6&WA6E<X._4X%6]XA'<OPG4>R4@4A$5ID(91^DA^S8.T"+9#TZ?_J@CR5HJD
M^+VEN3=;O-..+\?MRV(5A.*ZIP;F0N1/HC?[X7M[9/W<UN](F(>$,23,1\(X
M"*:IQ]VIQS719_<R"S^3#V(N1"+F),O)31#':NM6B4H)Z4[D43:_(/?+0"5O
MDX^1WU4^6YA;P<J2_S2;3BWU=S5XVA<&,B=#PGPDC(-@FC"&.V$,C<+XK2P\
MJ22?WHGD0>2M(X>1T+7KD3 /"6-(F(^$<1!,$\AH)Y#1>>O."*D>),Q#PA@2
MYB-A' 33U#/>J6=\RO!2$/%%Y&%4"++*HU"TZ<0(ZJH3),Q#PM@6-MDK?4Y_
M/-(+GX_,R$$PK?\GN_Z?&/M?#11S$3S$@NR48*HT1EA7#2!A'A+&D# ?">,@
MF*:5Z4XKT_-6FBE2/4B8AX0Q),Q'PC@(IJG'MAI[Q0+5FC??('VR6_5ECNHJ
M,"C-@](8E.9#:;RF[5=0VB\MEJ<V]>R9<[:QS^]R0=BZ],U.*U5F7&<Q(&D>
ME,:@-!]*XRB:+AK:B(:>MV35?)2*D#0/2F-0F@^E<11-5U'C[-I&ZZ_+ER0S
MJ;->H#8NE,:@-!]*XS5MO%>"K+YEV4=J4&/2VF:7]K5XC KRO\5"5*:LL?Q
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MY>4%ZOPBR^3S3IE@MP[Z[&]02P,$%     @ 984#50-HK\'K @  <0\  !D
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M-38Z^IG,YU[QQ_Z1,.28'(D))":1F )A5HPFAQA-G#%BT5.TTLGY)R)G:=\
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MU7)O2>^\(34.U014DU!-H30[;VV?@;K[#(=I.*HCE^CG-XZ5-K?6^QD/VF&
M:KS1CG^-@HE7_!W9OT8".JR$:@JEV>%JFP?4_<&".Z.)V)>?ENNVCN+F>J<+
MVCV :ARJ":@FH9I":78$V^X!G4"/Z*"=!*C&H!J':@*J2:BF4)J=P+;?0#M]
MM*'3.@JT[0#5&%3C4$U -0G55*--K=Z)Y_D7%E+:#@5U=RA<<VO_I11H P.J
M,:C&H9J :A*J*91FY[-M8%!H X-"&QA0C4$U#M4$5)-03:$T^Y0,;0,CZ-C
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M2YL40]TYYE=+MUK^J';OTFZR#76GFZ?(T(UTQ548/ZC!)@51=PXZRY5('BE
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M;H%&('0'?+[F7!UNM(/J+';^#5!+ P04    " !EA0-5G-SRD"(#  !H$0
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 984#52/TLHW0 @  -1$   \
M  !X;"]W;W)K8F]O:RYX;6S%F$M/XS 0@/^*E1-[V$T3H%!$.=#NHQ);*HK8
M(YHF$V+AV%G;*0N_?B?)5C@"67LQ/25^U/D\CN>+>_ZD].-&J4?VIQ+23*/2
MVOHLCDU68@7FBZI14DNA= 66BOHA-K5&R$V):"L1IZ/1.*Z R^CB?#?62L=N
M05G,+%>2*MN*.XY/YK6]+;(M-WS#!;?/TZB[%QBQBDM>\1?,I]$H8J943S^4
MYB]*6A#K3"LAIE'2-]RAMCQ[4[UN(6]A8[H:"YL;()!I-![1@ 77QG8]NO&!
M&+=(G?M28]4W+BSJ.5C\KE53<_G0#D.SB)UI=''87?L@GNG_":,J"I[A7&5-
MA=+V<=0H6D!I2EZ;B$FH<!K-U!9U.Q]ZP"+OYV8)RHF4/N/4H!=YAQ<21>8H
M#>:,[HP2/">.G%V" )DA<R!3#V2Z1\C[U($\]$ >[@5RW>+03QW((P_DT1XA
M!Y$\]D >[Q/RT($<>R#'82&78!N-3!7LLC%<HC$.UXF'ZR0LUR48;EJLE49#
M7;L>#MJI!^TT+-JBJBDEMVPSI96$+=>-80>SZ[O%_',R<2 G'LA)6,@;I-QL
MD-XVE3VR=4T&<U<V&?ER]2CP.T?>-6P%S] ]]Q7**Y# !EF7H+%4(J>PW;.O
MOQM2OLOF\T826!R_0&N0PP7T*2()[(@EC7NE#*TA:MH$5:4DZ^+G OKTD 3V
MPT^0\-#JRC*0.9MS31]ZJF.E40=Q] DB"6R(W;JR@]MV*YA/+IA/"LF'6X$=
MS-$"%X8M8?#-YW-$$E@2[R4Y!]3%]/DB"2R,0;X;!%)3YZV+Z3-&$E@9[V7
M]Z.9^NR1!K;'ZZ;YA^;NFM2GD#2P0MZ0L63 YCUZ?)!"WKY^.&#T:27=EU9Z
M:!?3)Y=TGW(9'#Y2GUS23B[Q[IB>8T&)-E_2(PS59R"RE6;MI?_\.#INDT/1
M"#&CNFMYI2#?G?IW_UA<_ 502P,$%     @ 984#57[94"(\ 0  L@\  !H
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W7S8Z",!# \5<A?0#+C(JZ
M$4][\;KQ!1H</B)0TG:S^O9+\(!#]K 7TSF1EC#]7_@%CE_4FM#8WM?-X)-[
MU_8^5W4(PX?6OJBI,WYE!^K'.Z5UG0GCTE5Z,,7-5*0Q33/M7F>HT_%U9G)Y
M#/2?B;8LFX(^;?'=41_^&*Q_K+OYFBBHY&)<12%7^M[.VUY/%UB-DU5RON;*
MG:^@=.P@9$$8/VC-@M;Q@S8L:!,_:,N"MO&#,A:4Q0_:L:!=_* ]"]K'#SJP
MH$/\($BYC*F I 76 K0&SC4(\!HXV"! ;.!D@P"S@:,- M0&SC8(<!LXW"!
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 984#506M5][O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M984#59E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !EA0-5LJ8RXD$&   [)   &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M984#51]\YQV7!0  _A0  !@              ("!A0X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &6% U60>N%F) ,  ,P*   8
M          " @5(4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !EA0-5-08PG+T'  #Y(P  &               @(&L%P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 984#5:Z]H)EL!@  U1D
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M965T.2YX;6Q02P$"% ,4    " !EA0-5*7^K7;T"  "!!@  &0
M    @(&+0@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M &6% U6>S>EZY (   4'   9              " @7]%  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 984#59B=?!CB @  H@8  !D
M             ("!FD@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !EA0-5;^+,2-P%  !:#@  &0              @(&S2P  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( &6% U5IFKVXC ,
M "P(   9              " @<91  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 984#55WQGWI4 @  N@4  !D              ("!
MB54  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !EA0-5
MX-3VMT\#   :"   &0              @($46   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( &6% U48*W)CGP@  !-=   9
M      " @9I;  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 984#50-HK\'K @  <0\  !D              ("!<&0  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !EA0-5UM.A(6P&  #'00
M&0              @(&29P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( &6% U5;^P@A&@@  -!@   9              " @35N  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 984#51X'WU\@
M!   GP\  !D              ("!AG8  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !EA0-5>#$Q_PT$   F#P  &0
M@('=>@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( &6%
M U5[V7VK]@(  ,P)   9              " @2%_  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 984#52<G$1@W!0  IR<  !D
M         ("!3H(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !EA0-5^499JPP$  "7%0  &0              @(&\AP  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &6% U6<W/*0(@,  &@1
M   -              "  ?^+  !X;"]S='EL97,N>&UL4$L! A0#%     @
M984#59>*NQS     $P(   L              ( !3(\  %]R96QS+RYR96QS
M4$L! A0#%     @ 984#52/TLHW0 @  -1$   \              ( !-9
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &6% U5^V5 B/ $  +(/   :
M              "  3*3  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( &6% U4KT'*.<@$  )\0   3              "  ::4  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     A "$ W@@  $F6      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>107</ContextCount>
  <ElementCount>153</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic</Role>
      <ShortName>Impact of Coronavirus (COVID-19) Pandemic</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Reverse Stock Splits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ReverseStockSplits</Role>
      <ShortName>Reverse Stock Splits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://sunshinebiopharma.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Management and Director Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation</Role>
      <ShortName>Management and Director Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/Warrants</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Nature of Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative</Role>
      <ShortName>Nature of Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/NatureOfBusiness</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Reverse Stock Splits (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative</Role>
      <ShortName>Reverse Stock Splits (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/ReverseStockSplits</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/NotesPayable</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Shareholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>Shareholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/ShareholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Warrants (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetails1</Role>
      <ShortName>Warrants (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Net Loss Per Common Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative</Role>
      <ShortName>Net Loss Per Common Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/NetLossPerCommonShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sunshinebio_i10q-063022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Management and Director Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative</Role>
      <ShortName>Management and Director Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sunshinebio_i10q-063022.htm">sunshinebio_i10q-063022.htm</File>
    <File>sbfm-20220630.xsd</File>
    <File>sbfm-20220630_cal.xml</File>
    <File>sbfm-20220630_def.xml</File>
    <File>sbfm-20220630_lab.xml</File>
    <File>sbfm-20220630_pre.xml</File>
    <File>sunshinebio_ex3101.htm</File>
    <File>sunshinebio_ex3102.htm</File>
    <File>sunshinebio_ex3201.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.gif</File>
    <File>image_001.jpg</File>
    <File>image_002.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="395">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>44
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sunshinebio_i10q-063022.htm": {
   "axisCustom": 0,
   "axisStandard": 7,
   "contextCount": 107,
   "dts": {
    "calculationLink": {
     "local": [
      "sbfm-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sbfm-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sunshinebio_i10q-063022.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sbfm-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sbfm-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sbfm-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 258,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 27,
    "http://sunshinebiopharma.com/20220630": 10,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 42
   },
   "keyCustom": 19,
   "keyStandard": 134,
   "memberCustom": 17,
   "memberStandard": 8,
   "nsprefix": "SBFM",
   "nsuri": "http://sunshinebiopharma.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://sunshinebiopharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:ReverseStockSplitTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Reverse Stock Splits",
     "role": "http://sunshinebiopharma.com/role/ReverseStockSplits",
     "shortName": "Reverse Stock Splits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:ReverseStockSplitTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Notes Payable",
     "role": "http://sunshinebiopharma.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Shareholders\u2019 Equity",
     "role": "http://sunshinebiopharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Warrants",
     "role": "http://sunshinebiopharma.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Net Loss Per Common Share",
     "role": "http://sunshinebiopharma.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:ManagementCompensationAndDirectorFeesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Management and Director Compensation",
     "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation",
     "shortName": "Management and Director Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:ManagementCompensationAndDirectorFeesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:WarrantsIssuedWithFinancingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Warrants (Tables)",
     "role": "http://sunshinebiopharma.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:WarrantsIssuedWithFinancingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-02-212022-02-22",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRedeemedOrCalledDuringPeriodShares",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Nature of Business (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
     "shortName": "Nature of Business (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-02-162022-02-17_custom_AegisOfferingMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "SBFM:ReverseStockSplitTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2019-01-312019-02-01_custom_FirstReverseStockSplitMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Reverse Stock Splits (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative",
     "shortName": "Reverse Stock Splits (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "SBFM:ReverseStockSplitTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2019-01-312019-02-01_custom_FirstReverseStockSplitMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Notes Payable (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative",
     "shortName": "Notes Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://sunshinebiopharma.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-02-012022-02-17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Shareholders\u2019 Equity (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
     "shortName": "Shareholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-02-012022-02-17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SBFM:WarrantsIssuedWithFinancingTableTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-012022-06-30_custom_PreFundedWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "SBFM:WarrantsIssuedShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Warrants (Details)",
     "role": "http://sunshinebiopharma.com/role/WarrantsDetails",
     "shortName": "Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SBFM:WarrantsIssuedWithFinancingTableTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-012022-06-30_custom_PreFundedWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "SBFM:WarrantsIssuedShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SBFM:WarrantsIssuedWithFinancingTableTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2022-06-30_custom_PreFundedWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Warrants (Details 1)",
     "role": "http://sunshinebiopharma.com/role/WarrantsDetails1",
     "shortName": "Warrants (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-012022-06-30_custom_TradeableWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Warrants (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative",
     "shortName": "Warrants (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-012022-06-30_custom_TradeableWarrantsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-012022-06-30_custom_TradeableWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Net Loss Per Common Share (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
     "shortName": "Net Loss Per Common Share (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-04-012022-04-22_us-gaap_PrivatePlacementMember_custom_AprilWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "SBFM:WarrantsIssuedNewShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "SBFM:ManagementCompensationAndDirectorFeesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Management and Director Compensation (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative",
     "shortName": "Management and Director Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "SBFM:ManagementCompensationAndDirectorFeesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "role": "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Nature of Business",
     "role": "http://sunshinebiopharma.com/role/NatureOfBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Basis of Presentation",
     "role": "http://sunshinebiopharma.com/role/BasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:ImpactOfCovid19PandemicTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic",
     "role": "http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic",
     "shortName": "Impact of Coronavirus (COVID-19) Pandemic",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshinebio_i10q-063022.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SBFM:ImpactOfCovid19PandemicTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 27,
   "tag": {
    "SBFM_AegisOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aegis Offering [Member]"
       }
      }
     },
     "localname": "AegisOfferingMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_AprilWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Warrants [Member]"
       }
      }
     },
     "localname": "AprilWarrantsMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs"
       }
      }
     },
     "localname": "CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock and pre-funded warrants issued in an underwritten public offering, net of issuance costs shares"
       }
      }
     },
     "localname": "CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCostsShares",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "SBFM_ConsultingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting"
       }
      }
     },
     "localname": "ConsultingExpense",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact Of Coronavirus Covid-19 Pandemic"
       }
      }
     },
     "localname": "DisclosureImpactOfCoronavirusCovid19PandemicAbstract",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "SBFM_DisclosureManagementAndDirectorCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management And Director Compensation"
       }
      }
     },
     "localname": "DisclosureManagementAndDirectorCompensationAbstract",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "SBFM_DisclosureReverseStockSplitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Splits"
       }
      }
     },
     "localname": "DisclosureReverseStockSplitsAbstract",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "SBFM_DisclosureWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "localname": "DisclosureWarrantsAbstract",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "SBFM_FirstReverseStockSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Reverse Stock Split [Member]"
       }
      }
     },
     "localname": "FirstReverseStockSplitMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_ImpactOfCovid19PandemicTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of Coronavirus (COVID-19) Pandemic"
       }
      }
     },
     "localname": "ImpactOfCovid19PandemicTextBlock",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SBFM_InvestorWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants 1 [Member]"
       }
      }
     },
     "localname": "InvestorWarrants1Member",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_InvestorWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants 2 [Member]"
       }
      }
     },
     "localname": "InvestorWarrants2Member",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_InvestorWarrantsAndAprilWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants And April Warrants [Member]"
       }
      }
     },
     "localname": "InvestorWarrantsAndAprilWarrantsMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_InvestorWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants [Member]"
       }
      }
     },
     "localname": "InvestorWarrantsMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_ManagementCompensationAndDirectorFeesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and Director Compensation"
       }
      }
     },
     "localname": "ManagementCompensationAndDirectorFeesTextBlock",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SBFM_NotePayable20211Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable - April 20, 2021"
       }
      }
     },
     "localname": "NotePayable20211Member",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable20212Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable - July 6, 2021"
       }
      }
     },
     "localname": "NotePayable20212Member",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable20213Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable - August 18, 2021"
       }
      }
     },
     "localname": "NotePayable20213Member",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_OfficeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Office"
       }
      }
     },
     "localname": "OfficeExpense",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_OfficerAndDirectorRemuneration": {
     "auth_ref": [],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer and director remuneration"
       }
      }
     },
     "localname": "OfficerAndDirectorRemuneration",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_OfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers And Directors [Member]"
       }
      }
     },
     "localname": "OfficersAndDirectorsMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_PatentingFees": {
     "auth_ref": [],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent fees"
       }
      }
     },
     "localname": "PatentingFees",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_PreFundedWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants 1 [Member]"
       }
      }
     },
     "localname": "PreFundedWarrants1Member",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_PreferredStockPurchasedFromRelatedPartyShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock purchased from related party, shares"
       }
      }
     },
     "localname": "PreferredStockPurchasedFromRelatedPartyShares",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_PreferredStockPurchasedFromRelatedPartyValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PreferredStockPurchasedFromRelatedPartyValue",
        "negatedLabel": "Preferred stock purchased from related party"
       }
      }
     },
     "localname": "PreferredStockPurchasedFromRelatedPartyValue",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_ProceedsPublicOfferingNet": {
     "auth_ref": [],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsPublicOfferingNet",
        "negatedLabel": "Proceeds public offering net"
       }
      }
     },
     "localname": "ProceedsPublicOfferingNet",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_ReverseStockSplitTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ReverseStockSplitTextBlock",
        "verboseLabel": "Reverse Stock Splits"
       }
      }
     },
     "localname": "ReverseStockSplitTextBlock",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SBFM_SecondReverseStockSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Reverse Stock Split [Member]"
       }
      }
     },
     "localname": "SecondReverseStockSplitMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_StockIssuedForNoteConversionsIncludingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for note conversions including interest"
       }
      }
     },
     "localname": "StockIssuedForNoteConversionsIncludingInterest",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_StockIssuedForPaymentInterestOnNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for payment interest"
       }
      }
     },
     "localname": "StockIssuedForPaymentInterestOnNotesPayable",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SBFM_ThirdReverseStockSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Reverse Stock Split [Member]"
       }
      }
     },
     "localname": "ThirdReverseStockSplitMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_TradeableWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tradeable Warrants [Member]"
       }
      }
     },
     "localname": "TradeableWarrantsMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_TrtPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TRT Pharma [Member]"
       }
      }
     },
     "localname": "TrtPharmaMember",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_WarrantExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Expiration Date"
       }
      }
     },
     "localname": "WarrantExpirationDate",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "SBFM_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsDisclosureTextBlock",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SBFM_WarrantsIssuedNewShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued new, shares"
       }
      }
     },
     "localname": "WarrantsIssuedNewShares",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "SBFM_WarrantsIssuedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares"
       }
      }
     },
     "localname": "WarrantsIssuedShares",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "SBFM_WarrantsIssuedWithFinancingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued with financing"
       }
      }
     },
     "localname": "WarrantsIssuedWithFinancingTableTextBlock",
     "nsuri": "http://sunshinebiopharma.com/20220630",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r365",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r305"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r9",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Equipment depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r38",
      "r39",
      "r40",
      "r336",
      "r349",
      "r350"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated comprehensive (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r305"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Capital paid in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r255",
      "r256",
      "r257",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r77",
      "r117",
      "r120",
      "r126",
      "r134",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r266",
      "r270",
      "r281",
      "r303",
      "r305",
      "r321",
      "r334"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r24",
      "r77",
      "r134",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r266",
      "r270",
      "r281",
      "r303",
      "r305"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r80",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r8",
      "r70"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r70",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and Cash Equivalents at End of Period",
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r286"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r74",
      "r77",
      "r95",
      "r96",
      "r97",
      "r99",
      "r101",
      "r109",
      "r110",
      "r111",
      "r134",
      "r142",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r193",
      "r194",
      "r198",
      "r202",
      "r209",
      "r281",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants exercise price",
        "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r305"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 18,885,632 and 2,591,240 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income [Member]"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45",
      "r52",
      "r326",
      "r342"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Net (loss)",
        "totalLabel": "Comprehensive (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r55",
      "r77",
      "r134",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r281"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r171",
      "r178",
      "r179",
      "r181",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r154",
      "r182",
      "r183",
      "r295",
      "r297",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Face Value"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r29",
      "r174",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r30",
      "r157",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r31",
      "r76",
      "r79",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r210",
      "r214",
      "r215",
      "r216",
      "r294",
      "r295",
      "r297",
      "r298",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r68",
      "r138"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r68",
      "r138"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r217",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r94",
      "r95",
      "r99",
      "r100",
      "r101",
      "r105",
      "r106",
      "r278",
      "r279",
      "r327",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic (Loss) per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r48",
      "r81",
      "r82",
      "r83",
      "r85",
      "r91",
      "r93",
      "r108",
      "r135",
      "r209",
      "r217",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r277",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r299",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r68",
      "r186",
      "r187"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Debt release",
        "negatedLabel": "Debt release"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "totalLabel": "Total General and Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r54",
      "r77",
      "r117",
      "r119",
      "r122",
      "r125",
      "r127",
      "r134",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r281"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r92",
      "r93",
      "r116",
      "r260",
      "r263",
      "r264",
      "r344"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (decrease) in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (decrease) in interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "(Increase) decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "(Increase) in prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InducedConversionOfConvertibleDebtExpense": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.",
        "label": "Loss on debt conversion",
        "negatedLabel": "Loss on debt conversions"
       }
      }
     },
     "localname": "InducedConversionOfConvertibleDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r49",
      "r115",
      "r293",
      "r296",
      "r329"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDebtSecuritiesOperating": {
     "auth_ref": [],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeDebtSecuritiesOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r62",
      "r65",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r324",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r21",
      "r305"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Stock issued for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r77",
      "r121",
      "r134",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r267",
      "r270",
      "r271",
      "r281",
      "r303",
      "r304"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r77",
      "r134",
      "r281",
      "r305",
      "r323",
      "r338"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r28",
      "r77",
      "r134",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r267",
      "r270",
      "r271",
      "r281",
      "r303",
      "r304",
      "r305"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Long-term portion of notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r31",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Flows Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Flows (Used) in Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r43",
      "r48",
      "r51",
      "r69",
      "r77",
      "r84",
      "r86",
      "r87",
      "r88",
      "r89",
      "r92",
      "r93",
      "r98",
      "r117",
      "r119",
      "r122",
      "r125",
      "r127",
      "r134",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r279",
      "r281",
      "r325",
      "r341"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net (Loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoninterestExpenseDirectorsFees": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.",
        "label": "Noninterest Expense Directors Fees"
       }
      }
     },
     "localname": "NoninterestExpenseDirectorsFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r11",
      "r322",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable [Default Label]",
        "verboseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r117",
      "r119",
      "r122",
      "r125",
      "r127"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "(Loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r37",
      "r38"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "(Loss) from foreign exchange translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r192",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Redemption price"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r305"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 10,000 and 1,000,000 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r136",
      "r137"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherShortTermDebt": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from short-term debt classified as other.",
        "label": "Note payable to pay fees"
       }
      }
     },
     "localname": "ProceedsFromOtherShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Accounting"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r43",
      "r48",
      "r63",
      "r77",
      "r84",
      "r92",
      "r93",
      "r117",
      "r119",
      "r122",
      "r125",
      "r127",
      "r134",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r265",
      "r268",
      "r269",
      "r272",
      "r273",
      "r279",
      "r281",
      "r330"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net (Loss)",
        "totalLabel": "Net (loss) before income taxes"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r140",
      "r305",
      "r331",
      "r339"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Equipment (net of $69,202 and $64,106 depreciation respectively)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r221",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r221",
      "r300",
      "r302",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of notes payable",
        "negatedLabel": "Payments of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r259",
      "r307",
      "r353"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "R&amp;D"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r217",
      "r305",
      "r337",
      "r348",
      "r350"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated (Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r81",
      "r82",
      "r83",
      "r85",
      "r91",
      "r93",
      "r135",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r277",
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r77",
      "r113",
      "r114",
      "r118",
      "r123",
      "r124",
      "r128",
      "r129",
      "r130",
      "r134",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r281",
      "r330"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r99",
      "r101",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r74",
      "r109",
      "r110",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r202",
      "r207",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r219",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of outstanding warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesFinancingTransactionAxis": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost.",
        "label": "Securities Financing Transaction [Axis]"
       }
      }
     },
     "localname": "SecuritiesFinancingTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuritiesFinancingTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Securities Financing Transaction [Line Items]"
       }
      }
     },
     "localname": "SecuritiesFinancingTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuritiesFinancingTransactionTable": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, as of the balance sheet date, of security financing transactions by type, the aggregate value of securities financing transactions by type and aggregate acquisition price by type of security financing transaction.",
        "label": "Securities Financing Transaction [Table]"
       }
      }
     },
     "localname": "SecuritiesFinancingTransactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuritiesFinancingTransactionTypeDomain": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement of financing transaction securities held."
       }
      }
     },
     "localname": "SecuritiesFinancingTransactionTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r12",
      "r13",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance shares",
        "periodStartLabel": "Beginnig Balance shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r74",
      "r77",
      "r95",
      "r96",
      "r97",
      "r99",
      "r101",
      "r109",
      "r110",
      "r111",
      "r134",
      "r142",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r193",
      "r194",
      "r198",
      "r202",
      "r209",
      "r281",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r46",
      "r47",
      "r48",
      "r81",
      "r82",
      "r83",
      "r85",
      "r91",
      "r93",
      "r108",
      "r135",
      "r209",
      "r217",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r277",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r299",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r108",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity",
      "http://sunshinebiopharma.com/role/WarrantsDetails",
      "http://sunshinebiopharma.com/role/WarrantsDetails1",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r32",
      "r172",
      "r209",
      "r210",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Common stock issued for services shares",
        "verboseLabel": "Stock Issued During Period, Shares, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r209",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Common stock issued for the reduction of note payable and payment of interest shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r33",
      "r209",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Common stock issued for services",
        "verboseLabel": "Stock Issued During Period, Value, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Common stock issued for the reduction of note payable and payment of interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Shares",
        "verboseLabel": "Redeemed shares"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r77",
      "r133",
      "r134",
      "r281",
      "r305"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r217",
      "r220",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Foreign exchange (gain) loss"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Common Shares Outstanding (Basic)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r354": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r355": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r356": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r357": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r358": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r359": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r360": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r361": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r362": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r363": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r364": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r365": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r366": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r367": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r368": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r369": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r371": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r372": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r373": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r374": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>45
<FILENAME>0001683168-22-005298-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-22-005298-xbrl.zip
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M=7,5?<KME^DVOU>4;?P*.U)OUA#(1I+C\FIY\P6FE/HJRO4, ,FO!;".DZV
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MZ0Z:Y\O]*973T9X?!.U@)=T75=MQ*/F7Z=>=^<&+%,,\MT"]I=(0L?&YP#,
M0U8-_K3PCIIYBI8_>Z^L.#,?+>"F/:M"OV:8<],8/]K(+6A\J$5#C/R'HEA4
M^FK*R#-@Q#*D,Q67^1'2><L:7SE5YH]X:!7M=:39'TM^]B?X<[95RXWLYRTE
MC01=B=ZO8Q>\Q>O]KKE#_GQ0_)+EGJ("R/I^!+IJL'GA'FY:8)CD?Q*>G?"*
M%,A8C4.@N+?2C7NEOQE=T[*Z8R1V_=[&O\T&OQ:%SC;X\GE.DM&6#U]#DB2#
MNX6DG]F(3<O -'QYN@T72^+[_9/"OIU.&EQ\DR*]6OGC#. 2;A2(7(C]CII(
M_KIJS?R9-# D5H<4T>?9RMP_U%';#JZ.[+AS!HCL(2G^QO+UL-%MW79TG._S
MJZI;-H)P#CZ4YI K#V9.FVA576F^=AH-DCT?_AG%O(..=*=XYS)8Y6AAKZVH
MKG^[["Y931AZ_(QW /;<7\]1A!0G/-!]!N"F*B]!'52$@#V-JG.<"^BVW+\E
M@1S<*[R-" DZ=*]SFGNN2A/9[-TO[A[(+3GK_G0_$=8.8:\S $H^L<KW0:A'
MG,RNV1N5U2M>G(8ZHZ=?9 /#U:RG:GI=O)I,-&1LL1,1;$0MZU]WTV^60:V(
MWH1+G5703W./"='G[+["V^I$KLWWU>D4^$2H-S3L'K=2/+N!]LN[$-,A&[7P
M3[C(JCSC4WYLZB*](<D+L\=EW]A>;.\=*IN/(FQQ@GD;OWES<8=P\LCT2C_<
MJ5>@STAGX]^N*MB-I9WN8*-P@J(0K&OX'VK"-^:4[;0VVZ><"1=CGV4;@Y1-
M+M<K/8QYRM-*LW%<+9X6\46$X37T#)"X6B_1XVT+C*$PEGM2%0A6"34-X7>N
MMTW_+"K;VBH9O#:]T9IS/6=N]TA)U\?), =M,R[T&2D:(H(#G[,K&KQ,4=TH
M,DF;AQ!K5D=PSX(< MFJ4QJN1+H7N3[PMHSX9N::9J^,XE#,>7(]^'5Q@9@3
M]CP0C6+:F=>!B2J#5&V8=I[C9& JR;@>$@3FA]0[6$*<)V0#EP5W_1Y-#OAN
M>H5"T ^_#78'Z[L71/U9\LY'!B6;@4FIZR(\\,DS $#G.O0"D';5:-U(^*BK
MX_K$BS9=+Y["6.5&$VVK,X#O^UZ<^^R1:C:'$4_K3Y;/94N:FL@XF"4IKP9F
M<_I>AX^BVT$0B=5669>]0;7K4KES?T50.ME[5*Z^VGFBFQ/+ZR7OPOE)58GE
MB]!=MDFV)!!-0Q$#*7<52]_GRTQ:?$:H:6GYVR*:<C+RL"5+RQ,BB]/[ZGX@
M@T&AHK7S8C/=7GF)F_^XX$&:(RZ03$L\+4_,8JG7/37#DW.YZ^MK;7 X',]+
M:]VK?@ ^VA*7$ZL'7JV[8.9 CS$!^J0SP'DNCTU0,1E+. .POAHUZ1^WUI--
MC:;8>5Q-RU.Z:4.=$D_8?TAX^+:NA#WMZI,(M9O>.U1VTF(WD.52)>0#M.Y[
M8W9N,J:E$]IFX!48B- Q#)',+ VYD?&+7^['R_:(JB(^.#I("0TV_40ZN$<=
M<9! OAI9; _=7UDTSQ]H4?%\H)4EEU?B?A'PL@0VD[=FEO00%?R85+Q>!5=H
M: &#2U&Y>-L^GB6ND.&)$L.DQXJ5%]\//^NO[KSVNT7!S$4S94QW1;D('3KP
MN';*Q9<?ZF'>.'VH\0I:PKFPHNL;(I0_EWY/0>K!HVN1NHT/K[ZS=WMGE40:
M(182CN*U.3Z2(@<>D! ?MT1X9?H+,!6O1L#2R1X]*,TDN_J*FL</)H %MU V
M7+%1PS0A]S6N=N14&;B19>=)K',#:*8S0'<GX?8L3" ;O70&<*VW]H7/><:H
M#G_F,)Q-><;Y%&%_T(YO <80!7R*, X&V,XW?]LDUDY]IBSP/VS+JGU=5-_+
MWE#Z[CG'=L/G4X)#'K?H-W'OI)]-U6)\?YQN@0+XB+8D\GI1/((+SKM(&NDF
M<CG #/!]WVMGZPN$7!KF2E-H HN6/NS77+<#OW=[HZ7["WML_RG<"&LGP@[U
M-?,4/Q<*B2:O[]DS)S85:R->=4QJK5^I0L3 N4G@<FC0HAZ^,[&#IZ_\^V;<
MBW^G/FC#N1]O1Z\]8P%<TI=]W6\&\$M.ML,\R^)-5LW0*?!KI1-\.$VX3M]D
M\?*1YH:'4)CE^&[ X#XP3K.L- 0%P74$_583"*^><-\;N;$?(M*WTG;4?5*Y
MA:B7?/W"_>M!@ZG-LFS#'7'!V!0/-2;9PJ&<63IPP T?OD_I.F;MCJ,$C[L$
MQVR>MI88)-8TFZ.^5AOE&\+R@;.$Y[UFVEM6-A'5L#E)?(TI6[<(%TP#BV"?
M7QC]TEUWOZ6]L>!R^[3J6_=@W8W^#WUOC>S]Y__JO: *L1P'-I/+R8(D*RJ[
M[X)'5Z@:6N" +&\0.?VHBTWY&EHP16, -?X*:5+#3'2<1C0@/,X 3$O!Z8.<
M2@7E?G3PXG*, P[69Y:\VHQN9#HNHC(A\>Z(Q,XZ9?]%=/5&H> ,Y- @N1J]
M_@*<Z3'?J3;2;/WUYPS+/+;C_:=WXNL2XO0' 60_&/UT]:)YQTR;6\V*],-:
MO0NC8GJ H'M-^@(BZA -=3=MKH,(,)8+3Q32#.I,)8L[H,W$=/T0U08RP78_
M-Y=DL5X\!L, _[MHC6OG*EH?A'<\3UAHL\1.MV416^IH0]@I$)3Z,^WI2+KU
M0R7#,X!F\N+K:./\0T%_M:MG (W.>N&V#GZ"W,?RK=N+][^6?-,19.:^5N7V
M-)*Y K9&B/J^,U GD%"J$^3^SX.M<KM0 4\WVI'WO/#"U.Q6)M8NW',PO9E&
MERY$QX$<NG;).41F0'LO#F9*"",[8L=PEJI'04YHDS"/QJR',G!W7*<2Q&VQ
M_I_,=G%&0D;WBL@TS*K*Z(M7L*J2O:V,%3-8IMEH0_U]_TZ2DO3@@*>;VSPK
M#7/J V'U5),Y'Q7F'<%$Z<3WHM&8:)0^AIF]YYHJIBVI\*-5A)YKQ;"=@VA-
M2Z%).'U?V+@EQ)'G0/0 $]B$BM%Z]]?E'2 JU?1[,_V5:X5*]GB#.-G F\C#
M5':O<9#'1B[DN9GB^D2Q')2(#"'0)_Y#<)'@.\;CR/I%6?V?UZ[5-QFN/QM8
MIK&+N'-'4;J7JD"YWTP0>J<)KR[N 5?8P,H>WWYD8/&/7NC2O7Y]]:J=)[^L
M? D"T[_=\%'!D[1J"?4:VK5?E=.75,?O  /SPZ6J?\<J+[I;I/;R<J'H<F3_
M7G0IS+G)>(?Z]P[9\E;U96G=U*<-(:REY>C!&FY=C4 /^J;KQBXH&;9&C9HK
M9+2X$N@N?BH9-%)+T,_P(*_*RMEBP:Y.O[*7TU]'$E!I!;TLSS=;F-D6%D&$
M@ITAER]>MM\R98[BE?LYNR*X#0D1NR'DTMKZC10E8_F44&I^%O' K&Q)-3<9
MPHK367F0H@V1JBG^"*!-$4S*< CO[+O\%(.*LE2'Z6$TY,4]<EY J@4>)/I=
M_) NOQQS,9]F__ X.?!^OO 98 YKE.9"EB1M.'Q.-:NU?)J)P%W)!IH5B?U#
M/B2%8,;BA6D2T -FU"XCV;_:Y%:_+UY6\F$Q0P>HP6_L\+\F&_*TOCR;EF>
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M@/1Y4DD)152U2061TK;6 DAA<W\-(J@2))=GI#X"6X_  [59=$=>E8.W;5)
MC;F-< "7D:"/4_)@I_Q%GZLL"133\V@U#)6V)L6?=_>*0(S&G&KN6<XVQ$Y
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M#"!%GCO.[2'?,#$:.0/09)_SL2!.^++C1<*C=BB.+0H&K-I&/ZJK7O9N.>Q
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MOFC]YX2][MMDKDJ:N?6%D7IIPT>XQ%K&BY3AA>LH40JJDKI0=+E->AWGKX4
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MD?#:<U<4P$= P@BO,T#,"E\MB89@B8@ZV<RN& KXLGSY/K$O4-H]UKEOT]9
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M\?(_YOJAJR_TGY1F\0X&#A1&5;V.K,G&V6%E;1=[.EEQN#WX=<]J)+1,$&)
M9;=[UC(SJU#JK6;'>>M3@+BT,H=RXJ]LSW4G5'I#!=G:*Y<O3D?&%--$<:F$
M:1">>HN &]I03?L0%<9-?78?R'#W_4OC'.\T:*R-;=@-Z+N!'- >C$&L\I@
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MX(,37B&33D!Q;1Y5VT6,D#8@%HR(D96//Y0>!3Z>.P-@KN!;O<89*9O@"I:
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M%J? DG"2MG SBVE8'_0CBV!)W.IV1AK'#;W7\?:44V8?E 0$P)< U-A<-GS
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M#/14U:S]6': +>#_!0@ % "    &  0@ @ 1!(@4@ @!1!@@(@ 9 ,@@0*8
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MDH^?W#)8%Y\_7GQ?HV?%8;F(X'$FW3X>?T9Q;/:>@YAJEH_U^T,$/_M_H3C
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M8A7Z6V/@KA9WIF)P8HWP^W<<CMD1,1T^#0GDG4G!/8Y+_\(5D$GJ?ZKQ )]
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M_<.A[JG))3ET@8!GXCEH\TG,^G#*J27>.QQT7$Z"ND_>A/3S 2UTQ$WT=<Z
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MGE3*>07]YFYXM&%I6G>&V'UB:H=D@)[KAR!6ZPZCG;OZ+B+F7^S'M)[+O='
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M^9AS1C&"FW5>PF[CEH&"MNUHG?N%\%V=.0FE/N2RE-4V%H(%[=S5<I4?OHO
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MTND^Z9\X"/X1DN?P'J.(A-A+%Q:RW0J@B-6,J)&#='2Z<_J=!*LP1C0)N:7
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M4U?'V2J>$^K_$XLV9H0ZE\OUC#(A?+!?MHDJN3-.HFPOO'$U\(,3'9O82L(
M:[Y4:9E><I2##M'3R![$GG><U1^W- I;3YBN#J#3U +F](<K2:$^,55KH&ID
M(Z(1AK1&J7YN&.F"ATAJ).JO$9)4@Q-0H'_4: Q+'PQO"&V/<(RG8[8B3--
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M/M13/:"A%\]<.3<C.K!A3T3S>#J-<,SO'3^+V(>HPG2U84N*F'EQRX 4<<J
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M*H$S1;6W+?N>__.((LR^^3]02P,$%     @ 984#54MY)\-G+P  \ID" !4
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M"7WZ3_H,UDO!^=4$0',HBA$(D2KTS !9-& BT83#@PACSM)EQ)YOTMC25:A
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M<?QKP9XY>Z"F0XA/X>C(]872OXY&&!I28R%TD.#-/V=T%:7)^=.*YB4U.Q0
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MIC?B-2JDG;B(<*;\HX<G445.Z'V:BWVJPMG/)<DO^RVIZS .NYT_Q=DZD2>
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MU*!0SY;FE$495\=QLDSS5)QZ6:6/M!FU:I^WV013&S@R5=JEMI/*'UJVH_E
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MGJFEQ/$L\W4<>9,@7/6'$8NG*OB6'XRUK8X97RI^?7?RX0,ZWKSSTQO^8P+
MO"2+C+L"5SWXI>8O"3AU@(#<8!#S61P))TK_-8!P(2^VC[3(-5D-$2R":LVZ
MC*<DB-3$*,0=(T37V6K\*!1:\H)&R]*@$9N:SW3ZM%YOFY1(1$UTK.:%CHC0
M=JH: 4I-2[T%AX.E26S"OR8&Q/[,!>RE&FX5=[/I5IB+C[Q&N>56E0#BVQ6\
M:HNBP+;18A18^_S[OFC#=4C&<EQK(D!@3U"1E:J%!>TE33P6S,J.1@7"%4GL
MV=D.:(F22#/$/1T'8O\AFK+203]E*(I@S]%6DXA6;20J^E$T)^$]G<7,P$!5
M$@C\]TX +U,2">__G!.64A8N() WA(&H_^ $Z@I5L:P2;A\E@0 *@GQ3&@C]
MCTY KU(6"?N'"0U#8<B2"-3O9?) _']R G^UP@XP</4LC &N#9R$4A$@#S\[
MQT-#;20JAI0%L<_58  2&L) ^#\Z ;]"553@KR(?"OM*%+RA<@CUFIY(F%\'
MB4?"O$77_'<R3W&IZ1)Q*/:XNUFCOJCX_S<E#(Q^21B*/>X&UZ#KCI&_F#-6
M:8QVPE%+0[''W=J:M-TQ^%=1&J0+<>WB;J[P]7*QIA04;-SMK$H[%) +9T:4
MBFLE.J#KDE"P<7>Q.BU1 +_@#68DO(E\^OH/NM AWA"%0HZ[>]7JB8+YD 53
MPA8/@6>>3YJR4-1Q]ZQZ35%@?R2O-SYO=C *\CM;9O251: DX&Y807JC<'$3
M>3&;Q26O]44\YR-T<1'[VFG?4!#*"^Y.U@(#%';ZOL]Q2Y;_$IJ<Z#B1BH-/
ML1Q@0J.O(_B?VN%_"L<?=X=KU-<1_,_L\#^#XX^[RS7JBXG_!?]QP![C%\7Q
MN5(8BCWN+M>@*R;R6?L';,CBYR"_\&Z"OU$"RH$+FU^]UJA#(+<((/V_D(0"
M[\)&6*XE)N##.$E)^#_!S&2(RN6AX+NP)=9IO&OW9MX!A%]$%2M5$X$"C;L+
MENJU:VP%U8P2=8>N2D"1Q=W:RK3:,;"WL3B4F<21UBW<E(("C+M'56FWZ\E9
M7$)+E+-"Z<_@H#W<J;>NSX[Q_,*"E+= 1-7/HZ4_2'& IQ"%XHR[L=3JN6/,
M'^(P\((TB,:?><M9L,X65 5<)@=%&W<;J=9PQU /&1644VZ^9Q%KX@(K&XQ&
MJME9)P^%'G<7:=88EX*;))E39DN$I!24#MP-)53[74]!U)OS&7%Q<OKT*&YD
M*R:@AA04=-S-I$J['8-\%S\R(I(^/BRF3W&HOEDC%81"C;MUU.BX8[0K[9#C
M7!.!(HR[9Y3JA31=7+UZ$Q*-J3H80RX)11IW#ZG3$FU^'H/FY['E_(R[EU1I
MAP1R'CO/Q]C@*0S&E41@<KRE!<!WE9R 7J/SKJ]'9M>F1.Y@-LW:<<U_D..O
M$(4BCWP55:?GKC&?^T%*_;Q)UT%$(H_OT=8I2Q7P&TM!F4"^JPK4'N7<X0L-
MPW]$\4OT0$D21]3/MPRZHP=E$2@=+IQ[&O1&X>*/.)QSN%@6#<L4HT(A"L7>
MA?-.A9XX :AYK/=J?<H3R>N@5Y6 ,N#"P:=>:Z20O)2*Y%W!,[TD*5FV4$>$
MJ@24"!<.0?5:HUTT8!=<@W&L/_FO"4)A=R$P6*HC"MH/4Q*&]7SH,K1K@E"T
M78@ ENJ(@O;5E+(QG^]^8_%+.EG>H=6AKB@ 1=^%.%^MSC@LO*ZO\N>W"K44
M2*3!*2-<P%^I+59V%,\3<2'YLA_YA"G@U\E#"7#C JM:XQU3,$@GE)6MKJPQ
MHOFZ& YS*2@=N!MAJ/8X"W$IJX)V':[(08%W8<LKTQ#G MK\*0R\ZS F6ON^
M(@8%VH7]K40_%)S/2?25S6>IMQBRV*-4G.LDJ_$'V&$!*X!RX\+.UPH3'(_$
M.N-HEC$^&<S3[.D^WCZM7T);#LJ1"YMB" )(ME.ROC5'_?/%/1U1)H(M'NEK
M>LX_]%5O2@&*0XER(R<4& \)7[\<-Q3DG_Q:_%7ZQTIM;5\(D#_R5WDIX+1W
MU%L!D3T5P#\4)=07/R5Q&/A"X=ZRIEY>5>^[WR.2._O_NOFS AOE,Q^,5@<-
MPSC?>VC>'Z@SKRV-D^VXGR0<8;,.=3E7\O$""*EE/Y9KC)YV.F_6<J&$\M$0
M=R:;;UM>% "@TR->J12O:O)_B53;SR04LW0_O2",+?CZF3V0JZ8+6!P[1[">
M@[B-2H[PMW15<)/4H[RM3R&]HZG:5"_PT);"SB=LPQ9$?W22;B*1=C%F"]XV
M-2E5*>S<PC8DR/1#!WW(Z(P$_M6K>'**&H>$0AP[V; -#5J-T?FXY)MFOF F
M%8W4?"C$L3,0V_"AU1B=#R /[?#O;+=IM388<.=MY]M/1OW;7&ME"[/FI7%*
MPDP2;T:+9Y2EBR'?1(IG]81Y,A-&J799T9?"SF1L-[^9]7=D6)G&$WX.8_N!
M] 9&T&U GH*0[]HHP#4@%78G"[+]3E2C/?JP*;4-["O0E7$G8_)&/+GJ-BBV
M7<M'G\$;SKH\>G)E -;R#:=<<W1BL@!!FJ108E3RZ)F7K8G1:XY.3%,?FXG-
M@>S,UH2H-=YG"R*.QH^43<M/WFN(E$JCYWZVIU*CM4LC"S2D',@$O<E8>@.#
M*#NJG\0A1SG)'_B$'#:JR[B38]K>V#-C@3[ AD7WRMIJ.!&2"CN0?]J(<L.7
MJM(9G8]2O(OI>*XAZ4#&:4LF5-JBT]#W_6R \Z%. O\FNB"S()4F2RJV#JH"
M#B2?MB3%H#L^-YXWG\Y#$72311&+,%9&)R*7V3,5,4A3>ALGR1WE,_8C>=5N
M7.TJ<B"1M2V7[;!"Y_B>IB2(J']%6"2B,DMZ7-*12/"EIA52UH&4V)9,PA%!
M)Z^IFXWIYT3.;$MRU!KOL25?=BE'O@VIYI+NI.3>S-6NPV6KU+L1(#O,H)W0
M-/!*!D$E6O9LTVC9WG>5KQRB9[O2[%'OWZK+F89LH].[-F[K"I6/\Y"IN*V'
MUVOH*,DZ1DFE0ZG +S6_O/5!)N B)$DR&&63>?\U@/#0++*/=#2U*(5;([E
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M?GIVJWX2AQS61*S6Z6+5XLI%]1_;7%0O5_[OA!N3?^OEWW#JWGHV]U4@L+K
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MU4KNQ -GX7ZS]+UU=CZL-%G5?C?'G&Y[Y;'I[J#?2.26W34[/SW4C\"KUUG
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MB4J!;<="80'*#7 P1,)5U!SU.[JZ#OBE+5/[QLG+46*?/TL]4;N'+S3THZ?
M-W<3%?)!8OU0W/V4Y-[58B6"8Q)&'-^APN5K\]W";GC<+2P^_SN$MVIZ?P &
MD1R">E9,SW,+ET^VQ\W2KV;O]^.P.\JOL6YX*F^#+Q?UK"?S^-C[#< S^OS2
MO/T6J5](EOHSMX"UQ\_G;.U7OO3MK[S.BNU#^=D;U$)3'=T.#5 >$R.WY'P)
M'^921 FR9:F96TRI.';+-EO)J<EC\:OVF.\T?UZ)":K)##)V)>YN=",D$\X2
M9,*<MIR?C9M=?''/?5XG%[:.MO@0_T<J- (69W#W@D)E5\G=E3!P4R\6/?@M
M%.^N[[K68V&=9%HX/9C/-&# :#'-X(<O. 75YEDUJ'S.L7?7HO& +71U54M\
M9?%CV&GR#)O3F7&>??[9/SL3[];9>%^M,]MEU)8V";92;3$)(NN:3+:5,.J,
MD-3#@#2\]8">>IANVY#X;KKO_/K5&^XM@J4:=1450D-15>%74OQ#(D80"1(O
M0IC8P<X#,.@D9!20;CCU/$[@Z(DW)^XS!)/D9U+/@^0A.=),'QT86,(T+N!X
M1,O13  &!@010.80W&VSIY/M;[=<QNJ)UASTZ$F<!9/ :+_L(/&60:(FHS>\
MC60'! E^[_P!%,CS]%%XB8#AC$-T 2#I.F4[ ]&T4(5%LC@R3Q84CYU)*M:&
MA@%OV\53Q-Z#;@W-@%S05;70;8E?2L4XRGV7S7_T\1<.\K^\-3@1RMQH>5CA
M_<Q@B*1/A,K[&SV.P?/O9[R2O4F]Q*.;1&1!6ON*98%\8Q6DUM U$E&J(T0N
M71RA.C$MY,C5(T9GHB7:)59SJCL=PYOZN1O"DWFV0+030MNA?9(#-7,M](:0
MH_2>%_AC>.#U*ZK>"JU(&9"*E!6*C#;58QO@B7IB\^WQ@N[EYRHP)G0@9'!4
MP5_W!N=*_NZ;8=;JO=ATSW_^K>G>ZU>.VF7:%YOV@;R+2(5Q,1(E";3/(,<9
MJ3P:9%GQ_18!HW.^/]#S(C"-X9IGD+4^$'?$D&44AH.EA^!PC^X-_<GJN3\?
MOW[5Q)A")^.NHM$:4KHM0WC-L^^#0*0_<^_=QQ8><'YGW <" 70??/V*K*7.
MTP'0NI,JFFU?.+Z3XUWWP.L3'*,W-<H#<#<33JPOA)P%13NDK#3'KBBX"BJH
MFFC&\OSIE;^ .>M];"9F=4(XST5#H+H]T".D@<,6185$-NCLP;2ZV:@!)>[U
MH*W]^ETG?S5LG?>L^+;V[8/9E/:2,[G?%O\,=!#1^=G2I<LIFAR!6B)-$8C:
M#+:-'DD*"@SHVZ=#4]&P&1 /='[_[HO*3SX_C%[)'N+HF \\(8^-Q2G=_E\N
MY\"Y_WH378>7UX"YTWVBL]7LR?Q9]_U[Z\)ZOI=X)=%3.DO@"GE09R>ED:$6
MWZ0<ONX2OXH!'V7.'WS]BCJ$2G<^/B&!& V_P AI.HV>AJ;MD\&\]&R@WP$?
M\.O(9.J(S/ZDP-Q$8C5 22>FY%$QJ5&C#81$E:RPI+8)'G[]BG1YE$5#-A&I
MYU;DH&U[X8WXUM^]RES_#5U_LP?.W\3.O $1H/ZW?3YCN7/[]CC6\,L>#$))
M^X/[_ZG5]GZU_'1.D^"SU)))RH-6S/^R)#UZ@5)X4^:%AZSUAWC&:C(+2=MK
MM(J(R(O=0,25G*GDN:5'KU])]G:J2;+6#!J(!GH4U2%&_V6/698#VT5*E62:
MW-2'%K46Q,B(=-#J\![F18)]6)>AZ97E]9">/1.[8TMC.FA;J3OB4F:%]MCL
MW'T_O^I\N>Q,W<,+P^[ZLYB27#+NT8Q,3=L/EW.L,"M'0#A9MV0L*>"X'"'G
M@_GO4?WFX@B1AB9T"+?7#%=FRN4"4Q0FQ_9<^":[ 38#C@]#MK8SRV3\_^1R
MZ$+!JGR";L5[_!X&^3O$FD1<-93+N1Z=K#P&'/@YG3_P8T^? \_Q!!5)C8_S
MA?M"D<8UTPC=&Y'/1^RS4RZ&VG,A^6+XM-2SG:6-BKOT#9\RL9F W.>)?-#9
M)@]U7;J^1Z2-QPFJ&F)'D=XCLMUET_Y&?X\: YH0.D&7B@P^%N& ,[5GJ'?N
M6.3G()B$.9@,Y;YGS2)"O$;78W1;^2QPV\#B0ZZ#08,!S $5D7 <GDBN1QZ]
MXCTSHQ<[0@M;]/9&RW9Q9,AIDN08P5;U].J<'+6O-6Y:YS>M>!L7'<4YU%[E
MZFR9WCQ=5R;G*).M4NO,=M#B\D<?;ZMW+50_)GVST$7]IGI3JU>O$"RTC;OK
M:LO35LH?=G]B3&A;]C<Q*T]T4@4G+N+ZYQ\7V!$^);$*J1#&<FW@EI.B;N$^
MXH[]3U?.\K*PBJP7D\!S4@0R+2X60^3.*,KO41!.0MPL0E,$_SJ6;"F"-9TD
M'4B,#9^HJT&SB*>B*I*5$.(/;)F.RTSZVR"WO0UZ\TT3A[("3[\E+K8-PAF6
M["Z8 D<?X_:)6'Q$8DU%@U"I,<!VV;2)W *)%DR":1S25)[1M;W_>TXS(K,T
M)8\0JGF)&R<%\PE34(B%@C71I$<YGZ84W#'="@G3+;\IW0C9:&C7TU58DLW_
M0W:M6E($*<9-D%EZK+3+-[H%Z[JEHPEZ*(!$25OP4K+K&!]F'5MMN:Y%#;P#
M@OSDY-:98DI#N^4049^J)JHC4Z$*.*49(:J=KR7/W&%SJ,Y;N3B)R?')4E,(
M1<V55NPK23$K($ZDHH@0!KY0W;\)756=-)4U4;6C#RVWH/).,1]B)5;"HI</
M1:PPILLR=-6DA+HU= G+0]H9.$%*Q+=?D\556XJKB,VWXRHGL&JT+L_OP@=5
MRX.G34,.P@$BK_\>\?[T2T]0PQ97UJK@>S#M5!5I46*\NEA.E 8VF;EJ*$J4
M5E&"F&1$&GGKQCX1(:174%Z%_C?-<^*Y*:KV=HOC.7KJU(GE_F;28Y^.U.P5
MM<*M^I55U#K#79&Z/]\&I 08:PH$)U,J[1-%0BWMM(']<J]2@2"L*78QB(O'
M[=DG2A1"46)E&J5!M\CKFKTC!V[Q/M&@&(H&*V.,\^>>TE'BC:XV0GU%H$F0
M6NGJ-V%LT0HEU6MD0%?D<NV9N,J>-VC;PP&7[-ORV;[MEO=M"<'Y;(<V-7N+
ML2L?V;2RM]+<H3LNG>:V9,FNFV,6EVZX[=7F]@*2A0F23K@7D+V,=0MZ.5H=
M7977&-76#=9'-^S5=$AN00*G\531!_2F/ :<)BFPQBC>V:?$_CNSR1]J#VQ+
M(#JSS,XTX=B2;-2R=<.M:!/8BS;'<>WQ.:=\^JN4=4T78%49]F&"$7WDQ+.E
MD M*J<]M#GJV&"(DOL(M9B$37S <++_WAC[49#*D;IR0OD06]LF(+2YVLZM:
MZ#,G?B]/2)ZOL)/BT:- !SAH1=T6C 4"(\?Q A<WC)&2;5['^ F3R6T]"P)A
M^8.^2;S 5_U=%W>[<;V9MPJB=^M]33!WPZ3WR+%9$Q/(#:SP9%GE>(<DFWU5
MSRRH/G#YC+=_B')Q(+II*!YHMGQ0#]@XF-G4[BP9?-.YEHSL)</$D++G;3QI
M!U,U35@>JQU2MBY9;>6T/>Y>J5]^UFM%@R\?K;^2&?>=-[Q09IS_O?42N-IL
MGI/JQ#C6A72M4CM:C\*X$BG&,UW0^"M+=4%9G)80,SI3ERI_AI5NTU2%>'4F
M&'0'#&0#=9)&BJ8+FM7&D-1T5369_$/VEQY%E3;0LFJB89"C?]_)R9VVPG+U
M=E^LC?NWE^WQ'^7IZH?QZU-/C<#X(+??"2J*Q7_\\EVT](QL=TGD YY"&I!M
MXL)MI\^?R;<G^V_0H/,)-#=K['N0R+UD/!2%@\X3+9Y+"SQ/Q'I.$]$;N/,<
M4^)+3&EZ(XOG*%$ U?S(L32I>!"$YG(<GR,Q5C1"\PR;+S!<L10?G?T5M^(U
MS/:!6_,.P@O M:/B&VRYK8-F];5R7GRRSKJ/%X\Q>S?!1LB%#AD3\)*VC\N%
M8QFYDE ^/K]2&':UD,1,J V5!PQ4I;PAK?RUI>;1EKKV"/#KQ@B0F=..F\=^
MX;'>O+YZO(]A.?LXF6FW;/0BG(A\LP5&*'%[*N0KJ;.A4'- G6*!342LO=[Y
MK8$'HB*?/P](.MC?^BLB?Z8_C9J/OXK;LOX.6 C;<)F[9;8OD1)QN,I,H>AW
M;GL?5"(\E3;UEBI,D5_MDD91#=ZC&F=XH)L*^'_> '9.-9ZM+V7NVX_.PZ\8
M QG?G*(+38A$WUKW3RXD'</*QSKCA)(?7WHGH64EIE!9;5E],ZAAB?,2N;*Q
M&Y<05]9,41$-;X&*6[:*$U7'5X/VV'KFV)_XZUF>?=C.*ABPN=#2+7)\9R:1
M=;CBE[@QR'-,I5QA!'[ULIM9A) LV3@;PE4*3%E(W!IDVP2[32/S,X&(/@ ^
MC&Y54;.JFDP2< -2K3(3;U-+++&U\^ZOG[UK3=JI)9Z B-YHF![4_:]/GREO
MOFW8)WW&L0R+J@'R3^O)X;.*R0= NMHG_37']/M @CCMJ$C/LL& '8#Z6.02
MHG^/IO#(GO%#I&MB 2L>XVP"#[&/32A6&!@NL*,52>PO$)]/BOBTGB;]Q%_;
M# <2/\]P;#&0^%Z$D8'- ::=X-71V\-=!)>9JR3<%(XIYC,/)2GF;!RZL,75
MB<S,6=EK9Z6X$#!Z(D7JEWP>?J^?2L.G9RO*MG8L?@E_3.^3:S5:U2LT6SD4
M)(;.*VLK.GT/R?JPH^)06[-KCK)&+))47%AAF4IQ]3:<+T6CV]U#9<C&42&,
MP90KZQO:4/S(3&TZ3>V5(G84E9[#GBD>&U1_&YKPM_7KS]8VI:[JU=/Z5;U5
M/V^BZLT9:EY6[\XO&U=GYW?-_T/G7[_56[_22.1T09,IVJZIOE+1_(HU6]6S
MWA_Q'K.*N.UB30]D6<5F1$Y?^!1^W8HC4IVSL+/YM?RK/:[V&WWIAU2Z^]:-
M<6MS29W7P(:&IG)$23)(@_<-M_\7/)[(M4RSI$HDP&?S3+&\]9JOK9)H0P\P
MSS.5$$F0*.IQ-E/I1=KFF):?>LCL5$.>2[];927_52W]V6D:VH77U:##S>OX
M<R:\-HZQH<NBV5LJ9;2-(O<^R[7%SI--U1\4I;RZ0CJV"H'24N?(D_PAUH!8
MA5&1:X\_WU3S8V7XH_DD)[ANAJH-\ !]N/*WR)E=KLZ945B'*1L:A K'\'PE
M=7GW98<YTQLVI N:U?4"5[IVW\)&G_:+=A:?&1^-6N/O_=MZ2QO>76I1BK8V
MM,8$Q!RLCGU$K\T$+=&[Y (];!Z^J^;'GLQ1VPN.;'IR@:FP+,.RZ:O>R@SS
M-K)+GK7?XR,3:TRLLLP_ML<Z_J+<G/WX/3 Z._"1Z=ZH)Y=_P"H_947F%*>>
M&YO;W<PA?F%VUWN(@5XSZEP28S?ZGMF_&34>&^8SVU"_XT3S^=FFZ-8W13/]
M2DJ_3F=/RG:Q86"9*MI<5Y,_OR#8Y.4_C]W/QL_A8^Q;9NX%\CF.-IAT+3C!
MPVT!/($/->UKDTD;1@@U3Q<+HR\"T;H5C89!&T7*%,-;;-#+ISPUYVV/Q7$:
M2M94T80UC(Y0?59,[S,4B-/96:YI.[OV0)8GY=,+T ,DY)YX&Q9$@4$ C7T7
MEK?CIXU2-1I*=B5W2E!:=;HV!%++W#P7@_82!"+=/ WNQZU[^W1B2#C>T5:0
M8(\YO^C5O_S=^<?6V^E5Y0-@++UG^_W"Y>/E0%FU :@.K9YN*&,L;U_M; C0
M%(1%50LVBK[@;U7%_,!?0R+G$=B).D51I5" )ZU"DQOH2?8G( ,40H?LV^F1
M.$'F/5I0H<(*&6P,+=,2-;)([DR'/# L*M'9"@3JICG<H?[;TT>102_6^Z4]
M#LZ[!)K;0&U(W=2\E+%KJLDN;/52-1'"J\DN8$].3;9EJV-5D_U:8!2*"-4;
M?<H-WQNQR3,+%V S,V<=DPYJUV%48@TAN5#[.KN*^^,AT<:-N\)M?FU:I5C3
M^WU="\Q%=,XUMM/Z6ZE^C9+N"UN<&"(M8</IVLV%5(3@CU*(/(37/L].LF;J
M@(T @G,"/#((R]N0K@8B!N6.&L-'A6X]O5H6G+.LWQFPN*+S '%8$IH'BT&(
M:+JZQG2KI&[MZ'?)A+%+V-K2M4Y,NQ%$@NM.)!NSGB_CM'_ NHK5S'+O.;]L
MQH4(<_5DX=S=9;BE1:I6QWJ;.:AEIEPN,$7![[1"#+'<2O$)9RE6B \74GS"
M3I:0^,1A N(3GSB@X9D"V<K/9_&-#P>2"VZ(TOIUN=F'Z"84@38^@5\(<?I^
MX].)$$.0@47U5E3DNE83!XHEJG/QS9=^N5$W[AK&YUX</;>=21!M.JQH"#]+
MV*2*,O$9=\O? *HDTAZUR A@ _*%?>W-O0ZM-E0)@6=*Y1(C;'QP,\2E4]-6
M8?1.<M#X@8%[6#/!/M<U2>_C*]TT;[#5Z+;$YSE]^7LZLKX*C_>G=U&.)46]
MP<$%&"CO 1:]40'0MTD+R9O0K=?"T#.F]G8 X+]'N04QRC.ETNJC;8O$. 0B
MKM^FSI^(O,!PPNKJQT BKEZ:[K E*AJ6ST5# U?*G.G>UU4DQ9K3.KU5^OSX
MX].7+Y&:E&Q8Z.S5OS<.?'O=D6^%+*[F3M(ZG >'FB_'=O A8U9BM@+6[6*A
MP'"EV*K7?8Q(5LB9RD+.Q4)ISSD58K8GYU2N'VZ^?/_Y_*78*NSJG,JR<NI]
M- O+K<(B:Q)J[0>!?IR6^M"/KH3DRZ;Y!8YCBB&NO\G.KQR*6<X'-/K39#\C
M[9AH:IJ%5I'_4?M1'M:CM".+;IIG&JRNTQ P2'CWNMOG*IYEC5GWFU5[TK+U
MG44.L\-G\M\/ W?0OFC<*_ F.WUM\''VD:ZN.94JJ*7TL8EN\!.ZT_NBQMA?
MV,=HNN^1/5C.T@<P(('-^<*%F!:[;#*!%U?[EOJ0DS8Q1J0)6W\@:N266D1/
M^!^[L&R&,)TC3@I.!IP,]9]<#ETH6)5/T*UX#[+=Q'^'6)/P"1)0+N<JF:P\
MAO5OO&0K^I"M2'E%A09(K:J.]%$))G^; U%R_YZ=$M8/51R8 )K[Z3URK^1E
MV7_>(T*.G*F,L5O_M,3C /C\1-RC%L[0@O!/D(URGYB_[]B6(!C,0UV7KN]1
M:S0  *L&F 3I/;H!0V'3_D8G!!>\+[USWR*_!,TN^-^V/*^LKJ)^> ?,]..K
M@<6'7 >#M0& !E08PO%R4>>]EGHP.Z,7.X*U+61;T)(.&-SXC$USJ)D]1</H
M5-$'/1$,-(/JFG2\G=FGQ0)_VRS+'[E;T#6=U 2:6$;PB>HC34!.JK'IIEIC
M@ UZ78A)MYYGLL:()(S1FV^:.)3!2Y/?;@>?6<Z%74C"V1#7X178\S;'">WQ
M-_ZR5BORMS\DLGLY[,,$(_K(R910*(?BI^71^A(>SO(=I;2G\R36J+!M6NF4
M9[EV>U+S-,XWNI]$26JQ3].;S5,2@$U!OR  <Q/0.1OTTN\?S\+U[9^?OQ[2
M"SIOTYH#T%VBIQ=8UJ:N RR7!+"VS[I23WQB4^I9/&$RM6W[@@!8># @P>A+
M--!)8L;_/2K.NSZ!WI;/?'Z>B("NX<&>B<[!J,FA<CK[CG(Q=I1#Y[%B%:!5
MA../EC#"CS!N]=EZ,V<@OA00=R/FD8P&'[?1(,MD&JUC$HAR+P71C*-)KW*A
M7$(/ZDN>W^_7_7=:N)DRID>L#;%IWZB+F^WQ!7LG7HSKS:Z8T&5*3J28+T.@
MZ$X?D$SB_@F0V_G'0J72)R&J?X9J59&*#>EL;OS"T/OV-D8^QW(QU)T76$9@
M5U?_+45\:79P7TC*34C*;4;2 L^40Y3V'#Y%032!E)RE;RZF?(EG*H75N_.'
M3U3.)NKF8EH!BOH>$8M(T=6;[#7=M!I=![MVWW3L/_[QY^%Q</6C\C4?XVZZ
MKTM"("!I2U-4#_E:BAE")[M^E$@77B$K98J+,;&M0ER9*7"%C#$Q:DQ<BQDG
MY)D"7\YX$Z/2Q+,F"B6&%1)1&O_5T=N Y).AF^:MH7?)08Z6?;$W+(\D3'J^
M*[7'W3OV;/SENO>U'F69C'2(BH*$!A2FI.OZELN AS@)KV<%ILAO_2+$+5$I
MML4%#)A0B'+::1^H%*NE+S/Y0Q:G>,QNH<"4*U%.(,9699U=[9Q!LZ6R<V\?
MM4]8PX:H5C6Y*O<532%7)I".%^?VU<,S=RCTAFRQI4O?+O/"UM9_&SQ:VC,+
M('(@S.[$SJ")7T5J,XU7]2XV3=I1X0+;USK95^P]?6Z/Q4_56K70JUY_Y>+H
MQ.%<)PV^_6Y7WGFDD_5Y\QS#%O>WLV8(4L675:DPY3UN0AI.JF+S?KD\4SYX
MP8K'!2YR#)]0XU9AIK\1M8XF6#AG!:?VU+VUE)A4=<3V?CT_72A/46XM779<
MT3/Y;EF[2(5D#6RYQ!1#G/=-IQZ$)-8*$QOKI:I[3:@X#6R99TK\X0O6,A.[
M1<$*-*_2T 1S2#8X-7.H6G/&=6)9[[Z7QU;>Z)8NU5C:QDUFVPT?FZ<7UR<+
M*"=<KL)RH?8;TR7Q:U J-D^5!T)%ZNJU)X2*TXRR)88K[UO#P?6$*J;],9XI
ME)+Q4F>Z,>![OV!??5+Y[B?CR^]"E(XXRSQ3.N%N5\,)SDD;T K#"?OJ,BPG
M4FRVLU)@6&%?=VU6"E)L-7GY B,45N^6[R.98K.8',LSW,;-; ,;M+J>9Z/;
M523LZW5:XZ^?A$^\7C)C\3KMF7:XY,V@FJRQK+!,/D1M=+H$/"218C.618[A
MN ,E4HS64B 5S-SJ>MN]I%.,YI)ERNRF\9V_N2S,FTNCJLEGBH$E2S?N<'^H
M.;T,9NWG;_QCH'Z3\U]J6VM>[8!']UUE!T!D>"#<N3 $D2Y9>\Q7XKC>;%_(
M%E\J@']!5(O19!<#;T0]1,+%9\,9-B\P%3[.@JZI%6>G5OQ6M##=K%],%0S.
MRY>-;O7+Q?6?!#LT'GVT04!=/#U.L@-NSQ B61,LP"JVEQJQFD:QV=LR(^QG
MYC64',57'< 40K31W$LRQ6=+\XDE7&</99M8-*0>62_P(U;U >GPY9M.^%5[
MKMT:ES_[]W&7!]S]K]@?O#_;;5IH*242+L,J,)7\OFUM1:=;C#59'%/:VS*C
M2 (7EPW.LR6F4-G7%&XDF8MI(ZQ09@KY3>_K6UT@?H8'X+XK/FD)*?]8E?^*
M#]6SI ]->V&8Q^]P3AEZL4PXB\'PY=7N87;X,QQ;XCO3QG"51*Y_>)%LB7&1
M*C!"B,-A&6-"ZTM,%<L0Y<9V@=7J5;$4_M@4O5&)'J F*R7I,T(/4']I7+8X
MMGQ=&R349VH>K:"[E71RV6N(LU6'*Z4K&)CP$>\2Q^1#5,UF%B4RKV);E/,\
MZ?N46?]D]2JVBB"&+4! &>(^XHQ?F^A67/LT)9YEN/SZ%^0D?>=9=AH_@R9V
M:/S=RJ+'K70NL]#NIW='3UU)XD*2Y(NBF^WQX_67A^K55^'B\Y9J0@)<R3<$
MQK>H"Y8!Z9.K./;97JZXN=>'17$[BP&7]A8K!:9469WQRZY7#LVD#;S$H)N5
MRV6F4(FMLUK&I W=PP V<4R%JS!<B#V;C%'K:%-4OS"03<5BGN'SJ;JF//,-
M,VBVY!MZ[VV_T35]5A']>C1=MRX']8<_7[N=+:48CSXVK!XVD T2>N, ]39K
MRY1!$[L^%#SZ<*$;&%ZN#0T#:]*H98B::2\.GT1%(XO4*;U)LR4^3_:MOS>%
M]KC0^GS9'+5^_?UVGVAEI@,@PL]23]3N,;H'N- ;E01,NRU;6(-T29?3[VGA
MQZ84C*_2\X42,,Z<<7H+MU8XYC%(8<P.>Y1Z)!^?W'_3M4ZN6<*F9;L:9[AC
M-;$T-.BE[I,89=;6ZS?CJTM>_?+G=\P']H/1<:%$"@5SMVH6BF0)G_?/%\EQ
MC-3J6%($C._PU(LC79PU_E3Z-BV3W#\2QK9'MZGT^9MUWL>L>VIG;MJRPM*Z
M&6K%A9M?PX?BE\=3<OM"@A[[Q'1C&Y1T,'^#DI2 UF0!BW?:F]^M\(;"T"O&
MDO\"4XQT#BWQV"\&,L5I@'FF'.F0U3[0*3XK2SK9A*B#6--[]IZP(B&!26("
M6#JT\V>R<@P5LT<.+#2Z9&F9]9PKMX,26QS51Y^B-&V)Y#D3()"!52SNVO2N
MI%72+;*8<HBK!M/ILT2C78RM!O:MC=[&0A=?%\*7*'8Q72##,?S&M%M]%T%=
MDX<2EFNZ!K:8= 9O=.W/EM)1:8 0[$5WNE)-N6('?WZ7$_2B ^J$"&<0,$TF
M-EZ:@+_7E4*K_(>0K$J/8_]B:F)7NGZ;L"Z^I8SA21_(^(K/][I()6%M6[Z(
M9OJ6:GV+9PTO,3Q;8,HA<M71JXW\=S8":SNFU;]D"9]4_P[JY]P=KW_[^3G*
M%G;<!\G\"T#V65Z7BVL@MQ*."@M%IA+B*L?,JD1A4_REP#R3)^U;"UG%=@(J
M%=_^4!X\K$RI$E.JF L,2HQ0J3 5(6ZERBJ",VC2!<WJJ]3LBY%G#XD1]Y"X
MB?A4;8\+ZA?AK/ZE)9QN[<+6&VPY)8ZH0VN/G#(89(G/R7>H7&&\I@3;TI&M
M I"N7(J2%MSU[M<*4B7A+95+E5!+\=X1*YD#3*52@>'8#0KNTDJN^)T&D*MB
MGN$B78 8>G_5]H9:XK/C$)UB#0.:LXEX:I:%>OVR5N>N.Y7.]A/Q0/Q'A>18
M"%%]C?,^>JVK\DN^K,D2[WO,IVBW?69\VH$^9:GUO>!4M&M.M\^GU3U+(0CQ
M:Z!!%E\2&Y7KM?:X^ZER>?^[]/B)+VTU-KK:X/C7?S?WO69(<[!1T%8(=1@Q
MT+9DZB BH&W)5;KCGRP_FD&S>VC\W8"*MYL6V9>NZ?V!@7O@_"B/>*IYP4<G
MJYI,_U)I*ZNJ_&=H6J2*</$T.?4C.D7KUU"[J'_YM=N>KMY&7-WYD^?6%*%]
M]G57]:E)AM];\I(XGBGF5U^$\!+VBE/$Y_B=O")38F/K\IZQ.39UCM]!Y9BB
MD'6"2QFGX_>NRTRI&+?=7MW^QH=<$%HTNHZ#8F<\J(<R_,7>_&G>7UP];G>[
M@3\N$)&< 70N_Q%$'.?5M:69OH=D?=A1L1]U%^*W-4<))\Y+6+.MC$N!8PHA
MKL3VI7LDZ_.R.)9(ZJ=<8$H1B@4SGH76LB1R4&7PYR+TI\RX%EK3XD^&E7BF
M$B'46L6SC7)DR^ZE3&\2)H-F7Z#Q]RCS'H_R7#0T$'?S%AO-GFC@4]%4I/;X
ML:"?6Y_+C[^K<;J/ 5:-SNDXB6B #3 )_3X8$9, =-B6T9?\L?J+]9N+ *MX
M2V<TCSZRQ^SZIY]>ZEH6GF-1_<40'...0S0\R#@60<<B>HNAM(Q;/R^4\2R$
MED7R%4-P3#B.</%&YB^FW"?*H%G77_06//_ 9'0L5T%HQ7M\,^QWL-'HVBK3
M&%JF)6I$'QP_4E'_?N%$]FM>B;/]2("M<V%##G"H9ON1-G#( QUZ0^';F1%=
M(\>^TI(N-Z1K\2M^QW-B5R>>"SEK7V$*<:Z%X>HY,UYNZ)(N\))GA K/%"-L
M;&:LC$,M-_%5%YA988H5CN$C;&IES(Q#+Z,[L3YZR5<$IASAN'0H5DZ<A'>6
M" 2#S^Y_/PS<@?NB<:_ V^STU<''V4>Z0(83Q+% ^9;2A_7Y!C^A.[TO:HS]
M!8.:V%"Z[Y$]6,[2!S @@<_YPH6:)?*SR01>?"5,6H"&G+2),:I*DMX?B-J(
M^!4WNH7-8Q>6S1"F<\1)P>0&G SUGUP.72A8E4_0+:C">WC^[Q!K$CY!>93+
MN:HM*X]A"PN\?"CZ\*%(F4\E$7BGJHY(T\T \K<Y$"7W[]DIP<E4Q8$)H+F?
MWJ,G1;9ZA 3L/^\1(4?.5,;8I@F9)C!F _C\],:C:\[0@O!/D&URG\C_XR>2
M,)B'NBY=WZ/6:   5@VQHTCOT0U8)IOV-SHA>-[[TCOW+?)+T.S"/[XF<-X"
MN-K_X1TPTX^O!A8?<O9Q\!,TH,(0CI>+1L2[/@QF9_1B1["VA6Q1J#NZ*L=G
M;)8K4+QS-8>:V5,TC$X5?0 6OB\RI.W2\79F_P#ZH]%8\&^;906BZN2;CS5=
MD\G9(AF"+(VJJD@BKZ8%_Y!Z'!/I7503S1ZZ4/4G$[WYIHE#&<(Y^>UV )]E
M4=C5*9P=<4-C@3UK<QS?'DMEI?[,Y['R]0]8F6$?)AC11TZF%$$YM '1CM:W
MT>',W%%\%?[S7@4Q@3:HJ_VSS;(@DUQ%)=\F_C#+L5S;_E04V/:XH=5_5RO/
MEU]JRI'?H#M,X$Q!%PC W 1TS@;=K-XICS^^-4^%2MR@VX[<2M;[<)BNC$_4
M[;7U-@B A0<#"ME]20AB1FS-OT?%^:4[T%OPF<]O)2VB:WBP9Z)S4$@Y5-7>
M"I1#IW5CI>8JPO%'2QCA1YC/0UAH!)99;^9] '$W#(HD[GS<XDX,81Q"O@^(
M<KO2YE"K@@_J?G@$#Y7@R*L;D=]@BW@GM)L(V,W3T3?P9>K:Y%*BJF0IC_2>
MHIGK:1_%!^/YJ_9WG-2IZQ728:]\'K^*9%W0!&HT!3N[OS:&+:+9#F5V8[+/
M/]ICX_(WWY)ZS7J/3V OR.ML.NYML?B/GR LGLB?"X&Y?P(,U_QCH?;'W:?G
MH_H#Z#*UE! '0-U='LH.0]O5Y7W3 S)F2[_#@*.DJ'CF.'I+7]NFLQQ8];/&
MX/NH+#5^6)7MG($]^NC!!EDZ,EQ\D 8J3?H/DF_)9XG8^B$)M!4-35J7(C$S
M])L:>N]II#,\ !8HHG,NJ]K7@?MC^B?("#^U_+_97\6GIG3ZXUL^8<N_B)(7
M2"1J,A(]8"9-]^769PG]DNZ 7&"$RNJ30KL2UWC)%MM5 45&*$7ITK):J[P-
M7K]I!H;7QUAV[W-N:'/G(<^PH3P"PH_8!%/N[5' DZZ#=M-!HGBU7V7K].N?
M[S4I&1,=3@4OYCL3O+D'S-Y2BYVT**UP *(3.Y47E.^ZR6?,Y(Q/<^/N >IM
M/%8WS:&H2;C1;5JZ]  FZ8=H&"(X*8!Z$QN/BH3-AE%31:5OTH519J=KXY]Z
MO7/-/14N:N+6UT8*+U( ?O"42&=0TX%VMP9^+8+&VG]POZ[&39J*L:E?A2LS
M+!O%H*U>.BMM+$%0H/=S.8IGG4HSH'@KCDBDX-[HVM!H;09\2[;X%M3P]O3'
M[YO;WW]O(QUXBFVI7-#(@8T%Q#$V&KN1J>;IQ?7)&N3-E#() L:FCR"E>3Z9
M>RL+$>^MG-7&H7A[=?I-_VIQ2:<*%W$,N+1RQ\9\)S?='8+F[>UU<U&T[VS-
MJ[_GPD7Y,U^^O>EU'W_N-%[<YI7@*P*:_;V>>=>AX+Y>S;PT[!-FKWXPB(2>
M8?O?ND8J@8?@7]]A"4.,Z[B9LRJ&)6MD5$=_BU]WD0JU(25)<=&!E231'6!W
M;9]7DW-K6V EIK1QIF_O"!G_;A?'5+@HJ9?5"QV_5!'KL*YKEFXHV%S4P.)9
M]:S4_S6Z/D]HWRJ<,KYQP7Y+2#G12\4!?;1C\[V4J$DO>I4*4PK1X"!]B][Z
M5(MMP>/!9H4X\;/F@E=:JF>W!AZ(BNR)XF95C5=O;KZ8#Y=73;SUQ<ZC7Z!6
M QM2A&U0=[WML(J4B7N59:8B1-G_2Y^"A2!<;#K&\4R%W8!L85(F08NWDQ@B
M&YZ29 RQ?*6('46EU0RSN^U?M9)X]H>_Y7Y'29[$ML"YJ* W[OKV=L;Q'-@(
MV7OR-DI;4\^H'M0R)B2MLT6.*>4W3=H= $GCRX(6F$*(F]6CN*?L"O?43ODZ
MJ-]@:TZ!NX6S/T7='.,H-[ANLFP&5'$'J+*[)^&J\CSE#JA9=1@F;BTZS8-E
M+J_?Y_<0>XPGQ+7X;(S E"JQ]0E?;7@N(E7K$_/CW)8&]H?8H2YWUQZSH^;@
MLZQ>UI[EG=7M!U@D4L,]<U 24*,VR<%.U_;Z9M/5UTF%Y.P6B\;+I3+#<JLW
M^5^"64J6?PF4I7-%A@\1V42_SV!C-R;%E=+I@F;USD6 ^%THFJA)P<>X/LL_
MNZ4?X^<\%R6;D]0QK@G4V3&NS:7D=%I,!=(A82R;M\..JDB-;A<;0&0[5N$F
M:3XK7VZ/E:?'ZZ]?.;;\:_M[6BZ8:$#A1+H#*#D&LL-2GT#J;2]($)A"D66$
MXJ:5!GM OV1VKLI,(:&:Q=KL:4F**4&%7HG4[.F&U<)&WZG1L$]04D53/__]
M\O./W"OS41(#L67V2*':)'UGZ>0CZN*=)]674W)KBE>I1*QU33RW'COYXJO/
MYQ+3M:I'U^ZP4TYK-KISU<!S2UJE9)2^M22S_RG*!9\)I."<:E':(4@CH+^
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MH4P?S^1+/%/F-[U@*CFCMEV6;(D9/EWQ\Z5]ZW2=$AXDDAWDBDRIP#+Y_.I
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M.DD0F_8GJMTB^?I"T2#6543U]:M)/&W&3Z<+I_/(M)5XG6B5TG=:BIL(8F\
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MB974/=UL(Z_F.YHFT$]BVW!)06H@9H>;CAL<WQPYE-H=T"7(=+94AF_" :2
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MUW09Q":&'\"2FC[W.6;4O+2?EW49?'F+P4@.\^=U%HRP:@D2]>TZ"VZJ51N
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M6"H(=LKB#;30]G-3!_#?FH$FG68'7NX^8+.M@9N#F6E;NFG>48E68'"<!T]
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M8#R&5&L\:)MZA,<+QBYE_[MT<WO_/LR\*CCJ"6:4CP7,M4;0BA3J>%T-LRQ
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M]N9)6&[^_"FT2T 8R_@I Y3#9*U;'JB@^,)E\9'Y;H9>#*+@KV(N52AEE]T
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MR]=2*K]X+3755BR-5)_IM9!SZT6'\.R5KOP'*Y[[_&W,BFEQ+A&L9GG_ORR
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M  !0$P  #0              @ $     :6UA9V5?,# Q+F=I9E!+ 0(4 Q0
M   ( &6% U70K-!$46L  %5L   -              "  2 3  !I;6%G95\P
M,#$N:G!G4$L! A0#%     @ 984#5:HB5:?)(   $B$   T
M ( !G'X  &EM86=E7S P,BYG:6902P$"% ,4    " !EA0-52L3NE X)  #I
M4P  $0              @ &0GP  <V)F;2TR,#(R,#8S,"YX<V102P$"% ,4
M    " !EA0-52WZXQ,8+  "0C0  %0              @ '-J   <V)F;2TR
M,#(R,#8S,%]C86PN>&UL4$L! A0#%     @ 984#5=7V^&M)&0  %:L! !4
M             ( !QK0  '-B9FTM,C R,C V,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( &6% U5+>2?#9R\  /*9 @ 5              "  4+.  !S8F9M+3(P
M,C(P-C,P7VQA8BYX;6Q02P$"% ,4    " !EA0-53PL+@@,C  !\4P( %0
M            @ '<_0  <V)F;2TR,#(R,#8S,%]P<F4N>&UL4$L! A0#%
M  @ 984#5;@0*W[P!@  =B@  !8              ( !$B$! '-U;G-H:6YE
M8FEO7V5X,S$P,2YH=&U02P$"% ,4    " !EA0-5(4"-$>D&  !G*   %@
M            @ $V* $ <W5N<VAI;F5B:6]?97@S,3 R+FAT;5!+ 0(4 Q0
M   ( &6% U7CH%3B\0,  +@0   6              "  5,O 0!S=6YS:&EN
M96)I;U]E>#,R,#$N:'1M4$L! A0#%     @ 984#502UD1J&J@  G2T' !L
M             ( !>#,! '-U;G-H:6YE8FEO7VDQ,'$M,#8S,#(R+FAT;5!+
4!08     #  , !$#   WW@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
